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ABSTRACT
Ionotropic glutamate receptors play key roles in the spinal processing of nociceptive
inputs, especially in chronic pain states, which involve sensitisation of spinal
neurones. The resulting hyperalgesia and allodynia are prominent in models of
neuropathic pain arising from peripheral nerve injury; a condition poorly treated with
currently available analgesics. The NMDA subtype of glutamate receptor is thought
to be involved particularly in inducing the central sensitisation that occurs in the
spinal cord during chronic pain, while AMPA receptors are more generally believed
to have a greater role in acute nociceptive and non-nociceptive processing.
Both NMDA and AMPA receptors have been shown to bind to a number of
intracellular adapter proteins, which link the receptors to a variety of proteins with
signalling, scaffolding and other roles. As there is little or no functional data for
these proteins in spinal cord, studies were carried out to assess whether they play a
role in the regulation of ionotropic receptor-mediated mechanisms of neuropathic
pain.
We show, using intrathecal drug administration in a rat model of neuropathic pain,
that AMPA receptors play a greater role in sensitisation than in normal
somatosensory inputs and could represent a novel target for selective intervention in
neuropathic hyperalgesia/allodynia. Furthermore, we have implicated for the first
time a possible role for the AMPA receptor adapter proteins SAP97, PICK1, GRIP
and NSF in neuropathic sensitisation from experiments with cell-permeable blocking
peptides for their interaction motifs. In addition, the levels of mRNA and protein for
GluR2 and GRIP and the mRNA for another adapter protein, Narp increased in the
spinal cord in response to peripheral mononeuropathy. In contrast, GluR 1 levels were
decreased and no observable difference was seen in NSF or PICK1, or SAP97.
Further experiments addressed the effects ofnerve-injury on phosphorylation of the
AMPA receptor GluRl subunit and on the association of the GluR2 subunit with
GRIP and PICK 1.
xvii
Additionally, we show that mutant mice expressing a truncated form of the PSD-95
adapter protein lack the NMDA receptor-dependent reflex sensitisation that is
characteristic of neuropathic pain. PSD-95 was found in spinal NMDA receptor
complexes and was expressed in lamina II neurons. Biochemical studies indicate
i
that NMDA-mediated Ca entry is unaffected in the mutant mice, yet the facilitation
of this process that is normally brought about by nerve injury is impaired, with a
corresponding deficit in nerve-injury induced phosphorylation of the NMDA
receptor NR1 subunit.
These studies suggest new pharmacological targets for chronic pain and a critical
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This thesis is concerned with the mechanisms underlying chronic neuropathic pain, a
pervasive clinical condition with unsatisfactory therapeutic treatment to date.
Specifically, we will examine the two major receptors that are known to contribute to
glutamatergic excitatory transmission of nociceptive processing in the central
nervous system, the AMPA and NMDA receptors, as well as their newly identified
intracellular interacting proteins and consider how they may be involved in
neuropathic pain processing in the spinal cord by use of an animal model of
mononeuropathy (Bennett and Xie, 1988). First, however, it will be necessary to
introduce normal somatosensory processing as well as current views on factors that
may contribute to the development and maintenance of neuropathic pain in the
central nervous system.
1.1 Chronic pain
Pain is a complex phenomenon. It is more than a mere sensation, representing a
highly subjective individual experience involving not only the transduction of
injurious environmental stimuli, but also the cognitive, emotional and situational
processing of this information. Acute pain is a self-limited normal sensation
triggered in the nervous system as an alert to possible injury thus serving a protective
mechanism. However, chronic pain is maladaptive and serves no apparent biological
advantage, can persist for weeks, months and even years, and is primarily due to
hyperexcitability in the nervous system, resulting in spontaneous pain and
hypersensitivity.
Chronic pain remains a major health care problem afflicting an estimated 70% of
patients with advanced cancer and inflammatory disorders and up to 94% of patients
with spinal cord injuries (Grond et al., 1994; Hiraga, Mizuguchi and Takeda, 1991).
1
The socio-economic impact of chronic pain is vast and there is gaping hole in
effective therapeutics.
Officially, pain is defined by the International Association for the Study of Pain
(IASP) as:
"
An unpleasant sensory and emotional experience associated with potential or
actual tissue damage or described in terms ofsuch damage
-Merskey, 1986
This definition highlights the distinction between 'nociception ', the physiological
detection of tissue damage by specialised cutaneous receptors, and 'pain', the
perceptual awareness of nociception that is subject to emotional and situational
interpretation.
Common chronic pain complaints include headache, low back pain, cancer pain,
arthritic pain and neurogenic pain, resulting from damage to the peripheral nerves or
to the central nervous system itself (Scadding, 1984). The prevalence of chronic pain
is difficult to establish. In the UK, 46.5% of the population report some chronic pain
with 14.1% reporting significant chronic pain (Elliot et al., 1999). In Australia,
prevalence is estimated at 17-20%, while 15-20% (50 million) of Americans are
reported to have some form of chronic pain that costs the economy billion of dollars
annually (Rudin, 2001).
1.2 Neuropathic pain
A major cause of chronic pain is trauma to or compression of peripheral nerves.
Peripheral neuropathy may be caused by diseases of the nerves or as a result of
systemic illnesses. Many neuropathies have well-defined causes such as diabetes,
AIDs, or nutritional deficiencies, mechanical pressure such as nerve compression or
entrapment as well as direct nerve trauma. A common example of entrapment
neuropathy is carpal tunnel syndrome, which has become more common because of
repetitive strain inflammatory injury due to the increasing use of computers.
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Although the causes of peripheral neuropathy are diverse, they produce common
symptoms including weakness, numbness, paraesthesias (abnormal sensations such
as burning, tickling, pricking or tingling) and pain (Scadding, 1984). This includes
increased responses to normally noxious stimuli (hyperalgesia) and painful responses
to normally innocuous stimuli (allodynia), as well as spontaneous pain.
1.3 Available treatments
Drugs have a limited efficacy in the treatment of neuropathic pain and currently the
mainstay of pain management depends on opiates, which have a limited use in
chronic neuropathic pain treatment where they are largely ineffective and there are
associated tolerance and dependence problems. Apart from trigeminal neuralgia,
which responds well to the anticonvulsant carbamazepine, pharmacological
interventions for neuropathic pain are seriously lacking. There are a number of
recognised medications that may aid in the management of chronic pain such as non-
opioid analgesic NSAIDs (non-steroidal anti-inflammatory drugs). However, the
action of these drugs in the treatment of chronic neuropathic pain is relatively minor
and highly variable. The search for adequate analgesics to treat neuropathic pain is
ongoing. However, the new compound, gabapentin shows clinical efficacy in chronic
pain treatment, although their mechanism of action is unknown at present (Rose and
Kam 2002). One focus of research has been the NMDA receptor (which will be dealt
with in greater detail later), a major receptor in the nervous system known to be
activated following peripheral nerve trauma. Blockade of this receptor with
antagonists like dextromethorphan or ketamine appeared initially to be a promising
therapeutic development but toxicity, low safety margins and psychotropic side
effects are unacceptable and limit their use.
Clearly it is vital to identify novel, more specific targets that alleviate chronic
neuropathic pain, without affecting normal acute responses. In order to do this, it is
necessary to understand the underlying mechanisms and factors involved in the
generation and maintenance of the neuropathic pain state which relies on an
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understanding of the normal somatosensory transmission and how this is altered
following nerve trauma.
1.4 Normal somatosensory processing in acute pain transmission
Somatosensory systems are concerned with the conversion of environmental to
electrochemical stimuli by transduction of cutaneous stimuli via a variety of
afferents, which innervate the skin, and relaying that information to the central
nervous system (CNS). The glabrous skin contains a complex array of free nerve
endings and axons which terminate in specialised end organs. Generally speaking,
information from stimuli applied to the skin, evoking sensations like vibration,
stretch, touch, itch, pressure and pain are detected by specialised receptors in the skin
and transmitted to the spinal cord via afferent sensory axons where they have highly
structured termination patterns in the dorsal horn of the spinal cord (Wall, 1960;
Brown and Fuchs, 1975). The terminal regions of the primary afferent fibres have
receptive fields with discrete innervation territories activated only by stimuli that
directly impinge on their receptive fields. Skeletal and visceral innervation are
beyond the scope of this work.
1.5 Peripheral nervous system
Mechanoreceptors and nociceptors innervating the skin are the two major
components of the peripheral sensory system involved in relaying information about
mechanical stimuli (such as light touch, vibration and pressure) and painful stimuli
(noxious pressure, pinch or temperature), respectively (Lynn, 1994) with distinct
activation thresholds that must be reached by such stimulation before they become
activated.
Peripheral nociceptors exist as free nerve endings and are classified according to
axon type. Briefly, Aa and A|3 fibres are large myelinated fibres (15-20pm in
diameter) with rapid conduction velocities (60-1 OOm/s) that relay information about
proprioception (muscle sense) and touch, respectively. These fibres do not normally
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contribute to pain but instead are involved with processing innocuous stimuli. A5
fibres are smaller diameter (l-5pm) myelinated fibres with conduction velocities of
~20m/s that respond to intense mechanical and mechano-thermal stimuli. C-fibres
are unmyelinated and so have slower conduction velocities (~2m/s) and respond to a
range of noxious mechanical, thermal and chemical stimuli (summarised below).
Thus, the normally accepted classification of afferent somatosensory inputs is based
on response characteristics to innocuous and noxious stimuli applied to the skin and
comprises non-nociceptive mechanoreceptors and thermoreceptors as well as
nociceptors.
1.5.1 Non-nociceptive mechanoreceptors
Cutaneous mechanoreceptors are a diverse group of highly sensitive sensory
receptors that have the ability to respond to a variety of tactile sensations. Receptors
innervating hair follicles in hairy skin respond to hair movements, with D-hair units
responding to movement of the fine 'down' hairs with conduction velocities in the
A5 range, G-hair units responding to rapid movement of'guard' hairs with the
highest mechanical thresholds conducting in the large myelinated A fibre range and
T-hair units, responding to movements of the least numerous, large 'tylotrich' hairs,
are rapidly adapting and conduct in the Aa,p range (Lynn and Carpenter, 1982;
Brown and Iggo, 1967).
Rapidly adapting ('RA') Meissner and Pacinian corpuscle receptors are
mechanoreceptors responding to light touch, pressure and vibration while slowly
adapting ('SA') type I mechanoreceptors associated with Merkel cells and SA type II
mechanoreceptors associated with Ruffini corpuscles are involved in stretch
perception and shape discrimination, respectively (Willis and Coggeshall, 1991).
These are associated with the rapidly conducting Ap fibres involved in innocuous
information transmission. Unmyelinated C-fibre mechanoreceptors have also been
identified as responsive to gentle mechanical stimulation and cooling of the skin
(Bessou et al., 1971).
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Cold and warm thermoreceptors constitute a further class of non-nociceptive
receptors responding to small variations in cold sensations (A5 and cold-specific C-
fibres) and to slight warming of the skin in the non-noxious range (30-37°C),
respectively (Iggo, 1959).
1.5.2 Nociceptors
The term 'nociceptor' was introduced by Sherrington (1906) who defined
nociceptive afferents as ' those primary afferent neurones that can be activated by
harmful orpotentially harmful stimuli and that give rise to the sensation ofpain '.
They are functionally divided into two groups consisting of A8 mechanical and C-
fibre polymodal nociceptors. In general, electrical stimulation of A5 fibres evokes
the rapid, sharp pain sensation ('first pain'), while stimulation of C-fibres produces
the dull, diffuse or burning pain ('second pain'; Woolf and Hardy, 1941).
A8 mechanoreceptors are functionally distinct fibres for recognising mechanical skin
stimulation and are excited by high threshold mechanical (HTM) stimulation of the
skin, such as pressure and pinch. About 20% of A fibres are HTM (other types of A
fibres being RA and SA type I and II, as discussed in the preceding section; Lynn
and Carpenter, 1982). A5 fibres are nociceptive in function and so become activated
after strong pressure stimulation that lowers the response threshold and causes
spontaneous tiring (Burgess and Perl, 1967; Lynn and Shakhanbeh, 1988). A
commonly used method to examine myelinated fibres is intracellular labelling with
cholera toxin (choleragenoid, CB) that, when conjugated to HRP, only labels the
terminals of these medium to large diameter myelinated afferents (Robertson and
Grant, 1985).
C-polymodal nociceptors respond to a wide range of stimuli including noxious heat
(>42HC), high threshold mechanical and chemical stimulation (Bessou and Perl,
1969). They differ from other sensory receptors in this ability to respond to multiple
stimulus modalities (Treede and Magerl, 1995). C-fibre responses to heat can be
increased by a variety of conditioning stimuli, such as capsaicin (the 'hot' factor in
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chilli peppers) and mustard oil (allyl isothiocyanate) both of which are considered to
selectively activate C-fibre nociceptors (Bevan and Szolcsanyi, 1990, Woolf and
Wall, 1986). These compounds, as well as intracellular labelling with wheatgerm
agglutinin (WGA) that, when conjugated to HRP, predominantly labels small
diameter C-fibre terminals (Robertson and Grant, 1985), are common tools to
examine C-fibre properties.
Other types of nociceptors include cold nociceptors, that respond to <0°C stimuli
associated with AS nociceptors and possibly cold-sensitive C-fibres (Simone and
Kajander, 1996). There may also be chemical nociceptors that respond specifically to
changes in extracellular pH and acidosis. Finally, 'silent' nociceptors, that require
sensitisation before responding to a stimulus, have been identified (Schaible and
Schmidt, 1985).
An important feature is that repetitive C-fibre stimulation results in an increased
responsiveness of dorsal horn neurones, a phenomenon known as 'wind-up', that
lasts several minutes and in normal spinal circuits is NMDA receptor-dependent
(Mendell and Wall, 1965; Mendell, 1966, see Section 1.7.3).
1.5.3 Fibre composition of the sciatic nerve
The sciatic nerve of the rodent, which is the target of surgical manipulation in the
present work (see Section 1.11.1), is divided into the sural, lateral sural, superficial
peroneal and tibial nerves. In consideration of the above types ofprimary afferents,
the fibre composition of the entire rat sciatic nerve at mid-thigh level is estimated at
-27,000 axons, 6% of which are myelinated motor axons, 23% are myelinated A
fibres, 48% are unmyelinated C-fibre sensory axons, and 23% are unmyelinated
sympathetic axons (Schmalbruch, 1986).
Sensory axons in the peripheral nerves are supported metabolically by their nerve
cell body, which resides in the dorsal root ganglia (DRG). Cell bodies with the large
diameters in the DRG give rise to the myelinated rapidly conducting A|3 fibres while
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small and medium diameter DRG cell bodies give rise to most of the nociceptive A5
and C-fibres (Willis and Coggeshall, 1991). The sciatic nerve projects to distinct
regions in the superficial dorsal horn, mostly to LI and LII, in L4-L6 spinal segments
in an orderly topographic pattern (Swett and Woolf, 1985).
1.6 Central nervous system
The first synaptic relay in the dorsal horn occurs between the primary afferent
terminals and dorsal horn neurones, a connection governed by attributes in the
presynaptic peripheral afferent fibres themselves, such as the type of neuropeptides
and neurotransmitters released, and the response properties ofpostsynaptic central
neurones (whether they are intrinsic or projection neurones) these afferent fibres
come into contact with. However, before examining the convergence of these
primary afferents and their specific terminations in the spinal cord, it is necessary to
explain the lamination pattern in the dorsal horn.
1.6.1 Dorsal horn organisation
The superficial dorsal horn is the first synaptic relay of the fine afferent fibres from
skin, described above, and is regarded as the initial processing site for signals
directly related to the transmission and modulation of pain (Cervero, 1988). The
current view of the spinal cord is based on the work of Rexed (1952) who classified
the 'butterfly' shape of the cat spinal cord grey matter into nine laminae, which make
up the dorsal and ventral horns of the spinal cord and a tenth lamina that surrounds
the central canal. This work has been extended to other species including the rat
(Molander, Xu and Grant, 1984; Fig. 1.1a). For the purposes of this work, emphasis
will be placed on the architecture of the rat dorsal horn (laminae I-V).
Lamina I (LI, 'marginal zone') is a thin layer extending medially and laterally around
the superficial edge of the dorsal horn with loosely distributed small (5x5pm) and
large cells (15x5pm, the Marginal cells of Waldeyer). LI is a major site of
tennination of thinly myelinated (AS) fibres, and correspondingly many cells in this
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lamina respond to noxious mechanical and/or thermal stimuli (Light and Perl, 1979;
Willis and Coggeshall, 1991). LI also contains cells of origin of the spinothalamic
tract (STT), which will be dealt with in more detail below (see Section 1.9) (Lima
and Coimbra, 1986; Giesler et ah, 1976).
Lamina II (LII, 'substantia gelatinosa') lies ventral to LI, has an outer zone (LII0)
with densely packed small cells (5x5pm) and a less compact inner zone (Lllj)
distinguished by the relative lack of myelinated fibres. LII is the main termination
site for unmyelinated C-afferent fibres from the skin with sparse A8 input (Light and
Perl, 1979; Rethelyi, 1977; Sugiura et ah, 1988). Neurones in LII are mostly intrinsic
interneurones with extensive local integration. While there is some projection into
LI, only ~1% of LII neurones send their axons to the brainstem (Willis and Leonard,
1979; Giesler et ah, 1978).
Lamina III (LIII), ventral to LII, is defined by the presence of transversely cut
myelinated fibres. LIII cells are less tightly packed than LII and are generally larger
(7-8pm x 10- 12pm). Large hair follicle afferents (G-, T, and smaller D- hair),
Pacinian corpuscles and RA mechanoreceptive afferents terminate in LIII. LIII cell
dendrites project to LI and IV, and this lamina contains cells of origin of the
spinocervical tract (SCT) and the postsynaptic dorsal column tract (see Section 1.9,
Brown, 1981).
Lamina IV (LIV) is thicker than the previous three laminae and is the first layer not
to show a lateral bend. LIV has scattered larger cells (10x15pm), and many of their
dendrites ascend into LI -III, such that LIV can receive a direct primary afferent
input from fibres that enter the superficial layers. A significant number of the larger
LIV cells are the cells of origin of the spinocervical tract and the postsynaptic dorsal
column tract (see Section 1.9, Brown, 1981).
Lamina V (LV) forms the neck of the dorsal horn and, in comparison to LIV,
contains a more heterogeneous neuropil with even larger cells (15x20pm).
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Many fine afferent fibres from muscle and viscera as well as some small myelinated
afferents from skin nociceptors project directly in LV (Brown, 1981). Together, LIII,
IV and the dorsal part of LV make up the 'nucleus proprius' (Brown, 1981). Many of
the cells in LV constitute the ascending projection to the thalamus (Giesler et al.,
1976).
1.6.2 Dorsal horn neurones and sensory discrimination
The dorsal horn is characterised by a wide range of cells of different sizes and
morphological appearances (see Fig. Lib). The neurones in the dorsal horn are
categorised by their response characteristics to the arriving primary afferent fibre
signals from skin and have been classified into three major groups; non-nociceptive
(Class 1), multireceptive (Class 2) and nocispecific (Class 3) neurones (Iggo, 1974).
Non-nociceptive neurones in the dorsal horn respond to cutaneous low threshold
mechanoreceptor units activated by hair movement, touch and pressure and are thus
involved in innocuous information processing (Iggo, 1974).
Multireceptive neurones are sensitive to cutaneous mechanoreceptors and
nociceptors, so are said to have a 'wide dynamic range' (Mendell, 1966) and are
mainly located in LIV-VI of the dorsal horn with some presence in LI (Woolf and
Fitzgerald, 1983; McMahon and Wall, 1983).
Nocispecific neurones are purely excited by nociceptive A8 and C-fibres activated by
noxious stimulation of the skin (Cervero, Iggo and Ogawa, 1976). These are located
mainly in LI and less so in LV, some of which will project to the thalamus and
brainstem (Christensen and Perl, 1970; Light and Perl, 1979).
There is a fourth class of dorsal horn neurone (Class 4), which are proprioceptive in
nature, responding to joint movement and pressure on deep tissues and, as such, are
beyond the scope of this work.
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Figure 1.1 Laminar organisation of and cutaneous afferent input to the
spinal cord
(a) Source: Molander, Xu and Grant (1984)
Schematic representation of the ten laminar divisions of Rexed (1952) in the L5




LSN- lateral spinal nucleus
IM- intermedio-medial nucleus
VM- ventro-medial nucleus
I-X- Rexed's ten laminae
(b) Source: Cervero and Iggo (1980)
A hypothetical cross-section of the spinal dorsal horn illustrating the afferent fibres
and neuronal endings in LI-IV. Rexed's (1952) laminar divisions are indicated on the
right, with the afferent fibre types terminating in each region of the dorsal horn
indicated on the left. Some neurone types are also illustrated; a LI marginal cell, a
LII limiting cell and two neurones of the nucleus proprius where the neurone
illustrated in LIII has dendrites projecting into LII.
II
CUTANEOUS AFFERENT















A variety of neurotransmitters and neuropeptides are released from primary afferent
nerve terminals in response to stimulation. These neurotransmitters and
neuropeptides act on their respective postsynaptic receptors to alter the response of
dorsal horn neurones. Next, we will examine the major excitatory amino acid
neurotransmitter, glutamate, and its associated receptors as well as a brief description
of some of the neuropeptides that may affect plasticity in the dorsal horn of the spinal
cord.
1.7 Excitatory amino acid receptors
Of particular interest here are the excitatory amino acid receptors in the postsynapse
that respond to glutamate activation. The presynapse has the machinery for
neurotransmitter release while the postsynapse assembles various signalling
molecules involved in synaptic plasticity. Cellular plasma membranes are a complex
aggregate of lipids, transmembrane proteins and associated cytosolic components
that are organised into domains, which have distinct structural and biochemical
properties. The synapse is one of the most highly ordered membrane structures, in
which transmembrane receptors, ion channels and cytoplasmic signalling proteins are
localised in a discrete focal structure that is tightly linked to the cytoskeleton (the
postsynaptic density).
The postsynaptic density (PSD)
Glutamate receptors are concentrated in the PSD, a disc-like structure tightly
apposed to the postsynaptic membrane first observed in the 1950s by electron
microscopy. The PSD may govern the precise alignment between pre- and post-
synapses and maintain neurotransmitter receptors and ion channels in their
appropriate locations. It is a dynamic structural matrix that consists not only of
functional receptors, but also of cytoskeletal frameworks and regulatory proteins,
some of which contact the cytoplasmic domains of ion channels in the postsynaptic
membrane and contribute to the organisation of Ca2+-dependent and other signal
transduction systems beneath the postsynaptic membrane.
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1.7.1 Glutamate, the excitatory amino acid neurotransmitter
L-glutamate is an endogenous excitatory amino acid transmitter that is released from
the terminals of primary afferent fibres following electrical nerve stimulation (Curtis,
Phillis and Watkins, 1960; Rizzoli, 1968; Davies et al., 1979; Duggan and Johnston,
1970). Glutamate has been localised to subpopulations of small and large DRG cells,
myelinated and unmyelinated dorsal root axons and fibres in the superficial laminae
of the dorsal horn so that it is widely involved as a neurotransmitter of primary
sensory afferents (Wanaka et ah, 1987; Battaglia and Rustioni, 1988; Weinberg,
1999; Westlund, McNeill and Coggeshall, 1989). Indeed, almost all primary
afferents terminating in superficial laminae appear to process glutamate in a fashion
consistent with a neurotransmitter role (Rustioni and Weinberg, 1989). Intrathecal
administration of glutamate produces an increase in primary afferent-induced
nociceptive responses (Woolf, 1986; Coderre and Melzack, 1992) and ionophoretic
application of glutamate or its receptor agonists can excite spinal cord and DRG
neurones (Curtis, Phillis and Watkins, 1960; Huettner, 1990).
1.7.2 Ionotropic receptors
Glutamate, released from presynaptic nerve terminals, activates ionotropic ligand-
gated ion channels and G protein-coupled metabotropic receptors. The various
subgroups of glutamate receptors are highly conserved between mammals and
constitute the major excitatory transmitter system, the best studied of which are the
ligand-gated ion channels ('ionotropic glutamate receptors'), which are permeable to
cations (Hollmann and Heinemann, 1994). The ionotropic receptors have been
divided into two major classes based on their pharmacological response
characteristics; A-methyl-D-aspartate (NMDA) and non-NMDA receptors. The non-
NMDA class of ligand-gated receptors are further subdivided into a-amino-3-
hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) and kainate receptor
subtypes. Glutamate produces a fast excitatory potential at the AMPA receptor site
and a long synaptic potential acting at the NMDA receptor site. As ionotropic
receptors are focus of this research, more attention will be paid to them here.
14
Mammals express four AMPA receptor subunits (GluRl, 2, 3 and 4 or GluR-A-D),
five high affinity kainate receptor subunits (KA-1, KA-2, GluR5, GluR6 and GluR7)
and five NMDA receptor subunits (NR1, NR2A, B, C, and D). Each subunit is a
glycosylated membrane-inserted polypeptide of -900 to 1500 amino acids in length
and all subunits contain four hydrophobic transmembrane segments (TM1-4), which
determine their transmembrane topology, with an extracellular amino terminus, an
intracellular C-terminus and a 'TM2' segment, which forms the channel pore (see
Fig. 1.2). Ionotropic receptors are believed to be pentameric in structure (Hollmann
and Heinemann, 1994; Seeburg, 1993; Wenthold et al., 1992).
1.7.3 Evidence for a role of ionotropic receptors in pain
Much evidence supports a role for glutamate receptors in both the peripheral and
central nervous system. Peripherally, injection ofNMDA, AMPA or KA into
glabrous skin increases paw withdrawals following both noxious and non-noxious
mechanical stimulation and induces biting and scratching behaviour, that may be
indicative of pain, and can be blocked with corresponding antagonists (Carlton,
Hargett and Coggeshall, 1995; Aanonsen and Wilcox, 1987; Zhou, Bonasera and
Carlton, 1996; Jackson et ah, 1995). In the CNS, AMPA and NMDA receptor
agonists both depolarise spinal nociceptive neurones (Aanonsen, Lei and Wilcox,
1990; Coderre, 1993). In addition, stimulation of A5 fibres induces non-NMDA
receptor-mediated excitatory postsynaptic potentials in LII neurones (Yoshimura and
Nishi, 1992).
Several reports suggest that monosynaptic transmission from primary afferents in the
spinal cord is mediated mainly by non-NMDA receptors whereas NMDA receptors
are more important in the higher order synapses and mediate the wind-up and
sensitisation of dorsal horn neurones evoked by C-fibre volleys. Wind-up is
mimicked by the application of L-glutamate or the agonist NMDA and is blocked by
NMDA receptor antagonists (Zieglgansberger and Herz, 1971; Davies and Lodge,
1987).
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Figure 1.2 General structure of an ionotropic glutamate receptor subunit
lonotropic glutamate receptor subunits follow the same basic structural pattern with
an extracellular N-terminus and an intracellular C-terminus that can be the site of
interactions with intracellular proteins. Transmembrane domains (TM) are shown,
where theTM2 domain is believed to form the channel pore.
The table shows the currently accepted nomenclature for the NMDA and AMPA














AMPA selectively activates channels with fast kinetics and depolarises spinal
nociceptive neurones. Under normal conditions and acute somatosensory processing,
activity at the AMPA receptor is dominant. AMPA receptors in the superficial dorsal
laminae mediate fast nociceptive transmission in the spinal cord and antagonists
disrupt acute nociceptive transmission and prevent the development of hyperalgesia
(see Section 1.12.1). AMPA receptor subunits (GluRl-4) can assemble in any
combination into both homomeric and heteromeric receptor configurations with
distinct functional properties (Boulter et al., 1990; Keinanen et al., 1990; Verdoorn et
ah, 1991).
High concentrations ofAMPA receptor subunits have been demonstrated in neurones
of the superficial laminae of the dorsal horn and at synapses (Furuyama et ah, 1993;
Henley, Jenkins and Hunt, 1993; Tolle et ah, 1993; Popratiloff, Weinberg and
Rustioni, 1996). All four AMPA receptor subunits are expressed in the spinal cord to
varying degrees. GluRl and GluR2 mRNA and immunoreactivity are dominant in
the dorsal horn and are thus of particular interest here, while GluR3 and GluR4
primarily reside in ventral horn (Furuyama et ah, 1993; Tolle et ah, 1993). GluRl
expression is confined to LI and LII0 (Tolle et ah, 1993) while GluR2, a particularly
prominent subunit in the dorsal horn, is especially high in LIIj and the superficial part
of LI (Henley, Jenkins and Hunt, 1993; Tolle et ah, 1993). So, in general terms, the
subunit composition of the AMPA receptors appears to be different between
neurones conducting nociception (in the dorsal horn) and those conducting other
sensations (in the ventral horn).
AMPA Receptor Properties
The GluR2 subunit dominates the properties of ion flow as virtually all GluR2
subunits undergo site selective RNA editing (by adenosine deamination) at the
glutamine/arginine (Q/R) site in the channel pore resulting in Ca2+ impermeability
(Burnashev et ah, 1992a; Melcher et ah, 1996; Verdoorn et ah, 1991). Neurones of
mice with genetic mutation of this Q/R site display increased calcium permeabilities
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through the AMPA receptor (Feldmeyer et al., 1999). Most AMPA receptors in the
CNS are believed to be calcium impermeable due to the nearly ubiquitous inclusion
of the GluR2 subunit (Burnashev et al., 1992a), although there is a report of a
population of specifically Ca2+-permeable AMPA receptors (presumably lacking the
GluR2 subunit) in the superficial dorsal horn, which may mediate the transmission of
nociceptive information (Engelman, Allen and MacDermott, 1999). In addition to
RNA editing, each of the GluRl-4 subunits exist in two different forms created by
alternative splicing, termed 'flip' and 'flop' isoforms, that are equally abundant but
show different regional distributions and differ in the efficacy of glutamate in
activating the receptor (Sommer et al., 1990; Tolle et al., 1995). The GluRl and
GluR2 subunits have received particular attention of late due to identification of a
variety of intracellular proteins differentially interacting with these subunits that may
govern AMPA receptor functions in synaptic plasticity (see Section 1.15).
1.7.5 Kainate receptors
Until very recently the lack of specific pharmacological agents discriminating
AMPA and kainate receptors has precluded their functional study. Kainate receptors
represent a distinct non-NMDA subtype of receptor (Wenthold et al., 1994).
Evidence for an AMPA/kainate receptor distinction came from the differential
sensitivity of C-fibres to the agonists kainate and quisqualate as compared to AMPA,
consistent with the reported concentration of GluR5 on primary afferent C-fibres
(Davies et al., 1979; Agrawal and Evans, 1986; Huettner, 1990; Simmons et al.,
1998).
The GluR5 subunit of kainate receptor has been the main focus of kainate receptor
research regarding somatosensory processing. It is expressed evenly throughout the
dorsal horn in LII, LIII-VI (Tolle et al., 1993). GluR5 agonists depress reflexes to
afferent C-fibre inputs significantly more than those to A fibres and selective
antagonists can prevent capsaicin-induced hyperalgesia and allodynia in humans and
animal models with little effect on acute physiological nociceptive responses (Procter
et al., 1998; Sang et al., 1998; Simmons et al., 1998).
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1.7.6 NM DA receptors
The NMDA receptor has attracted much attention due to the ability of its antagonist
AP5 to alter synaptic plasticity, by reducing long-term potentiation (LTP, a model
for learning and memory in the hippocampus induced by brief repetitive stimulation
of monosynaptic excitatory pathways that results in a persistent enhancement of
synaptic transmission lasting from hours to weeks) in the hippocampus and affecting
aspects of learning (Morris, 1989; Collingridge, Kehl and McLennan, 1983).
The NMDA receptor consists of two major subunits, NMDA receptor 1 (NR1) and
NMDA receptor 2 (NR2A, B, C and D), whereby the NR1 subunit contains a glycine
binding site and the NR2 subunits contain the glutamate binding site, both of which
must be ligand-bound before ion channel activation can occur (Moriyoshi et al.,
1991; Laube et al., 1997). None of the NR2 subunits alone can form functional
homomeric ion channels but instead must co-assemble with NR1 to form functional
heteromeric receptors (Monyer et al., 1992). In the spinal cord, NMDA receptor
antagonists have long been known to reduce frequency-dependent potentiation
(wind-up) of cells to repeated C-fibre stimulation and following mustard oil
application (Dickenson and Aydar, 1991; Woolf and Thompson, 1991).
NR1 is ubiquitously expressed in the dorsal horn of the spinal cord and NR1 mRNA
is also located in sensory neurones known to relay predominantly nociceptive
information (in the trigeminal nuclei and spinothalamic tract) as well as those
neurones relaying touch and proprioceptive information (dorsal column neurones)
(Kus, Saxon and Beitz, 1995). The NR2 subunits of the NMDA receptor are
differentially expressed throughout the dorsal horn of the spinal cord (Tolle et al.,
1993; Luque et al., 1994). NR2A and NR2B subunits are of particular interest here
with widespread NR2A mRNA expression in the spinal cord while NR2B expression
is largely restricted to the superficial dorsal horn, LI and II (Luque et al., 1994;
Boyce et al., 1999). The NR2 subunits have been the focus ofmuch research
regarding the mechanisms of neuronal plasticity due to the identification of
molecules interacting at their C-terminal sites affecting ion channel localisation and
NMDA-dependent signalling mechanisms (see Section 1.15).
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NMDA receptor properties
The NMDA receptor channel complex is uniquely ligand- and voltage- gated and
requires a number of events to occur for activation. Under normal (acute) nociceptive
transmission, the NMDA receptor is subject to a Mg2+ ion block and so is largely
inactive. For the channel to open not only must this block be relieved but the NMDA
receptor-channel complex requires glutamate and co-agonist glycine binding for
channel activation (Kleckner and Dingledine, 1988). Glycine binding sites, other
than the strychnine-sensitive inhibitory glycine receptor, co-localise with NMDA
binding sites (in brain) and glycine can potentiate NMDA receptor responses in the
dorsal horn of the spinal cord (Budai, Wilcox and Larson, 1992).
The NR1 and NR2 subunits contain an asparagine residue in the TM2 pore region
homologous to the Q/R site in AMPA receptors, which are crucial for divalent ion
permeation and ion block. In heteromeric NR1/2 receptors, Ca2+ permeability is
thought to be largely controlled by an asparagine residue in NR1 while sensitivity
towards Mg2+ ions is dominated by the TM2 asparagine in NR2 (Burnashev et al.,
1992b). In addition, differential splicing of three distinct exons of NR1 generates
eight NR1 splice variants arising through insertion or deletion of three short exon
cassettes in the N-terminus (Nl) and the C-terminus (CI and C2) domains. NR1
splice variants differ in their patterns of temporal and spatial expression and
pharmacological properties as well as interaction capabilities dictated by C-terminal
motifs, which will be dealt with in Chapter 4 (Sugihara et al., 1992; Hollmann et al.,
1993; Luque et al., 1994; Zukin and Bennett, 1995).
1.7.7 Metabotropic receptors
The metabotropic receptors (mGluR) are a group of G protein-coupled receptors with
seven transmembrane domains classified into three groups based on differential
coupling to second messenger molecules. The Group I metabotropic receptors are of
particular importance to nociception and will be the focus here. Activation of
mGluR 1 or mGluR5 (Group I) leads to phosphoinositide hydrolysis, intracellular
Ca2+ mobilisation and possibly, to a lesser extent, increases in cyclic adenosine 3',5'-
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monophosphate (cAMP) accumulation (Abe et al., 1992; Masu et al., 1991; Aramori
and Nakanishi, 1992). The remaining metabotropic glutamate receptors are linked to
inhibition of cAMP production and can now be distinguished, at least in part, by
agonist and antagonist selectivity.
Group I metabotropic receptor subunit mRNAs are concentrated in the superficial
dorsal horn LI and II (Jia, Rustioni and Valtschanoff, 1999; Berthele et ah, 1999).
Ionophoresis of first generation metabotropic glutamate receptor antagonists (AP3,
CHPG) was reported to inhibit the excitation of single dorsal horn neurones elicited
by the C-fibre specific algogen, mustard oil and to attenuate spinal cord neuronal
excitability associated with acute inflammation (Neugebauer, Lucke and Schaible,
1994; Young et ah, 1994). The non-selective mGluR agonist, trans-ACPD, facilitates
formalin-induced nociception (Coderre and Melzack, 1992). A selective Group I
mGluR agonist (RS-DHPG) decreases the latency of behavioural reflex responses to
hotplate (48°C), von Frey filaments and tail pinch stimulation (Fisher and Coderre,
1998). However, agonist stimulation of mGluRs alone may be insufficient to cause
neuronal firing and there is evidence of a synergistic action with ionotropic
glutamate receptors as metabotropic receptors participate in the nociceptive spinal
reflex with AMPA and NMDA receptors, where mGluR agonists can facilitate their
agonist responses on dorsal hom neurones (Boxall et ah, 1996; Bleakman et ah,
1992; Cerne and Randic, 1992). In addition, co-administration of AMPA and mGluR
agonists results in behavioural hyperalgesia in acute nociceptive tests (Meller,
Dykstra and Gebhart, 1993).
1.8 Neuropeptides
In addition to glutamate, various neuropeptides are released from the endings of
peripheral afferent fibres. Indeed, the co-release of presynaptic glutamate and
neuropeptides has been demonstrated and can cause a variety of (synergistic) effects
on the postsynaptic dorsal horn cells in the spinal cord. Specifically, glutamate and
substance P co-exist in DRG neurones suggesting co-release in response to primary
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afferent stimulation (Battaglia and Rustioni, 1988; DeBiasi and Rustioni, 1988, see
below).
Substance P (SP)
SP is a member of the tachykinin family of structurally related peptides that includes
neurokinin A (NKA) and neurokinin B (NKB), which preferentially activate NK|,
NK2 and NK3 receptors, respectively. SP and NKA have been proposed as primary
afferent neurotransmitters based on their distribution in superficial dorsal horn
laminae I and II and on the basis of their functional effects in intrathecal and
electrophysiological experiments. SP is synthesised in small DRG cells from where it
is axonally transported to the dorsal root and sciatic nerve (Barbut, Polak and Wall,
1981; Harmar and Keen, 1982). It is present in ~20% of all DRG neurones (Ju et al.,
1987), where it has been shown to co-exist with a number of other substances
including calcitonin gene-related peptide (CGRP), somatostatin (SOM) and
glutamate (Battaglia and Rustioni, 1988; Ju et al., 1987).
9-1-
SP is released into the dorsal horn in a Ca -dependent manner from primary sensory
C-fibres in response to peripheral noxious and inflammatory stimuli where it binds to
its receptor, NK|, which has been localised within the superficial layers of the spinal
cord (Helke, Charlton and Wiley, 1986; Quirion et al., 1983; Yashpal, Sarrieau and
Quirion, 1991). Immunoreactivity for SP is concentrated in LI and exogenous
application of SP increases the excitability of dorsal horn neurones in response to
noxious thermal and mechanical stimuli and selectively activates high threshold and
multireceptive laminae I and II neurones (Duggan et al., 1987; Wiesenfeld-Hallin,
1986; Henry, 1976; Duggan et al., 1995; Couture et al., 1993). Capsaicin treatment
causes the depletion of SP (and other peptides) from small primary afferents in the
dorsal horn in conjunction with increasing chemical and mechanical nociceptive
thresholds (Hayes, Skingle and Tyers, 1981; Nagy et al., 1981; Yaksh et al., 1979).
Indeed, SP release in the superficial dorsal horn has been reported only following
noxious heat (52°C), noxious mechanical or chemical stimuli that would be predicted
to activate fine (capsaicin-sensitive) afferents (Duggan et al., 1987).
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Intrathecal injection of SP or an NK, receptor-selective agonist elicits biting and
scratching behaviours in mice that may be indicative of pain sensation as well as
reports of hyperalgesia induction (Hylden and Wilcox, 1982; Courteix, Lavarenne
and Eschalier, 1993). Although mixed affects have been reported (Hayes and Tyers,
1979; Yashpal, Wright and Henry, 1982), NK! receptor antagonists are generally not
effective at reducing dorsal horn neurone responses to brief noxious stimuli
indicating these receptors may be more active in states of persistent pain (Fleetwood-
Walker et al., 1990; Couture et al., 1993; Garces et al. 1993; Picard et ah, 1993;
Seguin, Le Marouille-Girardon and Millan, 1995; Yamamoto and Yaksh, 1992). LII
neurones are reportedly insensitive to NKi (as well as NK3) agonists that may be due
to a lower NK| expression in this region than previously thought (Bleazard, Hill and
Morris, 1994). Moreover, NKj receptor antagonists have not proved to be efficacious
in clinical trials of chronic pain states (Hill, 2000) although there may be a
differential involvement of the tachykinins according to the model of neuropathic
pain used (Coudore-Civiale et ah, 1998; Coderre and Melzack, 1991). More recent
evidence using novel, highly potent NK| receptor antagonists suggest that NKi
receptor blockade attenuates the sensitised response elicited by innocuous
mechanical stimuli in primate STT cells following capsaicin injection without
affecting noxious mechanical responsiveness (Rees et ah, 1998).
There are reported NK2 binding sites in LI and II (Quiron and Dam, 1988) and NK2
receptor antagonists can attenuate endogenous thermal nociceptive responses
(Fleetwood-Walker et ah, 1990). The NK2 ligand, NKA, appears to originate from
small diameter primary afferent fibres (Ogawa, Karazawa and Kimura, 1985) and
intrathecal application of NKA induces hyperalgesia that can be blocked by NK2
receptor antagonists (Yashpal, Hui-Chan and Henry, 1996). Whether this is a viable
target in neuropathy has not been assessed.
Glutamate and SP
Activation of C-fibres and glutamate release can result in SP and NKA release (Go
and Yaksh, 1987; Duggan et ah, 1990). In addition, the co-existence of glutamate
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and SP in fine afferent fibres and the possibility of co-release may allow sufficient
membrane depolarisation for NMDA receptor activation from prolonged activation
of peripheral inputs. Indeed, the co-administration of NKi and NMDA receptor
antagonists results in a synergistic action, whereby their respective inhibitory effects
on nociceptive stimulation are enhanced (Coderre and Melzack, 1992). PKC-induced
activity following NK| receptor activation may provide a mechanism for this synergy
via NMDA receptor activity modulation by PKC (Rusin, Ryu and Randic, 1992;
Chen and Huang, 1992; Urban et al., 1994). lonophoresis of SP or NK] receptor
agonists facilitate NMDA receptor-induced activity, and this increment can be
inhibited by antagonists acting at the glycine site of NMDA (Heppenstall and
Fleetwood-Walker, 1997; Dougherty and Willis, 1991; Cumberbatch Chizh, and
Headley, 1994).
Calcitonin gene-relatedpeptide (CGRP)
CGRP is found in about 30% of DRG cells and is released into spinal cord laminae I,
II and V following noxious thermal and mechanical stimulation (Lee et al., 1985;
Carlton et al., 1988; Morton and Hutchison, 1989). Subpopulations of CGRP-
positive neurones contain SP, SOM or galanin immunoreactivity (Ju et al., 1987).
Indeed, a high proportion (-80%) of SP-containing DRG neurones also contain
CGRP (Battaglia and Rustioni, 1988; Ju et al., 1987). Intrathecal application of
CGRP is reported to decrease the nociceptive threshold for acute mechanical
stimulation (Oku et al., 1987) and CGRP synergistically increases the effect of SP on
dorsal horn neurones and enhances SP release in spinal cord slices (Oku et al., 1987;
Biellaetal., 1991).
Vasoactive Intestinal Polypeptide (VIP)
VIP expression is very low under normal conditions and may be restricted to DRG
cells though low levels of peptide immunoreactivity can be detected in LI and II
(Gibson et al., 1981; Kar and Quirion, 1995, Yashpal, Sarrieau and Quirion, 1991;
Knyihar-Csillik et al., 1991). VIP is recognised by the VPAC], VPAC2 and PAC
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receptors (Ishihara et al., 1992; Lutz et al., 1993; Hosoya et al., 1997). Intrathecal
application of VIP increases the excitability of the spinal cord to thermal much more
than mechanical stimuli suggesting that this neuropeptide may be released by
thermosensitive cutaneous afferents that respond poorly to mechanical stimuli
(Wiesenfeld-Hallin, 1987; Cridland and Henry, 1988). AS and C-fibre stimulation
from the sciatic nerve causes the release of VIP and its immunoreactivity increases in
the lateral part of the dorsal horn (Klein et al., 1992; Yaksh, Abay and Go, 1982).
Ionophoresis of VIP excites nociceptive and non-nociceptive neurones in the rat
trigeminal nucleus caudalis and spinal cord LI-VII (Salt and Hill, 1981; Jeftinija et
al., 1982) despite the fact that the levels of VIP within the spinal cord appear to be
lower than those seen in many other regions of the CNS (Emson et al., 1978; Loren
et al., 1979).
Galanin (GAL)
GAL is normally present in approximately 23% of small to medium diameter DRG
neurones, where it co-exists with several other neurotransmitters including CGRP
and SP (Ju et al., 1987; Zhang, Nicholas and Hokfelt, 1993; Ma and Bisby, 1997).
GAL has widespread CNS distribution and can be found in the dorsal horn
concentrated in LI-III, with moderate expression in IV-V and primary afferent
terminals (Kar and Quirion, 1995). Intrathecal GAL produces brief facilitatory
effects at low doses, which become inhibitory as the dose increases (Wiesenfeld-
Hallin, Villar and Hokfelt, 1988). In addition, in both electrophysiological and
behavioural studies, GAL inhibits the analgesic effect of morphine on noxious
thermal and mechanical stimuli (Wiesenfeld-Hallin et al., 1991a), while having no
effect alone on these nociceptive inputs. As such, GAL may be a modulator of
excitatory peptides as pre-administration of galanin intrathecally has been shown to
antagonise the excitatory effects of SP and CGRP on the flexor withdrawal reflex
(Wiesenfeld-Hallin et al.,1991b; Xu et al., 1990).
26
Somatostatin (SOM)
High levels of SOM peptide(s) are found in small diameter primary afferent neurones
in a distinct population to those that contain SP (Hokfelt et al., 1976; Nagy and Hunt,
1982). While SOM immunoreactivity is concentrated in LII (Hokfelt et al., 1976), its
role in nociceptive processing is unclear as both inhibitory and excitatory responses
of dorsal horn neurones to its application have been reported (Murase, Nedeljkov and
Randic, 1982; Randic and Miletic, 1978; Salt and Hill, 1983). Intrathecal SOM has
been reported to increase the excitability of the spinal cord following mechanical and
thermal stimuli (Wiesenfeld-Hallin, 1986).
Neuropeptide Y (NPY)
NPY is found in sympathetic ganglia and may be a major peptide involved in
sympathetic neurotransmission (Lundberg et al., 1983). While there appears to be
low expression in the DRG under normal conditions, NPY immunoreactivity exists
in the spinal cord dorsal and ventral horns that may arise from intrinsic neurones or
supraspinal tracts (de Quidt and Emson, 1986; Wakisaka, Kajander and Bennett,
1991). In the spinal cord, NPY may co-exist with GAL or GABA (Zhang, Nicholas
and Hokfelt, 1993; Laing et al., 1994; Rowan, Todd and Spike, 1993). However, the
functional role ofNPY is unclear as intrathecal NPY has revealed a biphasic action
for this peptide, where at low doses it appears to be excitatory and at high doses,
inhibitory (Xu et al., 1994).
1.9 Ascending pathways
The processing of afferent input at the level of the spinal cord and the convergence of
the primary afferents into the central nervous system via the dorsal root ganglion
underpin an important regulation of the functional properties of dorsal horn
neurones. Many of the dorsal horn cells in the spinal cord are part of neuronal
pathways that carry information from cutaneous and subcutaneous mechanoreceptors
and nociceptors in ascending projections to brainstem and midbrain structures
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including thalamic nuclei and medullary structures, known to be involved in relaying
nociceptive signals. In addition, these neurones are also under descending control
from these and other areas. Each will be dealt with in turn.
Spinothalamic Tract (STT)
The STT carries information from the dorsal hom to the thalamic nuclei in the brain
and is of interest as transection of the STT causes analgesia and is occasionally used
to alleviate intractable pain in humans (Dubner and Bennett, 1983). The cells of
origin of the STT tract, based on retrograde HRP transport studies, are located in LI,
II and IV-VI, most of which are nocispecific or multireceptive neurones (Giesler et
al., 1976; Willis, Haber and Martin, 1977). Indeed, the nocispecific neurones of
lamina I are a feature of the STT (Dubner and Bennett, 1983; Giesler et ah, 1976).
Stimulation of various brain regions, such as the nucleus Raphe magnus (NRM) in
the rostral ventromedial medulla (RVM) and the periaqueductal grey (PAG), can
inhibit the responses of STT cells to both noxious and tactile stimuli originating from
myelinated fibres (Willis, Haber and Martin, 1977).
Spinomesencephalic Tract (SMT)
The mesencephalic tegmentum is a target for various somatosensory inputs
originating from the spinal cord, and the SMT terminates in numerous areas of this
region, including the periaqueductal gray (PAG). Using HRP tracing, the projections
of spinal cord neurones to the mesencephalic tegmentum are mostly contralateral
from LI and the lateral neck of the dorsal horn (LV-VI) (Menetrey et ah, 1982). A
significant proportion of lamina I neurones contribute to the SMT and
electrophysiological recordings of these neurones indicate that many of them are
nociceptive in nature (Menetrey et al., 1982).
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Spinocei~vicaI Tract (SCT)
Neurones of origin of the SCT are mostly located in LIV, while very few of the SCT
neurones, which project ipsilaterally, have been found in LI/II of the spinal cord. The
majority of SCT neurones respond to tactile stimuli from hair follicles, though some
are activated by intense cutaneous pressure, pinch and thermal nociceptive
stimulation (Brown, 1981; Cervero, Iggo and Molony, 1977).
Postsynaptic Dorsal Column system
The postsynaptic dorsal column fibres, primarily located in LIII/IV of the rat spinal
cord, project ipsilaterally through the dorsal funiculus to the nucleus gracilis and
nucleus cuneatus (Giesler, Nahin and Masden, 1984). There are two types of fibre in
this system, some of which are modality specific and respond only to gentle
stimulation (these can exert a segmental inhibitory influence on spinal cells relaying
high threshold afferent messages) while others are modality convergent and respond
more vigorously to noxious cutaneous stimulation (Brown et al., 1983). Polymodal
cells of the nucleus gracilis and the fibres of the fasciculus gracilis are exited by
innocuous hair movement, pressure, pinching and cooling as well as nociceptive
stimuli (Angaut-Petit, 1975).
1.10 Descending inhibition
The spinal cord dorsal horn is under the influence of numerous neuronal pathways
that descend from the brain and the activity of these pathways include actions on
primary afferent fibres, on neurones that give rise to ascending pathways and on
interneurones, and as such provide a feedback system onto the dorsal horn. The
existence of a modulatory pain system was alluded to by Melzack and Wall (1965) in
the 'Gate Control' theory of pain, which proposed that spinal nociceptive
transmission could be inhibited by non-nociceptive inputs. It is now clear that
nociceptive processing is modulated by segmental control from intrinsic
interneurones, Ap fibre activity and supraspinal influences, highlighting the fact that
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the dorsal horn is not merely a passive transmission station but rather a site where
dynamic inhibitory and modulatory events occur.
The finding that electrical stimulation of certain brain areas, such as the PAG could
have an analgesic action (stimulation-produced analgesia; SPA), by inhibiting the
transmission of nociceptive input at the level of the dorsal horn, clearly demonstrated
the existence of descending systems that contribute to pain modulation (Reynolds,
1969). Furthermore, suppression of nociceptive responses is produced by supraspinal
administration of narcotic analgesics as well as electrical stimulation at midbrain
sites (Hayes et al., 1979). PAG stimulation inhibits the responses of WDR and NS
neurones in dorsal horn (Bennett and Mayer, 1979). Indeed, neurones within the
dorsal horn are under a modulatory control that involves inhibitions from descending
pathways in the brain, local actions of inhibitory interneurones and the various
inhibitory neurotransmitters.
1.10.1 Tonic descending inhibition and supraspinal modulation
Excitation of dorsal horn neurones by impulses in unmyelinated primary afferent
fibres is subject to a powerful tonic inhibition from supraspinal sites that reduces
firing to peripheral noxious stimulation with little effect on responses to non-noxious
stimulation, such as hair deflection (Morton, Johnson and Duggan, 1983). The fact
that dorsal horn neurones were under tonic descending inhibition was highlighted
with the use of a reversible cold block that essentially isolates cells caudal to block
from descending inhibitory controls on dorsal horn neurones of the spinal cord (Wall,
1967). This demonstrated that descending systems could change neuronal response
properties, whereby dorsal horn neurones previously responsive to low threshold
mechanical stimulation can exhibit a greater firing frequency with increased
stimulation intensity under cold block condition such that LTMs become responsive
to a wide range of stimulus types and so resemble WDR neurones (Wall, 1967;
Brown, 1971).
30
Descending pathways from the brainstem modify spinal function. In recordings from
RVM while monitoring tail flick responses to noxious heat, Fields and Heinricher
(1985) identified two main classes of cells in this site of SPA. 'On-cells' were
consistently excited by noxious heat while 'Off-cells' were inhibited by the same
stimuli, and a significant proportion of these cells project to the spinal cord (Fields
and Heinricher, 1985). The medullary nucleus Raphe magnus (NRM) provides a
major serotonergic input to the dorsal horn LI/II and V cells (Basbaum and Fields,
1978). Also, analgesia to nociceptive responses (with little effect on innocuous
transmission) can be produced by electrical stimulation of the serotonin-rich
neurones in the central inferior Raphe nucleus region (Guilbaud et al., 1977; Hope et
al., 1989; Willis, 1977; Oliveras et al., 1974; Duggan and Griersmith, 1979). These
inhibitory effects alter nociceptive transmission in LI, IV-VI, and their associated
ascending pathways (SCT and STT) with little apparent effect on LII cells (Cervero,
Molony and Iggo, 1979).
There are also a number of endogenous factors contributing to the modulation of
nociceptive transmission, including the opioid system, and inhibitory transmitters,
such as y-amino butyric acid (GABA) and glycine, acting either presynaptically, at
the level of transmitter/peptide release from primary afferents, and/or
postsynaptically, acting directly on dorsal horn neurones. Additionally, inhibitory
segmental controls produced by the large diameter A(3 fibres exist that alter the
responses of spinal neurones to nociceptive stimulation whereby cutaneous
stimulation of large A fibres selectively inhibits C-fibre- and noxious stimulation-
evoked excitation of dorsal horn neurones (Woolf and Wall, 1982).
Endogenous Opioids
Major advances in the understanding of physiological pain modulation came with
finding that endogenous opioid peptides mimic narcotic analgesics in producing
prolonged analgesic effects in animals. Opioid peptides, such as enkephalin and
dynorphin are localised (in the spinal cord) to LI-III and LV of the dorsal horn and so
highly associated with areas receiving small diameter afferent primary fibres (Glazer
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and Basbaum, 1981; Cruz and Basbaum, 1985). After brain stimulation or systemic
morphine administration, the nociceptive receptive fields of WDR and NS neurones
shrink so that gentle mechanical stimulation can now evoke neuronal discharge.
Spinal enkephalin terminals are presynaptic to STT neurones and this arrangement is
presumed to underlie an important inhibition of spinal nociceptive transmission
(Ruda, 1982). Fields and Heinricher (1985) proposed that brainstem 'Off-cell'
activation by morphine underlies opioid suppression of nociceptive transmission,
while 'On-cells' are likely to facilitate nociceptive transmission at the dorsal horn
level (Fields and Heinricher, 1985). Nociceptin/ orphanin FQ (N/OFQ), the
endogenous ligand for the orphan opioid receptor OLRi, has been reported to have a
generalised inhibitory effect on neurones, does not co-localise with opioid receptors
and can block opioid analgesia (Yamamoto et al., 1999).
GABA
A role of the postsynaptic inhibitory neurotransmitter GABA in spinal modulation
comes from evidence that ionophoresis of GABA can inhibit dorsal horn neurones
(Curtis et al., 1970; Zieglgansberger and Sutor, 1983). Application of a GABA
analogue can reduce tonic inhibition after reversible cold block (Foong and Duggan,
1986) and GABA-like immunoreactivity has mostly been localised to LI-III, LIV-VI
and it is present in interneurones (Barber, Vaughn and Roberts, 1982; Todd and
McKenzie, 1989).
Glycine
Ionophoresis of glycine results in strong depression of the activity of dorsal horn
neurones (Curtis, Hosli and Johnston, 1967; Zieglgansberger and Sutor, 1983).
Glycine immunoreactivity can be found in LI-III and most commonly in LIII, such
that GABA and glycine co-exist in some LI-III neurones (Todd, 1990). Interestingly,
glycine has two opposing actions, an excitatory action, where it is a co-agonist for
the excitatory NMDA receptor and an inhibitory action via the strychnine-sensitive
glycine receptor (Budai, Wilcox and Larson, 1992).
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1.11 Alterations in somatosensory processing following nerve damage
Following nerve damage, there are long-lasting structural, physiological and
phenotypic alterations in the peripheral and central nervous system resulting in the
generation of a state of hypersensitivity. Alterations in baseline somatosensory
sensitivity arise as a result of increased nociceptor sensitivity and are accompanied
by the generation of primary afferent impulses at abnormal locations ('peripheral
sensitization') as well as increased gain in CNS processing circuits ('central
sensitization').
Peripheral neuropathy results in pain hypersensitivity and spontaneous pain, and so
manifests as either stimulus-evoked or stimulus-independent pain. Stimulus-evoked
pain is exemplified by the behavioural states of hyperalgesia, hypersensitivity to a
painful stimulus, and allodynia, a painful response to an innocuous stimulus, such as
light touching of the skin. Stimulus-independent pain manifests as spontaneous pain
in humans that may also be a feature and is characterised by continuous superficial
burning and/or a deep aching pain. In addition, cold allodynia is a striking feature
that occurs only in a neuropathic pain condition, although the precise underlying
mechanisms are still unknown (Frost et al., 1988). It has been reported that allodynia
to cooling is a characteristic of'reflex sympathetic dystrophies' (Attal et al., 1990a)
whereby in humans, cold aching, burning and prickling sensations can be
experienced following a cold stimulus (Davis, 1998). Paralleling some aspects of
neuropathic sensitisation, noxious skin stimuli intense enough to produce tissue
injury generate prolonged sensory disturbances, like continuing pain, increased
sensitivity and allodynia. As in neuropathic pain, these changes could result from
either sensitisation (a reduction in the thresholds of skin nociceptors) or an increase
in the excitability of the CNS so that normal inputs now evoke exaggerated
responses.
In an effort to determine the mechanisms of neuropathic pain, various animal models
involving a variety of peripheral nerve manipulations have been developed that aim
to mimic the behavioural aspects of neuropathic pain reported in humans. Most
neuropathic pain patients have a partial nerve injury, and a complete lesion is only
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usually seen after amputation, where the special situation of'phantom limb pain'
arises. Partial nerve injury models mimic the most common type of injury seen in
humans. The research presented here has utilised the chronic constriction injury
model (CCI) of Bennett and Xie (1988), a widely used, highly reproducible model
that results in the hallmark behavioural signs of neuropathic pain; hyperalgesia and
allodynia.
1.11.1 Chronic constriction injury (CCI) model
The Bennett and Xie model, developed in an effort to reproduce the sensory
disorders accompanying human peripheral neuropathies, produces a chronic, painful
mononeuropathy. The model involves tying chromic catgut ligatures around the
sciatic nerve at mid-thigh level (see Fig. 1.3) and within one week, the cutaneous
territory of the sciatic nerve is hyperalgesic, accompanied by the presence of
allodynia and spontaneous pain (dysaesthesia) (Attal et al., 1990a; Bennett and Xie,
1988). Importantly, the ligatures constrict but do not sever the sciatic nerve such that
there is partial denervation and many axons are left in continuity. The hyperalgesia,
allodynia and ongoing pain associated with peripheral nerve injury reflect
morphological and physiological changes in the peripheral and central nervous
system as well as alterations in the distribution, excitability and/or phenotype of
primary afferent neurones and central synapses.
1.11.2 PNS structural reorganisation
CCI selectively injures axons in the sciatic nerve with a substantial degeneration of
large myelinated axons and a partial degeneration of thinly myelinated and
unmyelinated axons (Basbaum et al., 1991; Coggeshall et al., 1993). The constriction
produces a massive loss of myelination of the large Aa and Ap axons distal to injury
as well as reducing the number of functional small myelinated A5 and C-fibre axons
to cause a partial and differential deafferentation of the sciatic nerve territory
(Munger, Bennett and Kajander, 1992; Gautron et al., 1990; Nuytten et al., 1992).
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Figure 1.3 The Bennett and Xie model of chronic constriction injury
Schematic illustration of the Bennett and Xie model, showing the placement of
chromic catgut around the sciatic nerve at mid-thigh level (3 ligatures used for mice
and four ligatures for rat) to loosely constrict the nerve, which causes primary
afferent demyelination and results in the behavioural manifestations of neuropathic













In the periphery, alterations in the excitability of primary afferent neurones, neuronal
degeneration, neuroma formation and the generation of spontaneous inputs occur
following CCI. Abnormal pain sensations begin at about the same time as
abnormalities in primary afferent function, when large Ap and A5 fibres become
incapable of conducting impulses through the injury site where, by day three
following induction of CCI, 89% of AP fibres, 87% of A5 fibres and 32% of C-fibres
are reported to be unable to conduct through the injury site (Kajander and Bennett,
1992). Axons at the injury site can form neuromas which are a source of intense
ongoing electrical activity. This 'spontaneous' activity may be due to Na+ channel
accumulation and may arise because the neuromas become abnormally sensitive to
various stimuli (Koltzenburg, Torebjork and Wahren, 1994; Devor, 1991).
Spontaneous firing in DRG and peripheral nerve increases with injury. Fibre cross-
excitation by abnormal contacts or ephapses (where impulse activity in one axon
activates a neighbouring one) accompanied by crossed afterdischarge, where the
activity of a group of neurones asynchronously engages the endogenous repetitive
firing capability of their neighbours, also occur (Tal and Eliav, 1996; Kajander and
Bennett, 1992). This situation predicts that, in the presence of remaining cutaneous
innervation, painful responses may be evoked with normally innocuous gentle to
firm mechanical stimulation (Devor and Wall, 1990).
1.11.3 The sympathetic nervous system
Under normal conditions, there is no evidence for communication between
postganglionic sympathetic neurones and afferent neurones in the periphery.
However, by four days following CCI, sympathetic axons sprout and invade the
DRG in parallel with behavioural manifestations of neuropathic sensitivity,
providing an anatomical substrate for sympathetic maintenance of pain that may lead
to sensitisation of neurones (Janig, Levine and Michaelis, 1996; Ramer and Bisby,
1997). Following CCI, guanethidine sympathectomy can reduce abnormal reactions
to cold and heat (45°C) without affecting responses to mechanical stimulation or the
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presence of spontaneous pain (Perrot et al., 1993; Attal et al., 1990b), suggesting a
differential sympathetic involvement in the different modalities of neuropathic pain.
1.11.4 CNS structural reorganisation
The peripheral injury of CCI is associated with structural and functional changes in
the CNS, changes in somatosensory processing in the spinal cord and a chronic
rearrangement of the highly ordered laminar termination of primary afferents within
somatotopically appropriate regions of the dorsal horn. Many of these alterations
could readily outlast nerve regeneration and reinnervation (Sugimoto, Bennett and
Kajander, 1990).
The spinal cord is bombarded by high levels of spontaneous discharge from many of
the injured nerve's afferents triggering central changes and consequently a long
lasting increase in the excitability of dorsal horn cells with abnormal characteristics,
such as an increase in the spatial extent of the cutaneous receptive fields of dorsal
horn neurones, amplified responses, threshold reductions and high spontaneous
activity; i.e. the state of central sensitisation (Woolf, 1983; Wall, 1991). Altered
central processes are believed to underlie the phenomenon of secondary
hyperalgesia, whereby a zone of mechanical hyperalgesia develops in uninjured skin
surrounding a local cutaneous injury in the absence of alterations in the sensitivity of
afferents (LaMotte et al., 1991; Hardy, Wolff and Goodell, 1950).
A|3 fibres under normal conditions signal light touch, vibration and position sense,
but never pain. However, following CCI, sprouting of low threshold Ap fibre
terminals from LIII into LII occurs and if this redistribution results in the
establishment of functional contacts with cells that would normally receive C-
nociceptor input, this may explain abnormal responsiveness to innocuous stimuli,
allodynia (Woolf, Shortland and Coggeshall, 1992). Such new Ap activation of
previously nociceptive cells might affectively bypass the inhibitory controls that
large myelinated fibres (and other influences) usually confer on small afferent fibre
inputs (Gautron et al., 1990). This may be a mechanism whereby large diameter
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LTM afferents can elicit the sensation of nociception through central changes after
nerve injury that strengthen the synaptic ties between central pain signalling
pathways and LTMs (Woolf 1983; Cook et al., 1987; Campbell et al., 1988).
1.12 Ionotropic glutamate receptors following nerve injury
Central sensitisation is accompanied by a number of alterations in the expression of
neuropeptides, neurotransmitters and their respective receptors in primary afferent
neurones and in the spinal cord that may contribute to hyperexcitability.
There may be a differential role for ionotropic receptors in the generation and
maintenance of chronic pain states. NMDA receptors have been implicated in
nociceptive inputs for AS and C-fibres, suggesting they are involved in a
hyperalgesia response, while AMPA and kainate receptors may be important in AS,
C- and large myelinated fibre inputs and may mediate both hyperalgesia and normal
responses (Dougherty et ah, 1992; Gerber and Randic, 1989; Dickenson and
Sullivan, 1990). The co-activation of AMPA and NMDA receptors is thought to
produce thermal hyperalgesia induced by peripheral nerve injury (Mao et ah, 1992a).
On the other hand, when AMPA and Group I metabotropic receptors are co-
activated, mechanical hyperalgesia is produced (Meller, Dykstra and Gebhart, 1993).
NMDA and non-NMDA, but not metabotropic, antagonists inhibit flexion
withdrawal during normal sciatic nerve stimulation (Silva, Cleland and Gebhart,
1997).
1.12.1 AMPA receptors
It has been reported that GluRl and GluR2/3 subunit densities are upregulated
following CCI (Harris et ah, 1996) and downregulated following inflammation,
deafferentation or contusive spinal cord injury (Pellegrini-Giampetro et ah, 1994;
Helgren et ah, 1999; Florenzano and DeLuca, 1999; Grossman et ah, 1999). AMPA
receptor antagonists prevent the development of hyperalgesia in rats with CCI
(Harris et ah, 1996) as well as attenuating responses to noxious mechanical/thermal,
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and/or non-noxious mechanical stimuli (Budai and Larson 1994; Cumberbatch,
Chizh and Headley, 1994; Dougherty et al., 1992). The enhancement may be due to
increased sensitivity of AMPA/kainate receptors to glutamate, which may result from
the activity of PKC and CaMKII in the postsynaptic neurone, causing direct
phosphorylation of glutamate receptors.
1.12.2 Kainate receptors
While there is still little information regarding a role for kainate receptors following
CCI, it has been reported that selective antagonists of the GluR5 subunit of kainate
receptor can attenuate the frequency of responses to mechanical stimuli and the
latency of response to thermal stimuli that occur following CCI with no effect on
normal rats (Sutton, Maccecchini and Kajander, 1999).
1.12.3 NMDA receptors
During normal nociceptive processing AMPA receptors mediate the fast excitatory
transmission in the spinal cord, while the NMDA receptor ion pore is subject to a
Mg2+ block. As mentioned, during brief excitation of nociceptors and following the
afferent barrage produced by neuropathic pain, co-release of glutamate and SP is
thought to depolarise postsynaptic cells via AMPA, metabotropic and/or neurokinin
receptors. Indeed, in the spinal dorsal horn simultaneous activation of the multiple
receptors NMDA, NKi and NK2 is required for LTP induction by natural noxious
stimulation (Rusin et al., 1993; Liu and Sandkuhler, 1995). Depolarisation will result
in the elimination of the Mg NMDA receptor block, activating the ion channel and
allowing Ca2+ entry and it is likely that the alterations in intracellular calcium and its
downstream targets contribute to persistent changes in dorsal horn excitability
(Coderre, 1993; Coderre and Melzack, 1992).
NMDA receptor-ligand binding sites and NR1 protein levels are reduced in the
superficial dorsal horn following CCI (Hama et al., 1995). lonophoresis of the
NMDA receptor antagonist MK-801 in the spinal cord of rats with CCI reduces
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noxious-evoked responses (Sotgui and Biella, 2000; Mao et al., 1992a) and MK-801,
as well as the selective NMDA antagonist D-CPP, can reverse the facilitated
behavioural withdrawal reflexes seen following mustard oil and conditioning
electrical stimulation of afferents (Woolf and Thompson, 1991). In addition,
intrathecal injection of selective NR2B subunit selective antagonists can inhibit CCI-
induced facilitated responses and wind-up (Boyce et al., 1999).
At most glutamatergic synapses calcium influx through NMDA receptors, AMPA
receptors or calcium release from intracellular stores (e.g. triggered by metabotropic
and/or tachykinin receptors) may also be involved.
Such calcium influx following depolarisation and its release from intracellular stores
leads to the activation of kinases, such as protein kinase C (PKC) and
Ca2+/calmodulin-dependent kinase (CaMK). Ca2+/calmodulin also activates some
isoforms of adenylate cyclase, which increase cAMP and activate protein kinase A
(PKA). These kinases may modulate AMPA and NMDA receptors by
phosphorylating specific residues that regulate channel function. Here, we will
briefly examine some evidence implicating these kinases in nociceptive processing.
1.13 Involvement of kinases in nociceptive sensitisation
PKA has been implicated in central hyperexcitability. Application of cAMP or the
catalytic subunit of PKA can enhance dorsal horn responses to glutamate-gated ion
channel activation and result in hyperalgesia (Cerne, Jiang and Randic, 1992; Aley
and Levine, 1999) and mutant mice with a knockout of the Rip subunit of PKA have
normal acute nociceptive responses but have a reduction in response during the
second phase of the formalin test implicating at least one subunit of PKA in
inflammatory hyperexcitability (Malmberg et al., 1997a).
Little is known about a role for CaMKII in nociceptive processing although
presynaptic injection of CaMKII itself increases neurotransmitter release in the
hippocampus (Llinas et al., 1985). Mutant aCaMKIl mice are deficient in both
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spatial learning and LTP (Silva et al., 1992) and CaMKII antagonists can prevent the
induction of LTP (Bortolotto and Collingridge, 1998). Moreover, the active
autophosphorylated form of CaMKII can increase excitatory transmission in dorsal
horn neurones (Kolaj et al., 1994). In addition, spinal neuronal responses to mustard
oil application are reduced following ionophoresis of CaMKII inhibitors (Young et
al., 1995).
There is substantial evidence supporting a role for PKC in regulating persistent pain.
Application of PKC activators can results in an enhancement of nociceptive
responses and there are increases in PKC ligand binding in the spinal cord following
peripheral nerve injury and noxious stimulation (Munro, Fleetwood-Walker and
Mitchell, 1994; Coderre, 1993; Mao, et al., 1992b). PKCs and PKCy mutant mice
fail to develop behavioural correlates of neuropathic pain behaviour while normal
acute nociception is retained (Khasar et al., 1999; Malmberg et al., 1997b). In
addition, sustained dorsal horn neuronal activity following mustard oil application is
reduced following ionophoresis of PKC inhibitors (Young et al., 1995).
Activation of these kinases leads to post-translational changes that modulate activity
of both AMPA and NMDA receptors and this will be dealt with in further detail in
Chapters 3 and 4, respectively.
1.14 Neuropeptide changes in neuropathic pain
In addition to the structural and physiological alterations that occur following
peripheral nerve injury, neurochemical alterations occur in many afferent neurones
such that they may switch their phenotype and so exaggerate the central response to
innocuous stimuli (Hokfelt, Zhang and Wiesenfeld-Hallin, 1994, see Fig. 1.4). In this
way, there may be a qualitative change in function, which could explain how
presynaptic transmitter changes may initiate new postsynaptic alterations in ion
channel excitability and expression levels (Wall, 1991). Although this is not an
exhaustive list, the main changes observed include a down-regulation of the
excitatory peptides SP and CGRP as well as decreased SOM, while levels of VIP,
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NPY and GAL are all seen to increase such that these peptides are differentially
regulated following nerve damage and inflammation, but we will focus on nerve
injury here.
SP, CGRP and SOM
SP and CGRP are among the two main peptides that decrease their expression
following nerve damage. Under normal conditions -30% of small to medium
diameter neurones in the DRG express SP (Ju et al., 1987; Smith, Seckl and Harmar,
1993). There is a significant decrease in the expression of SP mRNA in these DRG
neurones that is accompanied by depleted SP binding and mRNA in the dorsal and
ventral horn after unilateral nerve section, ligation or dorsal rhizotomy (Jessell et al.,
1979; Barbut, Polak and Wall, 1981; Nahin et al., 1994; Kajander and Xu, 1995).
However, SP immunoreactivity has been reported to increase in a model of partial
nerve injury in spared DRG neurones (Ma and Bisby, 1998). Furthermore, NKi
receptor immunoreactivity and mRNA is upregulated in the LI and LII following
sciatic nerve section and ligation (Abbadie et al., 1996; Aanonsen et al., 1992).
However as mentioned in Section 1.8, mixed effects for NK| receptor antagonists in
neuropathic pain have been reported and clinical trials with NKi receptor antagonists
have proved disappointing (Hill, 2000) although trials with more potent NKi receptor
antagonists as analgesic agents are currently in progress (Walpole et al., 1998). NK2
receptor antagonists have been reported to be anti-hyperalgesic following nerve
ligation and involved in the maintenance ofhyperexcitability during inflammation
(Neugebauer, Rumenapp and Schaible, 1997).
CGRP is abundant in DRG neurones under normal conditions but following CCI,
there is a marked decrease in the expression of CGRP mRNA in small to medium
DRG neurones as well as decreased levels of CGRP immunoreactivity in the
superficial dorsal horn (Nahin et al., 1994; Kajander and Xu, 1995). SOM is
normally present in approximately 20% of small to medium diameter DRG (Ju et al.,
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Figure 1.4 Schematic of the principal changes in the CNS following
peripheral nerve injury
Schematic representation of a small and large primary afferent sensory neurone in a
dorsal root ganglion sending a central branch to the dorsal horn of the spinal cord and
a peripheral branch which has been injured by axotomy. Arrows indicate changes in
the levels of neuropeptides and their receptors.
In small diameter DRG neurones, SP, CGRP and SOM peptide levels are decreased,
as is NPY receptor mRNA, while levels of VIP GAL, CCK and NPY are increased.
In large diameter DRG there is an increase in NPY and NPY receptor along with
smaller increases in VIP and GAL, while CRGP peptide and opioid receptor levels
decrease. Summaries of the structural and physiological changes from the peripheral
to the central nervous system are indicted.
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1987; Smith, Seckl and Harmar, 1993), however following nerve transection there is
a marked decrease in the production of SOM by primary afferent neurones with a
corresponding decrease in SOM immunoreactivity in the superficial dorsal horn
(Shehab and Atkinson, 1986; Villar et al., 1989; Zhang et al., 1993).
VIP, GAL and NPY
Following CCI, there is a reported ipsilateral spinal cord increase in VIP, GAL and
NPY mRNA in DRG (Nahin et al., 1994). VIP expression is relatively low in the
superficial dorsal horn and primary afferent neurones under normal conditions
(Knyihar-Csillik et al., 1991; Fuji et al., 1983). Following axotomy and crush, there
is a significant increase in VIP expression in small to medium diameter DRG
neurones, where it is often co-localised with GAL, with a corresponding increase in
VIP immunoreactivity in the superficial dorsal horn (Nahin et al., 1994; Zhang et al.
1995; Knyihar-Csillik et al., 1991; Shehab and Atkinson, 1986). In addition,
following CCI, spinal VPAC2 receptor mRNA increases ipsilateral to CCI while
there is a decrease in VPACi receptor mRNA and no change in PACi receptor
mRNA expression (Dickinson et al., 1999). VIP predominantly has an excitatory role
and so it is possible that this peptide takes over the role of SP as a primary
neurotransmitter within the CNS of neuropathic animals.
Galanin is upregulated in medium and large DRG neurones after complete and
partial sciatic nerve transection and in ipsilateral dorsal horn after CCI (Ma and
Bisby, 1997; Hokfelt et al., 1987; Villar et al., 1989; Colvin, Mark and Duggan,
1997). The pattern of co-expression of GAL with other neuropeptides also changes
following nerve injury with an increase in the co-existence of GAL with NPY and
VIP (Nahin et al., 1994). In addition, intrathecal GAL alleviates mechanical and cold
allodynia following ischemic peripheral nerve injury (Hao et al., 1999). The
expression of NPY in the DRG is low under normal conditions (Gibson et al. 1984),
but following nerve injury, NPY is upregulated in laminae 1II-V of the dorsal horn
and expression is induced in many large or medium diameter primary afferent
neurones (Kar and Quirion, 1995; Nahin et al., 1994; Zhang et al., 1995).
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1.15 Ionotropic glutamate receptor interacting proteins
While there is a vast body of information for the role of the AMPA and NMDA
receptor ion channels in the plasticity of neuropathic pain, there is little information
regarding their underlying mechanisms and second messenger cascades.
Over the last few years, biochemical indices have identified a number of intracellular
proteins that interact with the intracellular C-termini of AMPA and NMDA receptors
that may mediate their localisation and ability to interact with intracellular signal
transduction machinery. These proteins are of two types, those that contain PDZ
domains (discussed below) of which there are specific examples that interact with
either AMPA or NMDA receptors, and those that do not contain PDZ domains,
largely interacting with AMPA receptors. Together with their respective glutamate
receptor ion channels and associated molecules, these proteins form large complexes
that may regulate neuronal transmission and plasticity. In general, it is believed that
the AMPA receptor and the NMDA receptor exist as distinct macromolecular
complexes.
PDZ domain-containingproteins
PDZ domains mediate protein: protein interactions, and were first recognised as
repeats of -90 amino acids in the amino terminus of the PSD-95 (MAGUK) family
of cytoplasmic proteins where they are thought to have an organising function at sites
of cell-to-cell contact (Kennedy, 1997). PDZ domains are named after three proteins
with these repeats (PSD-95/SAP90, Dig-A and tight junction proteins, ZO-1) and are
found throughout phylogeny in diverse organisms.
Multiple PDZ domains are modular protein-binding domains that have at least two
distinct mechanisms for binding: they can bind to specific recognition sequences at
the carboxyl termini of proteins or they can dimerise with other members of the
MAGUK family via N-terminal interactions and indeed seem to be able to do both at
the same time (Fanning and Anderson, 1996). Many cytosolic signalling proteins and
eytoskeletal proteins are composed of modular units of small protein: protein
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interaction domains that allow reversible and regulated assembly into larger protein
complexes.
PDZ domains have been observed in many cytosolic proteins and may co-operate to
enhance binding to their common targets or help to bind simultaneously to multiple
different targets as well as showing specificity of binding (Sonyang et al., 1997).
PDZ domain-containing proteins may be crucial for the maintenance of clusters of
glutamate receptors at synapses in dendritic spines (Rao et ah, 1998) though they are
not essential in cluster formation (Migaud et ah, 1998) or directly in the translocation
of these clusters to synaptic sites (van Rossum and Hanisch, 1999).
The Membrane Associated Guanylate Kinase (MAGUK) protein family members
use multiple domains (including PDZ domains) to cluster ion channels, receptors,
adhesion molecules and cytosolic signalling proteins at synapses. All MAGUKs are
associated with the plasma membrane. Distinct MAGUKS interact with the
intracellular C-tennini of both the GluRl AMPA and NR2 NMDA receptor subunits.
This will be discussed in more detail in Chapters 3 and 4, respectively.
There is a growing list of proteins that do not belong to this MAGUK family,
although they do contain PDZ domains. A protein called GRIP (Glutamate Receptor
Interacting Protein) interacts with the C-terminal of GluR2 subunits of AMPA
receptors and may be important for receptor clustering as well as coupling AMPA
receptors to signalling and cytoskeletal molecules. Other identified GluR2 interaction
partners include PICK1, a PDZ protein that binds to the a isoform of PKC and may
regulate AMPA receptor modulation, and NSF, a non-PDZ domain-containing
protein with an identified role in vesicle trafficking. These will be discussed in more
detail in Chapters 3.
1.16 Aims
The aims of the present work were to further examine the underlying mechanisms of
both the AMPA and NMDA subtypes of glutamate receptors in central neuropathic
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sensitisation by an examination of their interacting partners and the potential changes
in function that they may have in the CCI model (Bennett and Xie, 1988).
We have used the CCI model to investigate GluR2-interacting proteins such as
GRIP, PICK1 and NSF, by examination of expression levels in the spinal cord under
normal conditions and following CCI, as well as the effects of inhibiting these
interactions by use of intrathecally-applied blocking peptides. In addition, we will
examine functional modulations affecting the AMPA receptor by an analysis of the
effects of GluRl serine residue phosphorylation by kinases such as PKA and
PKC/CaMKII in the spinal cord following CCI. These results are presented in
Chapter 3.
Hypotheses
1: Given that non-selective AMPA receptor antagonists have been reported to reduce
behavioural sensitivity following nerve injury, we tested the possibility that highly
selective AMPA receptor antagonists would have a similar effect when administered
locally by intrathecal injection in the spinal cord following CCI.
2: Based on the assumption from previous in vitro work, whereby blocking particular
proteins that interact with the intracellular C-terminus of the GluRl and GluR2
subunits ofAMPA receptors (such as SAP97, GRIP/PICK1 and NSF) causes
reduced receptor clustering and localisation as well as a run-down of AMPA receptor
mediated currents, we tested the possibility that such specifically targeted C-terminal
myristoylated peptides will disrupt AMPA receptor involvement in neuropathic pain.
3: If the second hypothesis proves to be the case, then it would be expected that there
will be a regulation of expression of receptor subunit levels and associated adapter
proteins in the spinal cord following CCI. For this, mRNA analysis via in situ
hybridisation and protein analysis via Western blotting will be carried out.
4: We will also set out to examine how the mechanism of action ofAMPA receptor
subunits may be altered following CCI and the effects of phosphorylation by kinases
on this by use of subunit selective phosphorylation-specific antibodies.
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To examine any functional effects of NMDA receptor interactions during neuronal
plasticity following CCI, we have used mice with a mutation in the best-
characterised PDZ domain-containing protein, PSD-95, which interacts with NR2
subunits of NMDA receptors, and characterised the development of behavioural
neuropathy following CCI. We show that in the mutant mice there is a striking
failure to develop neuropathic sensitisation and some of the possible underlying
mechanisms are investigated. In addition, an examination of NMDA receptor
channel modulation by PKA and PKC was undertaken to establish any alteration in
NMDA receptor phosphorylation following CCI. These results will be presented in
Chapter 4.
Hypotheses:
1: Learning and memory in the hippocampus and central sensitisation in the spinal
cord share the common mechanism ofNMDA receptor dependence. Given the effect
of a PSD-95 mutation on tests of learning and memory, we predict that PSD-95
mutant mice will also show an altered phenotype for the behavioural sensitivity
following the induction of CCI.
2: The NMDA receptor dependence factor of any findings from hypothesis 1 will be
tested using NMDA receptor antagonists following CCI and the activation of the
NMDA receptor via application of an agonist in naive mice.
3: Based on the finding that NMDA receptor activation can result in calcium entry
through the ion channel and a cascade of Ca2+ associated kinases, we will test the
possibility, via enzyme activity or phospho-specific antibodies, that any alterations in
the phenotype observed from Hypothesis 1 will be NMDA receptor dependent and/or
mediated via the closely associated protein kinases such as CaMKII and PKA which
are known not only to be involved in hippocampal behavioural paradigms but also
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2.2: Methods common to Chapter 3 and 4
2.2.1 Animals
Adult male Wistar rats were used for the experiments described in Chapter 3 (150-
200g; Charles River, UK). They were housed in standard laboratory cages in groups
of four, with food and water supplied ad libitum. Adult C57/BL6/MF1 mice, either
wild-type or PSD-95 mutant strains (Gift from Prof. Seth Grant, Dept. Neuroscience,
University of Edinburgh) were used in the experiments described in Chapter 4. They
were housed in standard laboratory conditions with littermates, with food and water
supplied ad libitum. All experiments were carried out in accordance with the UK
Animals (Scientific Procedures) Act 1986.
2.2.2 Surgical preparation of animals with chronic constriction injury (CCI)
Rats and mice were initially anaesthetised with sodium pentobarbital (Sagatal;
0.01 ml/kg, i.p., for mice was diluted by 1:10 in dH20; Rhone Merieux, UK) and this
was then supplemented with halothane 02 (AstraZeneca, Ltd.). Under aseptic
conditions, using the method of Bennett and Xie for rat (Bennett and Xie, 1988), the
sciatic nerve was exposed at the mid-thigh level proximal to the sciatic bifurcation.
Four chromic catgut ligatures (4.0 for rats; Ethicon, Edinburgh) separated by 1mm
were tied loosely to constrict the tibial branch as viewed under 40x magnification. A
slight modification of the Bennett and Xie CCI model was developed for mice,
whereby three chromic catgut ligatures (5.0 for mice; Ethicon, Edinburgh) were
applied to the sciatic nerve in the same manner as described above. Vascular supply
was not compromised. The overlying muscle and skin were sutured and the animals
were placed in a recovery cage. A sham operation was performed as a control and




Behavioural testing was carried out to assess the development and progression of the
neuropathic pain sensitivity characteristic to the CCI model, as indicated by the
presence of hyperalgesia and allodynia. Testing procedures were the same for rats
and mice. To eliminate bias, the experimenter was blind to genotype/drug treatment.
(i) Thermal Hyperalgesia
Thermal hyperalgesia was monitored using a Hargreave's Thermal Stimulator
(Linton Instrumentation, USA). A radiant thermal stimulus of infrared intensity 30 or
15 (manufacturer's scale) for rats and mice, respectively (>50°C; Hargreaves et al.,
1988) was applied to the mid-plantar surface of the hindpaw. The withdrawal
response was characterised as a brief paw flick. The latency of withdrawal was
recorded for the ipsilateral (injured) and the contralateral (uninjured) hindpaws
('PWL', paw withdrawal latency). The means of between 5 and 10 readings were
recorded at 3-5 min intervals, which ensured no hypersensitivity to the test was
established (see Fig. 2.1a).
(ii) Mechanical Allodynia
Mechanical allodynia was measured as the withdrawal threshold to calibrated
Semmes-Weinstein von Frey filaments (Stoelting, Wood Dale, IL) with a bending
force of 8.41 -4830.62mN.mm~2. Animals were placed on a wire cage and the
filaments were applied to the mid-plantar surface of the hindpaw from beneath until
the filament started to bend. This stimulus was repeated 8-10 times at 1-2 sec
intervals for both the injured and uninjured hindpaws. The mean threshold required
to elicit a withdrawal response was recorded ('PWT', paw withdrawal threshold).
The filaments were applied in ascending order, and responses were characterised as a
brief paw flick. The withdrawal threshold was defined from the lower of two
consecutive von Frey filaments that elicited a response. Data were expressed as the
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Figure 2.1 Photographic description of behavioural tests
(a) Shows a mouse placed in a Perspex box on the Hargreaves thermal
stimulator, where the animal withdraws the hindpaw following noxious
thermal stimulation
(b) Shows a mouse placed in a wire cage box and a von Frey filament was
applied to the hindpaw, until the filament started to bend
(c) Shows a rat (mouse reactions are too rapid for photographic capture) placed
in a glass tank on an elevated metal grid floor covered (~lcm) with a mixture
of ice and water (3-4°C). The hindpaw is elevated above the water level under
conditions of neuropathic pain.
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threshold indentation pressure (i.e. the bending force/ per cross-sectional area at the
tip of the filament; see Fig. 2.1b).
(Hi) Cold Allodynia
In order to test for the presence of cold allodynia, animals were placed in a glass tank
with an elevated metal grid floor. This was covered (~lcm) with a mixture of ice and
water (3-4°C), which ensured both the glabrous and hairy skin of the foot was
covered with water. Animals were placed in the tank for a 30 sec period, the first 10
sec of which were to allow the animals to acclimatise. During the remaining 20 sec,
measurements were made of the amount of time the animal elevated the injured paw
above the water level, defined as the Suspended Paw Elevation Time (SPET). To
ensure paws returned to body temperature, testing was carried out only every 10 min
(see Fig. 2.1c).
2.2.4 Intrathecal injections
Baseline measurements were recorded for thermal hyperalgesia (Hargreave's test)
and mechanical allodynia (von Frey filament test) in animals that had undergone
chronic constriction injury and were at the peak of neuropathic reflex sensitisation.
Animals were briefly anaesthetised with halothane and O2. Drugs (see Table 2.1 for
details of compounds used) were injected intrathecally (in 50pl saline vehicle for rat
or lOpl saline vehicle for mice), at the L4 level of the spinal cord (Hylden and
Wilcox, 1982) using a 25.1 G syringe or a U-100 microfine insulin syringe (for rat
and mouse injections, respectively; Becton Dickenson, Ltd.). The experimenter was
blind to the content of the injections so as to eliminate bias. 15 min following
injection, animals were re-tested using the same procedures and measurements were
taken to determine the effects of drug on hyperalgesic and allodynic behaviours.
Animals were tested every 5 min until readings returned to baseline levels.
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-Drugs
The drugs used for blocking the AMPA receptor were NBQX, an AMPA/kainate
antagonist with 50 fold selectivity for AMPA over kainate, the selective AMPA
receptor antagonist NS-257 and SYM 2206, a highly potent AMPA receptor
antagonist. The vehicle, saline, was used in control injections. In addition, a number
of myristoylated peptides (for increased cell permeability) designed to block specific
regions on the GluR2 and GluRl C-termini were designed for use in intrathecal
injections, myr-NVYGIESVKI, myr-AKRMKVAKNAQ, myr-SGMPLGATGL. The
inactive myristoylated peptide, myr-GRRNAIHDE' (Gift from Dr. Roger Clegg,
Hannah Research Institute, Ayr) was used in control injections. The agonist AMPA
was used to examine activation of spinal AMPA receptors. (R)-CPP, the highly
selective NMDA receptor antagonist and NMDA, the NMDA receptor ligand were
used to examine the basic pharmacology of the NMDA receptor in vivo. In addition,
the CaMKII inhibitors, myristoylated autocamtide-2-related inhibitory peptide, KN-
93 and its inactive structural analogue, KN-92 and the vehicle, saline, were used in
control injections (see Table 2.1 for a summary of drugs and specific doses).
2.2.5 Statistics
In each behavioural study, data were pooled, either for each test day (for the
development of neuropathic reflex sensitivity), or for test block minutes (following
intrathecal injection). Data were displayed as the average ± the standard error of the
mean (SEM). In the test of thermal hyperalgesia, paired Student's t-tests were
performed to determine any significant differences between ipsilateral and
contralateral hindlimb values, while a one-way ANOVA followed by a Dunnett's
post-hoc test were used to examine any alteration of post-treatment responses to pre-
treatment baseline responses. In the test of mechanical allodynia, Mann-Whitney
Rank sum tests were performed to determine any significant differences between
ipsilateral and contralateral hindlimb values, while a Kruskal-Wallis ANOVA
followed by a Dunn's post-hoc test were used to examine any alteration of post-
treatment responses to pre-treatment baseline responses.
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Table 2.1 Compounds used for intrathecal injections
This table provides a brief summary of the compounds used for the intrathecal





NBQX 1.5, 5, 13 nmol Non-competitive antagonist
NS-257 28, 83, 166 nmol Competitive antagonist
SYM 2206 1.5 nmol Potent non-competitive
antagonist
AMPA receptor agonist
AMPA 50pmol AMPA receptor ligand
Myristoylated inhibitory peptides
myr-NVYGIESVKI 4.5nmol Blocks PICK1/GR1P site on
GluR2
myr-AKRMKVAKNAQ 4.5nmol Blocks NSF site on GluR2
myr-SGMPLGATGL 4.5nmol Blocks SAP97 site on
GluRl
myr-GRRNAIHDE 4.5nmol Inactive control peptide
NMDA receptor antagonist
(R)-CPP 1 OOpmol Competitive antagonist
NMDA receptor agonist
NMDA 0.25nmol NMDA receptor ligand
CaMKII inhibitors
KN-93 120pmol Blocks calmodulin binding
site
KN-92 120pmol Inactive structural
analogue ofKN-93




A laminectomy (L3-6) was performed on anaesthetised animals (n=3-6) at the peak
of behavioural neuropathic sensitivity and the spinal cord was hemisected to separate
contralateral from ipsilateral sides. This was then immediately gently homogenised,
in a hand-held homogeniser (Fisher Scientific, Ltd.) at 4°C containing freshly
prepared Laemmli buffer.
(ii) Solutions
SDS Laemmli lysis buffer (5x stock)
0.625M Tris-Cl, pH 6.8; 2% (w/v) SDS
0.1 % (w/v) bromophenol blue
50% (v/v) glycerol
SDS-PAGE electrophoresis buffer
1M Tris base, 0.1M glycine
Phosphate buffered saline (PBS)
0.1M Na2HP042H2O, 0.1M
NaH2P042H2O, 150mM NaCl; pH 7.4
Protein transfer buffer
0.1M Tris base, 0.5M glycine, 0.01%
(w/v) SDS
(Hi) SDSpolyacrylamide gel electrophoresis (SDS-PAGE)
Polyacrylamide gel electrophoresis was performed using the Tris-glycine buffer
system for protein separation described by Laemmli (1970). Pre-cast polyacrylamide
ready gels (4% stacking, 10% resolving, 15 wells; BioRad) were placed in a buffer
chamber and wells were cleared of gel fragments by washing with buffer prior to
sample loading. Electrophoresis running buffer (lx) was added to the buffer
chamber. Samples and molecular weight marker proteins were loaded into the wells
of the stacking gel and electrophoretically separated at a constant voltage of 100V
until the samples passed into the resolving gel, at which point the voltage was
increased to 150V and run until the samples reached the bottom of the gel.
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(iv) Transfer ofproteins
PVDF membranes were wetted by briefly soaking in methanol, which was then
removed with several brief dFLO washes. The gel was removed from the stabilising
backing plate, placed in lx transfer buffer and sandwiched between filter paper and
sponges. This 'sandwich' was placed in the buffer chamber, immersed in transfer
buffer and cooled with an ice block. Electro-blotting was performed at 100V for 45
min using BioRad Protean II Gel Transfer apparatus.
(v) Protein loading
Prior to immunoblotting, membranes were temporarily stained with PhastGel Blue R
(Amersham Biotech, Ltd.) to ensure even protein loading of the lanes. This stain was
removed with methanol prior to membrane blocking. As a further control for protein
level normalisation, membranes were stripped ("Re-Blot" reagent, Chemicon
International, Ltd.) and reprobed for the ubiquitous housekeeping enzyme
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) where possible. GAPDH has
previously been shown to serve as a stable and consistent housekeeping protein
whose cellular levels are unaltered for example in cases of spinal cord and brain
insult (Medhurst et ah, 2000).
(vi) Immunoblotting
Membranes were blocked overnight at 4°C in 4% Marvel/0.1% Tween-20. Following
blocking treatment, membranes were incubated in primary antibody (made up to the
desired concentration in 4% Marvel/0.1% Tween-20) for 1-2 hr at room temperature
in a sealed bag on a rotator (See Tables 2.2 and 2.3 for primary antibody details).
Membranes were washed five times in wash buffer (PBS, 0.1% (v/v)/ Tween-20) for
5 min at room temperature and incubated with the relevant horseradish peroxidase
(HRP)-conjugated secondary antibody for 45 min at room temperature on a shaker,
followed finally five times in wash buffer for 5 min at room temperature.
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(vii) Enhanced chemiluminescence detection
To detect bound antibody, membranes were incubated with a minimal volume of
enhanced chemiluminescence (ECL) detection reagent (Amersham Biotech, Ltd.) for
1 min at room temperature. Excess reagent was drained off the membranes which
were then wrapped in cling-film, placed in a cassette and exposed to X-ray film for
varying amounts of time (30 sec-20 min) depending on signal strength.
(viii) Densitometry Analysis
X-ray films were scanned using ' Colour It' scanning software. Densitometry was
performed using 'Scan Analysis' software whereby grey levels of positive protein
bands and background grey levels were quantitatively measured. Where possible, the
grey levels of the protein of interest were normalised against GAPDH levels.
While quantitative measurement of the levels of protein expression was carefully
made by ECL film image densitometry (and compared to GAPDH expression) the
relationship between this and protein concentration is not necessarily strictly linear
so values should formally be considered as a comparative estimate of protein levels.
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Table 2.2 Antibodies used for Western blots and immunoprecipitations of
spinal cord (Chapter 3)
This table provides a brief summary of the antibodies used for Western blotting and
immunoprecipitation experiments specific to Chapter 3, stating specific primary
antibody details and dilutions as well as secondary antibody details and dilutions.
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Primary antibody Dilution Secondary antibody Dilution
Polyclonal anti-GluRl























































Table 2.3 Antibodies used for Western blots and immunoprecipitations of
spinal cord (Chapter 4)
This table provides a brief summary of the antibodies used for Western blotting and
immunoprecipitation experiments specific to Chapter 4, stating specific primary
antibody details and dilutions as well as secondary antibody details and dilutions.
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Primary antibody Dilution Secondary antibody Dilution
Polyclonal anti-NR^l




(Santa Cruz Biotech) 1:100
Polyclonal anti-NRl
















































2.3: Methods specific to Chapter 3
2.3.1 In situ hybridisation histochemistry (ISHH)
Unless otherwise stated, all solutions were made up in dH20 that had been treated
with the nuclease inhibitor, DEPC. RNase contamination was minimised by using
sterile glassware, DEPC-treated dH20, and all surfaces were treated with RNase Zap
® (Sigma).
(i) Oligonucleotide Probes
Oligonucleotide probes for GluRl, GluR2, GRIP2, NSF and Narp mRNA were
designed on the basis of previous publications and/or confirmed by homology
screening with the Basic Local Alignment Search Tool (BLAST) online at the
National Centre for Biotechnology Information (NCB1). Probes were synthesised and
HPLC purified by Oswell Chemicals (University of Southampton) and each probe
was dissolved in 1ml of sterile water, at a given concentration (pg/ml). All probes
were aliquoted into 200pl samples and stored at -70°C until required. A summary of
all probes is given in table 2.4, showing the length and mRNA sequence site
complementary probes were designed against. Probe sequences can be seen in Figure
2.2.
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Table 2.4 Oligonucleotide probe details
Summary of oligonucleotide probes used against GluRl, GluR2, GRIP2, NSF and
Narp mRNA showing details of probe length, target sequence identification and
probe concentration. Probes were based on either the details of previous publications









GluRl 45 mer 1893-1937 780 Keinanen et al.
(1990)
X17184
GluR2 45 mer 2032-2076 795 Keinanen et al.
(1990)
M85035
GRIP2 39 mer 2148-2186 987 Bruckner et al.
(1999)
AF072509
NSF 45 mer 76-120 416 BLAST sequence
specificity
AF189019




Figure 2.2 Sequence and design of oligonucleotide probes
DNA sequence is shown in black from the 5' to the 3' region for each of GluRl and
GluR2 AMPA receptor subunits, as well as that for GRIP2, NSF and Narp. The
antisense oligonucleotide is shown in red and the complementary base probes were
highly selective for each target as determined by BLAST screening at NCBI. GluRl,
GluR2 and GR1P2 probes were based on previous publications (Keinanen et al.,
1990; Bruckner et al., 1999), while the probes for NSF and Narp were generated
using BLAST screening at NCBI, with high selectivity for NSF and Narp mRNA.
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GIuRl (45 mer) mRNA; nucleotides 1893-1937 (Keinanen et al. 1990)
5'cacagcga agagtttgaa gagggacgag accagacaac cagtgac3'
3 gtcactgg ttgtctggtc tcgtccctct tcaaactctt cgctgtg5
GluR2 (45 mer) mRNA; nucleotides 2032-2076 (Keinanen et al., 1990)
5 cacactgag gaatttgaag atggaagaga aacacaaagt agtgaa3'
3'ttcactact ttgtgtttct cttccatctt caaattcctc agtgtg5'
GRIP2 (39 mer) mRNA; nucleotides 2148-2186 (Bruckner et al., 1999)
5 cac catctccggt acagaggaac cttttgaccc catcat 3'
3 atg atggggtcaa aaggttcctc tgtaccagag atggtg 5"
NSF (45 mer) mRNA; nucleotides 76-120
5' gaacg aaaaggatta ccagtctggc cagcatgtga tggtgaggac 3'
3' gtcct caccatcaca tgctggccag actggtaatc cttttcgttc 5
Narp (48 mer) mRNA; nucleotides 671-717
5' gaagacgaga agtccctgct ccacaatgag acctcggctc accggcag3'
3' ctgccggtga gccgaggtct cattgtggag cagggacttc tcgtcttc 5'
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(ii) Tissue preparation
Neuropathic rats at the peak of behavioural reflex sensitivity and sham and age-
matched controls (n=4 for each condition) were anaesthetised with a gaseous mixture
of halothane and Cb, a laminectomy (L3-6) was performed, and the fresh spinal cord
tissue was snap frozen in isopentane (-40 to -45°C) and mounted vertically (rostral
end down) on a cryostat chuck with mounting medium (OCT, BDH, UK) and
orientation for the ipsilateral side was noted. 10pm thick frozen transverse cryostat
sections were taken and maintained at -18°C using a Cryotechnics Bright cryostat
and thaw-mounted onto Polylysine ® microscope slides (BDH, UK). Tissue was
stored at -70°C.
(Hi) Probe labelling
All probes were labelled with deoxyadenosine a[35S]-triphosphate ([35S-dATP],
specific activity <1250 Ci/mol; NEN Dupont) at their 3' ends using recombinant
terminal deoxynucleotidyl transferase (rTdT) to yield a specific activity of
approximately 2xl06 cpm per sample in lOOpl of hybridisation buffer. The reaction
was carried out for 90 min at 37°C in an autoclaved eppendorf tube containing the
following: x pi of the appropriate oligonucleotide probe (calculated to ensure 3x
more pmol [35S]-dATP than oligonucleotide), lOpl of potassium cacodylate tailing
buffer (TdT buffer), 4pl rTdT enzyme (15 units/pl), 4pl [35S]-dATP (70pmol; 1.5-2
x 10 Ci/mmol) made up to a final volume of 40pl DEPC H20. Prior to incubation the
mixture was vortexed briefly then spun down (13,000 x g, 3 min). Following the
-5 ^
initial incubation period, a further 2pl of [ S]-dATP and 2pl of rTdT enzyme were
added to the reaction mixture to optimise conditions, vortexed and incubated for a
further 30 min after which the reaction was stopped by cooling on ice for 15 min. 2 x
1 pi of pre-spun samples were taken.
The resultant labelled probe was separated from incorporated nucleotides by
purification through a Nu-Clean D25 (Sepharose) disposable spun column and
centrifuged for 4 min at 4,000 x g. Duplicate aliquots (2x1 pi) of the pre- and post-
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spun mixture were P-emission counted by liquid scintillation in 1ml of Optiphase
scintillation cocktail to calculate the specific activity and percentage incorporation of
radioactivity (all probes showed between 50-65% incorporation). The labelled probe
was then stored at -70°C until required (for a maximum of 14 days).
(iv) Post-fixing
Slides were brought to room temperature and immediately fixed in 4%
paraformaldehyde in PBS (0.1 M; pH 7.4) for 10 min, then rinsed in two washes of
fresh PBS (0.1 M; pH 7.4) for 5 min each. Non-specific binding of the probe to the
glass and tissue was reduced by treating the slides for 10 min in ethanolamine
solution (0.1M TEA and 0.026M acetic anhydride). Subsequently, the sections were
dehydrated through increasing concentrations of ethanol (50%, 70%, 80%, 90% and
100%), each buffered with ammonium acetate (0.3M) for 2 min each, with a final 2
min stage in 100% unbuffered ethanol. Slides were thoroughly dried for 1-2 hr prior
to hybridisation.
(v) Hybridisation
Previously prepared stock solutions of hybridisation buffer and de-ionised
formamide (stored at -20°C) were brought to room temperature, then aliquoted
together to obtain a lx hybridisation buffer/40% de-ionised formamide solution:
dextran sulphate (10%; w/v), sodium chloride (600mM), Tris pH 7.6 (lOmM), EDTA
(ImM). Dcnhardt's solution (0.1%; w/v), salmon spenn DNA (0.01%; w/v), Baker's
yeast tRNA (0.005%; w/v) glycogen (0.0005%; w/v) and formamide (40%; w/v).
The radiolabeled probes were then added in a volume that gave a final count number
of 2 x 106cpm/l OOpl hybridisation buffer. The resulting hybridisation mixture was
heated to 60-70°C for 10 min, and then subsequently cooled on ice for 1 min before
the reducing agent, dithiothreitol (DTT; 1 OmM), was added. This helped to protect
the [35S]-dATP from oxidation and ensured that the probe remained in a single-
stranded state even after the solution had been cooled. 100pl of this final solution
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was then carefully pipetted onto slides and a DEPC-treated coverslip was lowered
gently onto the solution. Hybridisation was carried out in sealed containers
containing 2 sheets of Whatman (No. 1) filter paper saturated with a solution of 50%
de-ionised formamide: 50% 4x Standard saline citrate (SSC) solution, at 37°C for 18
hr.
(vi) Post-hybridisation washes
Following the overnight incubation, the coverslips were removed, slides were placed
into racks and washed in decreasing concentrations of SSC solutions (2xSSC;
1 xSSC; 0.5xSSC; pH 7) at 40°C for 2 hr each, to remove any excess hybridisation
buffer solution and any non-specifically bound probe, and dehydrated through
ascending concentrations of ethanol buffered with 0.3M ammonium acetate (50%,
70%, 80%, 90%, 100%) for 2 min each and lastly in 100% absolute ethanol for 2
min, before being left to air dry overnight. Slides were exposed to Hyperfilm P-max
in a dark room and left to develop in a sealed autoradiographic cassette with
intensifying screen for approximately 10 days at 4°C. The film was then developed
using a standard X-ray Film developing machine (X-Omatic, MRC Membrane and
Adapter Proteins Co-Op, Division of Biomedical and Clinical Laboratory Sciences,
Edinburgh). The intensity of the latent image was used as an indicator for the length
of slide exposure to autoradiographic emulsion that was required prior to final
developing.
(vii) Emulsion coating
Under darkroom conditions, the dried slides were dipped in 20ml (1:10 diluted with
dH20) of llford K5 liquid autoradiographic emulsion at 43°C for approximately 5
seconds, blotted lightly then left to dry in an upright position overnight in the dark
before being sealed in light-tight Kartell boxes containing silica gel desiccant,
wrapped in black plastic and stored at 4°C for 6-12 weeks, depending on the
intensity of the autoradiographic image developed previously.
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(viii) Developing and staining
Following the assigned exposure time, slides were brought to room temperature, and
the exposed silver grains were developed under safe-light conditions at 15°C in
Kodak D-19 developer for 4 min, rinsed in distilled water for 30 sec, then fixed in
Ilford Hypam K5 fixer (diluted 1:5 (v/v) with distilled water) for 5 min. All traces of
fixer were removed with excess washing in dH20. Slides were lightly counter-
stained with Mayer's haematoxylin (4 min) and 5% eosin (2-3 sec), with distilled
water washes between each stain, before being dehydrated through 50%, 70%, 90%
and 100% ethanol (2 min each). The slides were then placed in fresh xylene solution
(2 min) and finally mounted in DePeX mounting medium.
(ix) Controls
Data for each rat were obtained from a number of parallel assays to minimise
experimental variation, whereby hybridisations using coronal brain sections (where
expression for each probe has been documented) acted as positive controls to verify
the sensitivity of the ISHH methodology. Controls used to demonstrate specificity of
the respective oligonucleotide consisted of (1) pre-treating sections with RNase A (1
mg/ml; Sigma, Poole, UK) for 1 hr prior to hybridisation and (2) co-incubation of the




The number of cells positively hybridised for each probe within lateral and
mediolateral locations of laminae I-V was calculated at x40 magnification (total grid
area 175 x 175 pm). Cells were considered to be positively labelled if the silver
grains showed a dense pattern around the nucleus and were 5-fold denser than a
typical non-expressing cell within the same field area or background levels. The total
number of positively hybridised cells was determined for each spinal cord section,
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(n=5 sections) and these values were used to calculate the mean number of positively
hybridised cells per unit area in the lumbar spinal segments L3-6 (neuropathic, n=4;
sham-operated, n=4; naive, n=4).
-Silver grain density
To assess any changes in the relative expression of mRNA following chronic
constriction injury, the mean silver grain density per positively labelled cell was
measured using 'Image 1.44' software (Improvision, U.K.) with video input from a
CCD camera (Sony, Japan) mounted on a Zeiss Axioscope microscope (x40
magnification). For each section, counts were made both ipsilateral and contralateral
to the nerve injury in lateral and mediolateral zones. A minimum of five positively
hybridised cells was counted in each region and a pixel count was obtained, which
was converted to a silver grain number via a pre-determined calibration procedure.
The mean number of silver grains per cell was calculated for each section (n=5
sections) and was compared using a Student's t-test.
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2.3.2 Immunoprecipitation of the AMPA receptor subunits
Due to resultant smaller samples achieved with immunoprecipitation, the
PhastSystem was used for all immunopreeipitations, as it requires less sample
loading. Immunoprecipitation (IP) was achieved using a method adapted from
Schopperle et al. (1998).
(i) Tissue preparation
A laminectomy was performed on anaesthetised rats and the spinal cord was
hemisected to separate contralateral from ipsilateral sides following CCI or following
the application of AMPA (50pM) or saline vehicle, that were applied in a volume of
500pl for 15 min before rapid removal to cold buffer on ice. This was then
immediately gently homogenised in a hand-held homogeniser containing freshly
prepared 2.0ml IP buffer (PBS pH 7.5, 1% CHAPS, 0.75% sodium deoxycholate,
2pg/ml aprotinin, 4pg/ml leupeptin, ImM AEBSF, 2pg/ml pepstatin, ImM vanadate,
ImM sodium tluoride, 5mM sodium molybdate and soya bean trypsin inhibitor
(50pg/ml)). The homogenate was transferred into eppendorf tubes and incubated
(with rolling) at 4°C for 1 hr. The samples were then centrifuged at 12,000 x g for
15min at 4°C to remove particulate material.
(ii) Protein estimation
The bicinchoninic acid (BCA) Protein Assay Reagent Kit (Pierce) was used to quantify
protein concentrations between samples. This is based on the affinity of BCA for Cu2+,
produced by protein reacting with Cu2+ in an alkaline medium. The reaction produces a
purple precipitate that exhibits absorbance at 540nm and was carried out in MaxiSorb
96-well microtitre plates (NUNC). Aliquots of 200pl of the reaction mix were added to
the wells followed by the addition of lOpl of sample, according to manufacturer's
supplied protocol. Absorhance at 540nm was measured using a SpectraMax 250
microtitre plate reader. Known concentrations of bovine serum albumin were used to
create a standard curve, and the average protein concentration was calculated from this.
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(iii) Immunoprecipitation ofGluR2
Supernatants were pre-cleared with Protein G-Sepharose 4B fast flow (Sigma-Aldrich
Co Ltd, UK) (20pl/ml) (1:1 beads:IP buffer) for 45 min at 4°C. The following two
controls were processed in parallel: (1) IP buffer replaced the sample supernatant and
(2) the GluR2 antibody was replaced with normal immune mouse serum. After a pulse
spin to concentrate the beads (Eppendorf micro fuge, 10 sec, 13, 000 x g) the
supernat ant was removed to another Eppendorf tube containing a mouse monoclonal
GluR2 antibody (0.5pg/ml diluted to 1:50) (BD, UK). The antibody and Protein G-
Sepharose (1:1) 40pl/ml were pre-incubated together ~1 hr before addition of
supernatant and the mix left overnight (with rolling) at 4°C. The beads were pulse spun,
washed once in IP buffer and twice in PBS before 40pl of x2 Laemmli buffer was
added per ml of original supernatant. Western blots were performed on the resulting
samples to detect immunoprecipitated and co-immunoprecipitated proteins.
(iv) Immunoblottingfor GIuR2-interacting proteins
The IP pellets previously resuspended in 2x Laemmli buffer (2% sodium dodecyl
sulphate (SDS), 20 mM Tris, 5% mercaptoethanol) were boiled for 5 min. SDS-
PAGE was carried out on pre-cast 7.5% SDS polyacrylamide gels followed by
electroblotting on to polyvinylidene fluoride membrane (ImmobilonPSQ), (Millipore
UK Ltd.) using the PhastSystem (Amersham Biotech, Ltd.). Before immunoblotting
was carried out, blots were temporarily stained with PhastGel Blue R (Amersham
Biotech UK Ltd) to check that protein loading of the lanes was even.
The blots were blocked with 5% Marvel in PBS to reduce non-specific background.
Immuno-detection was carried out as described previously (Johnson et al., 2000)
using a rabbit polyclonal antibody to GluR2 or GluRl receptor (0.1 pl/ml diluted to
1:100; Chemicon International Ltd.) followed by pre-absorbed HRP-conjugated anti-
rabbit secondary antibody (Chemicon International Ltd.). Visualisation of antibody
bands was carried out using Luminol (NEB, UK Ltd.) followed by exposure of the
blots to ECL film (Amersham Biotech UK Ltd.).
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For GluR2 immunoprecipitations, the blots were stripped ("Re-Blot" reagent,
Chemicon International Ltd.) and re-probed with either a mouse monoclonal
antibody to GRIP (250pg/ml diluted 1:500; Transduction Labs, UK Ltd.) or a rabbit
polyclonal antibody to PICK1 (200pg/m diluted 1:75; Santa Cruz Biotechnology
Inc.).
(v) Immnnoprecipitation forphospho-GluRl
Hemisected spinal cords from rats at the peak of neuropathic behavioural sensitivity
were homogenised at 4HC in 20mM Na Hepes, pH 7.5, with 5% glycerol, ImM
EGTA, ImM DTT, ImM AEBSF, 2pg/ml aproptinin, lOpg/ml leupeptin, 2pg/ml
pepstatin, 50pg/ml SBTI, 25mM Na ^-glycerophosphate, ImM Na-orthovanadate,
ImM NaF, 1 pM calyculin A, lpM cypermethrin. The extract (0.5 ml) was incubated
for 1 hr on ice and clarified by centrifugation at 13, 000 x g for 1 hr at 4°C. The
clarified supernatant was incubated for 4 hr at 4°C with 3.5 pg/ml of rabbit anti-
GluRl IgG, (UBI) before precipitation with Protein G Sepharose CL-4B (15pl) and
the samples were kept under constant agitation overnight at 4°C. Samples were
washed five times with 0.5 ml cold extraction buffer before solubilisation in
Laemmli buffer. Protein samples were subjected to reducing SDS-PAGE and
transferred to PVDF membrane at 4°C for 90 min at 75 V in 10% (v/v) methanol, 10
mM CAPS pH 11.0. Blots were probed with pan-GluRl (UBI, 1:100), phospho-
Ser83l-GluRl and phospho-Ser845-GluRl antibodies (UBI, 1:100). Signal detection
was carried out using a pre-absorbed rabbit HRP-conjugate (1:5,000, Chemicon)
secondary antibody enhanced chemiluminescence.
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2.4: Methods specific to Chapter 4
2.4.1 (3-galactosidase staining in heterozygous PSD-95 mutant mice
(i) Perfusion
Heterozygous PSD-95 mutant mice (n=3, naive) were deeply anaesthetised with
halothane until breathing had ceased but cardiovascular function was still evident.
An incision into the thoracic cavity was made, the heart was exposed and a 25.1G
needle was inserted transcardially. Initially, heparinised saline (0.9% NaCl/ 0.25%
(v/v) heparin) was infused before perfusion with 4% paraformaldehyde in 0.1 M PBS
for 5min. A laminectomy was performed and the spinal cord, DRG, sciatic nerve and
brain were dissected out and placed in ascending concentrations of sucrose in PBS at
4°C (5%, 30min; 10%, 2 hr; 25%, overnight). Following snap freezing in isopentane
at -40°C, tissue samples were mounted on a cryostat chuck (spinal cord mounted
vertically with rostral end down or in longitudinal orientation, and transverse
sections for all other tissues) and embedded in OCT (BDH). 10pm thick cryostat
sections were cut at -22°C, thaw mounted onto Polylysine ® microscope slides and









0.05% (w/v) potassium ferrocyanide
0.05% (w/v) potassium ferricyanide
0.01% (w/v) X-Gal in DMF
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(Hi) Tissue staining
Slides were placed in small plastic slide holders (10ml capacity) to minimise reagent
usage and 7ml of the detergent wash was gently pipetted onto the back end of the
slides and placed on ice for 15 min. The excess was poured off and the wash was
repeated (3x 15 min). Sections were then rinsed with 0.1M PBS/2mM MgC^ for 10
min at 4°C. This was poured off and 7ml of the stain solution was added and slides
were incubated in the dark at 37°C for 4-6 hr. Slides were then washed with 0.1M
PBS/2mM MgCl2 at room temperature (2x5 min), dH20 (10 min), dehydrated in 50,
70, 100% of ethanol for 5 min each, placed in xylene (2x5 min) and coverslipped
with Pertex. Slides were stored under darkroom conditions before viewing under a
microscope.
(iv) Light microscopy
Positively stained sections were viewed under a Zeiss Axioscope microscope at x40
magnification to qualitatively determine the presence and location of |3-galactosidase
positive regions and photographs were taken.
2.4.2 Molecular composition of NMDA receptor complexes in spinal cord
To detennine the presence of a basic PSD-95: NMDA receptor complex in the spinal
cord, a laminectomy was performed on deeply anaesthetised wild-type mice (n=4)
and whole spinal cord was homogenised at 4°C in 50 mM Tris pH 9.0, with 1% Na
deoxycholate, 50 mM NaF, 20pM ZnCl2, ImM Na-orthovanadate, 0.5 mM PMSF, 2
pg/ml aprotinin and 2 pg/ml leupeptin. The extract (0.5 ml) was incubated for 1 hr
on ice and clarified by centrifugation at 13, 000 x g for 1 hr at 4°C. As described
previously (Husi et al., 2000), MAP-NR1 IgG, PSD-95 IgG, NR2A IgG or NR2B
IgG were incubated with extract for 4 hr at 4°C. Protein G-Sepharose (15 pi) was
subsequently added and the samples were kept under constant agitation overnight at
4°C. Alternatively, an affinity reagent based on the C-terminal 6 amino acids of
NR2B (SIESDV; 'pep6', Flusi et al., 2000) was used directly. Samples were washed
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five times with 0.5 ml cold extraction buffer before solubilisation in Laemmli buffer.
Protein samples were subjected to reducing SDS-PAGE and transferred to PVDF
membrane at 4°C for 90 min at 75 V in 10% (v/v) methanol, 10 mM CAPS pH 11.0.
Primary antibodies used to probe blots were as described previously (Husi et al.,
2000) and signal detection was carried out using peroxidase-linked secondary
antibody enhanced chemi luminescence.
2.4.3 Light microscopy to examine myelinated fibres in the sciatic nerve
(i) Perfusion
PSD-95 mutant mice and matched wild-type littermates (n=3, naive; n=3 CCI, in
each case) were deeply anaesthetised with Sagatal (dose) and perfused transcardially
initially with heparinised saline before being perfused with 4% paraformaldehyde in
0.1M PBS for 5 min (see section 2.4.1 (/)).
(ii) Analysis
1 pm resin-embedded transverse (Reichert Ultracut UCT ultramicrotome) sections of
the tibial branch distal to CCI were stained with toluidine blue and examined using
'
Image /.44' software (NIH). The cross-sectional area of the tibial nerve was
measured at x 100 magnification in 5 randomly generated regions on each nerve
section, which were chosen using a 4x4 grid. For analysis, 30 myelinated fibres
closest to the centre of the screen were selected and the axon areas, external areas,
and G ratios (axon diameter/ external diameter) were measured to quantify myelin
thickness (adapted from method used by Coggeshall et al., 1993; see Fig. 2.3).
2.4.4 Electron microscopy to examine unmyelinated fibres in the sciatic nerve
(i) Perfusion
PSD-95 mutant mice and matched wild-type littermates (n=3, naive; n= 3 CCI, in
each case) were deeply anaesthetised with halothane and perfused transcardially
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initially with heparinised saline, as above, before being perfused with 2.5%
gluteraldehyde, 2% paraformaldehyde, 0.1M Na+ cacodylate buffer, pH 7.3, ImM
CaCl2 for 5 min. Sciatic nerve distal to CCI was removed and fixed for 2 hr in the
same fixative, post-fixed in 0s04 and embedded in araldite. Ultra-thin 80nm
transverse sections were stained with uranyl acetate and lead citrate, mounted onto
copper slot grids and examined in a transmission electron microscope (Phillips
BioTwin Electron Microscope).
(ii) Analysis
25 random areas were photographed at x2300 magnification and then printed at a
final magnification of x5750, which was used to count all the myelinated and
unmyelinated fibres. For analysis, five negatives were chosen at random and scanned
using a flat bed scanner for computer analysis using 'Image 1.44' (see Fig. 2.3). The
axon diameters/areas of 30 unmyelinated C-fibres were measured from each of the
photomicrographs, the fibres being selected from clusters consisting solely of
unmyelinated fibres.
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Figure 2.3 Morphological analysis of the sciatic nerve
(a) Light microscopy analysis of myelinated fibres
(i) Shows the tibial branch of a toluidine-stained transverse section of the
sciatic nerve with a total area of 96058mm .
(ii) Illustrates the grid used for random and unbiased selection of regions of
the nerve to be analysed.
(iii) Computer-captured image of tibial nerve at x 100 (oil immersion)
magnification.
(iv) Image analysis threshold of the same region of nerve shown in (iii) from
which axon diameters, external diameters, and G ratios were measured.
(b) Electron microscopy analysis of unmyelinated C-fibres
(i) Photomicrograph selected for C-fibre cluster analysis.
(ii) Computer-generated threshold of the fibres represented in (i).
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2.4.5 Ex vivo CaMKII activity assays
Spinal cord tissue was rapidly homogenised in buffer with protease/phosphatase
inhibitors, solubilised with CHAPS and cleared prior to immunoprecipitation of
CaMKII with mouse monoclonal IgG/Protein G Sepharose. [33P] phosphotransferase
activity of immunoprecipitates was measured using autocamtide-2 as a substrate and
conventional separation by phosphocellulose binding. The protein content of the
original homogenate was determined by the Coomassie binding method (see section
2.3.2 (//)).
Following lumbar L3-6 laminectomy under anaesthesia, PSD-95 mutant (nai've, n=3;
CCI, n=4) and wild-type mice (nai've, n=3; CCI, n=4) were treated by topical
application of agents to the dorsal surface of the spinal cord. NMDA (500 pM) with
the co-agonist glycine (100 pM), ionomycin (10 pM), (R)-CPP (10 pM) or saline
vehicle were applied in a volume of 500pl for 15 min before rapid removal to cold
buffer on ice. Constitutive (autophosphorylated) and Ca2+/calmodulin-elicited
activity of CaMKII (Hanson et al., 1989; Jones and Persaud, 1998) were measured
by the following procedure. Samples were rapidly homogenised on ice in 20 mM Na
HEPES pH 7.5 with 5% glycerol, ImM EGTA, ImM dithiothreitol, ImM AEBSF
(4-(2-aminoethyl) benzene sulphonyl fluoride), 2 pg/mF1 aprotinin, 10 pg/ml
leupeptin, 2 pg/ml pepstatin, 50 pg/ml soybean trypsin inhibitor, 25 mM Na P-
glycerophosphate, ImM Na-orthovanadate, ImMNaF, 1 pM calyculin A, 1 pM
cypermethrin. Following a 30 min incubation on ice with 0.25% CHAPS (3-([3-
cholamidopropyl] dimethylammonio)-1 -propanesulphonate) and clarification,
samples were incubated at 4°C for 2 hr with 3 pg/ml mouse anti-a-CaMKII IgG
(clone CBa-2; Zymed) and then with excess Protein G-Sepharose for 1 hr. Aliquots
of washed immunoprecipitates were incubated for 20 min at 30°C (linear range of
assay) with 50 pM autocamtide-2, 50 pM ATP (with [33P]y-ATP to 0.25 pCi/tube),
10 mM MgC^ and 8 pg/ml purified bovine calmodulin, in the presence of 0.5 pM
PKC-CX19-3I and 0.5 pM PKI6-22 amide (to suppress any PKC and PKA-mediated
activity, respectively) before termination with cold TCA (to 10% w/v), centrifugation
and spotting of the supernatant onto P81 phospho-cellulose paper (Whatman).
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Samples were washed extensively in 75 mM H3PO4 and dried before scintillation
• • • • 2+ •
counting. Constitutive and maximal Ca -evoked activity was measured in the
absence and presence of 2 mM CaCh, respectively. Zero time and substrate-free
blanks were less than 2% of maximal activity. Parallel immunoblotting experiments
were attempted with phospho-specific antisera for Thr2X6-CaMKII (the key
autophosphorylation site), but gave insufficient signal: noise ratios for further use.
2.4.6 Immunoblotting for phospho-NRl
Spinal cord samples were initially homogenised in the buffer as for CaMKII assays
(without CHAPS) and a membrane fraction was prepared. This was solubilised in 1%
deoxycholate-containing buffer for 1 hr at 4°C and then the clarified supernatant was
incubated for 4 hr at 4°C with 3.5 pg/ml of goat anti-NRl IgG, (SC-1467, Santa
Cruz) before precipitation with Protein G-Sepharose CL-4B for 1 hr at 4°C. After
washing, bead-attached proteins were solubilised in Laemmli buffer prior to SDS-
PAGE separation and transfer on to Immobilon P (Millipore) membranes and
detection by peroxidase-linked secondary antibody enhanced chemiluminescence
(ECL).
Blots were probed with pan-NRl (Chemicon, 1:100), phospho-Ser897-NRl and
phospho-Ser8%-NRl antibodies (Upstate Biotech, 1:100). Mean relative phospho-
Ser897-NRl:pan-NRl immunoreactivity ratios were calculated in each case.
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CHAPTER 3: A role for the AMPA receptor and its interacting
proteins in neuropathic pain behaviour
3.1: Introduction
As mentioned in the general introduction, the AMPA receptor comprises four main
subunits, GluRl-4. The GluR2/3 subunits of AMPA receptors have received
particular attention due to the identification of a number of intracellular proteins
found to interact with the extreme intracellular C-terminus of these subunits to
provide a mechanism for clustering receptors in the plasma membrane and to direct
kinases and phosphatases to their sites of action (O'Brien, Lau and Huganir, 1998;
Scannevin and Huganir, 2000).
GluR2/3 subunits of AMPA receptor have a consensus PDZ binding motif (IESVKI)
in their extreme C-terminus which interacts with several proteins including GRIP1,
(Glutamate Receptor Interacting Protein 1) (Dong et al., 1997), ABP (AMPA
receptor Binding Protein) and its splice variant, ABP-L (also called GRIP2)
(Srivastava et al., 1998; Bruckner et al., 1999; Dong et al., 1999a; Wyszynski et al.,
1999) and PICK.1 (Protein Interacting with C Kinase 1) (Xia et al., 1999; Dev et al.,
1999). NSF (vV-ethylmaleimide-Sensitive Fusion protein) interacts with a different
site on the GluR2 C-terminus (VAKNAQ). These interacting proteins may be
involved in trafficking the receptor from the cell body to synapses, play a role in
AMPA receptor stabilisation at the synaptic plasma membrane and possibly link the
receptor to downstream signalling pathways (Torres et al., 1998; Ye et al., 2000).
The GluR2 C-terminal 5 residues represent the interaction site for GRIP, ABP and
PICK1 and are also thought to be essential for AMPA receptor stabilisation at the
synaptic plasma membrane (see Fig. 3.1 for summary).
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3.1.1 Glutamate receptor interacting protein (GRIP) family
The first protein described to interact with AMPA receptors was isolated in yeast 2-
hybrid screens by Dong et al. (1997) and named GRIP (Glutamate Receptor
Interacting Protein, now termed GRIP1) characterised as containing seven PDZ
domains. Several splice variants have since been identified and are known as ABP
(AMPA receptor Binding Protein), a shorter splice variant ofGRIP1 and ABP-
L/GRIP2 (hereafter referred to as GRIP2). There is a 68% homology between GRIP1
and GRIP2 (Wyszynski et al., 1999).
The 4th and 5th PDZ domains of GRIP1 and GRIP2 and the 4th 5th and 6th PDZ
domains of ABP interact with the consensus motif TESVKT specific to the GluR2/3
subunit C-termini. Although enriched in the PSD at synapses, a large proportion of
GRIP appears to be cytosolic (Wyszynski et al., 1998) and located in post-Golgi
vesicles suggesting that GRIP may be involved in AMPA receptor transport to the
plasma membrane and perhaps also its localisation in dendrites (Dong et al., 1999).
The interaction between GluR2 and GRIP is crucial for precise apposition of GluR2
at the postsynaptic membrane (Dong et al., 1997).
The splice variants of GRIP differ in their developmental regulation and expression
profiles. Although GRIP1 co-localises with AMPA receptors at excitatory synapses,
it has also been localised at synapses presynaptically positive for GAD (a marker of
GABAergic input) suggesting that GRIP may well have additional AMPA-
independent functions (Wyszynski et al., 1999). Both GRIP1 and GRIP2 are
expressed in the spinal cord but the precise localisation has not been documented and
GRIP2 is believed to be the predominant form expressed in adult nervous system
(Dong et al., 1999b; Bruckner et al., 1999).
3.1.2 PICK1
PKC phosphorylation of Serine residue 880 (IESVKI) in the GluR2 C-terminus
prevents GRIP binding and so is suggestive of a potential role for protein
phosphorylation in the regulation of the GluR2:GRIP interaction (Matsuda et al.,
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1999). Since AMPA receptors are regulated by PKC phosphorylation, PICK1, a PDZ
domain-containing protein that docks both GluR2/3-containing AMPA receptors and
PKCa, may mediate this regulation. PICK1, originally identified by its interaction
with PKCa, interacts with the same motif in the C-terminus of GluR2/3 as GRIP,
although the site of interaction of GluR2 and PKCa on PICK1 is different,
suggesting that P1CK1 can bind both GluR2 and PKCa at the same time (Xia et al.,
1999; Dev et al., 1999). PICK1 itself is an efficient substrate for PKC
phosphorylation both in vitro and in vivo and can induce GluR2 clustering on the
plasma membrane through interaction of the receptor C-terminus with the PDZ
domain of PICK 1 (Staudinger, Lu and Olsen, 1997).
PICK1 may function to localise activated PKCa to the plasma membrane and so
bring the kinase in proximity with specific substrates, including the AMPA receptor
(Staudinger, Lu and Olsen, 1997). Indeed, the co-expression of PICK1 and GluR2
results in both proteins being much more closely localised in their intracellular
distribution (Xia et al., 1999). PKC activation in neurones increases the
phosphorylation of Ser8X() on GluR2 and induces internalisation of the GluR2
subunits suggesting that the regulation of the GluR2 interaction with PDZ proteins
by phosphorylation may modulate surface expression of AMPA receptors during
synaptic plasticity (Chung et al., 2000). The presence and distribution of PICK1 in
spinal cord has not been specifically documented.
In addition to interacting with PDZ domain-containing proteins such as GRIP and
PICK1, the GluR2 subunit also interacts with proteins that do not have PDZ
domains, such as NSF (N-ethylmaleimide-Sensitive Fusion protein) and Narp
(Neuronal activity-regulated pentraxin).
3.1.3 A-ethylmaleimide-sensitive fusion protein (NSF)
NSF, a hexameric ATPase essential for various membrane fusion events, is enriched
in the PSD and can form a protein complex with the AMPA receptor GluR2 C-
terminus at a site distinct from the GRIP/ABP/PICK1 binding site (Osten et al.,
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1998; Song et al., 1998). The function of this interaction, given the established role
of NSF in vesicle cycling and fusion, may be in the insertion and/or stabilisation of
AMPA receptors at the postsynaptic membrane and such a role may be important for
surface expression of AMPA receptors in the postsynaptic membrane (Noel et al.,
1999). NSF is expressed in the spinal cord and DRG although precise localisation
has not been carried out (Piischel, O'Connor and Betz, 1994).
Infusion of an inhibitory peptide that blocks the NSF:GluR2 interaction in
hippocampal neurones reduces AMPA receptor current magnitude and abundance at
the synapse, and therefore the NSF binding region appears to be a functional domain
of the C-terminus involved in receptor trafficking and/or stabilisation at the synapse
(Song et al., 1998; Liithi et al., 1999). The NSF:GluR2 interaction appears to be
essential for the maintenance of stable synaptic excitatory currents in hippocampal
neurones (Nishimune et al., 1998; Song et al., 1998) as well as surface expression of
AMPA receptors (Noel et al., 1999).
3.1.4 Neuronal activity-regulated pentraxin (Narp)
Narp is an 1EG, its mRNA is enriched in the brain and, like other IEGs, it is activity-
regulated, and rapidly induced by seizure (Tsui et al., 1996; Reti and Baraban, 2000).
Narp is thought to be completely extracellular and so it is present both pre-and post-
synaptically. Although no direct interaction between Narp and the AMPA receptor
has so far been elucidated in detail, Narp has been found in GluRl, 2 and 3 co-
immunoprecipitations. Narp has no PDZ domains neither does it have access to the
intracellular domains of the AMPA receptor so it is likely to interact with
extracellular AMPA receptor domains. However, it is enriched at excitatory
glutamatergic synapses and is reported to induce AMPA receptor clustering (Fong
and Craig, 1999; O'Brien et al., 1999). Narp is expressed in the spinal cord, although
its precise localisation has not so far been documented, and it may contribute to the
clustering of GluRl subunits in cultured spinal neurones where 73% of GluRl
clusters have associated Narp immunostaining (O'Brien et al., 1999).
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3.1.5 GluRl interactions
All of the above interactions occur at the GluR2/3 C-terminus but recent evidence
suggests that the GluRl subunit of AMPA receptor can bind to a PDZ domain
containing protein known as SAP97 (Synapse Associated Protein 97), a member of
the MAGUK family of proteins (which will be discussed in more detail in Chapter
4). SAP97 binds to the extreme C-terminus of GluRl and does not appear to interact
with GluR2/3 (Leonard et al., 1998). AMPA receptor complexes (in brain) contain
SAP97 and SAP97 is closely associated with GluRl in the plasma membrane and
may be co-localised with AMPA receptors at postsynaptic sites (Leonard et al.,
1998). There is little functional information relating to this interaction so far, but
targeting of PKA to GluRl, which facilitates the phosphorylation of Ser845 in the
GluRl C-terminus, may occur via a SAP97: AKAP79/150 protein scaffold (Colledge
et al., 2000, see Section 3.1.6).
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Figure 3.1 Schematic representation of the GluRl and GluR2 adapter
proteins
This schematic diagram shows the AMPA receptor subunits GluRl and GluR2 in the
postsynaptic membrane. The C-terminus of the GluRl subunit binds to SAP97 via a
specific GluRl C-terminal peptide 'SGMPLGATGL' (although the PDZ domain of
SAP97 mediating this interaction is unknown). Narp, an extracellular protein, can
cause clustering of GluRl in particular, though a direct interaction between Narp and
AMPA receptors has not been shown.
The C-terminal sequence IESVKI interacts with GRIP via PDZ4 and PDZ5 domains
and with PICK1, via its single PDZ domain. NSF (a non-PDZ domain-containing
protein) also interacts near the GluR2 C-terminus at an internal site distinct from that




3.1.6 AM PA receptor phosphorylation
AMPA receptors are modulated by phosphorylation and this may play a role in the
expression of synaptic plasticity at central excitatory synapses. The GluRl subunit
phosphorylation sites have been identified (see below) and phosphorylation here may
alter single channel properties of the AMPA receptor or act to convert a non¬
conducting (silent) receptor channel to a conducting (active) one. An increase in the
2_j_
responsiveness of postsynaptic AMPA receptors subsequent to Ca influx has been
proposed to induce LTP (Lee et al., 2000) and AMPA receptor phosphorylation by
Ca2+-activated protein kinases is believed to play a pivotal role in LTP expression
(Lee et al., 2000).
The PKA (Ser845) and CaMKII/PKC (Ser831) phosphorylation sites located in the
intracellular C-terminal domain of GluR 1 have been identified (Roche et al., 1996;
Mammen et al., 1997). Phosphorylation of Ser831 by CaMKII potentiates GluRl
current (Derkach, Barria and Soderling, 1999) while PKA activity at Ser845 increases
AMPA responsiveness through a modulation of channel gating and channel open
probability without affecting channel conductance (Banke et al., 2000).
AMPA receptors are constitutively phosphorylated (and therefore potentiated) by
PKA owing to the specific targeting of PKA to the synapse by AKAP79/150
mediated by SAP97 (Rosenmund et al., 1994; Colledge et al., 2000). PKA
localisation is required for the modulation of AMPA/kainate currents and AKAP:
PKA interactions are important in the regulation of synaptically-activated AMPA
channels. PKA has been associated with both LTP and LTD (Lee et al., 2000) and its
phosphorylating activity increases when the kinase is targeted to the channel via a
SAP97: AKAP79/150 complex. A mutation in the PDZ binding site in the tail of
GluRl, which uncouples the receptor from SAP97, reduces the basal level of Ser845
phosphorylation. This is interesting given the recent evidence implicating a GluRl:
PDZ domain interaction in the delivery of AMPA receptors into synapses (Colledge
et al., 2000; Hayashi et al., 2000).
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While PICA has been implicated as underlying both LTD and LTP, CaMKIl
phosphorylation appears to be essential for the induction of LTP. LTP induction or
increased CaMKII activity induces delivery of AMPARs into synapses that is
thought to require the predicted PDZ domain interaction motif but is not dependent
on the GluRl CaMKII phosphorylation site, Ser831 (Hayashi et al., 2000).
To date, evidence for the functional significance of proteins interacting with the C-
terminus of GluR2 subunits is largely lacking. GluRl subunit phosphorylation has,
however, been implicated in synaptic plasticity in the hippocampus. Here, we
addressed the possibility that interactions of these adapter proteins with the GluR2
subunit and phosphorylation of the GluR 1 subunits may have a functional role in the
establishment and/or maintenance of neuropathic pain.
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3.2: Results
Chapter 2 (sections 2.2 and 2.3) contains the details of methods used in this chapter.
3.2.1 Intrathecal injection of AMPA receptor antagonists
The AMPA receptor is believed to play a role in both the acute and chronic
sensitisation following afferent nerve damage. To examine the question of a role for
the AMPA receptor in neuropathic pain conditions, we assessed the contribution of
spinal AMPA receptors to CCI-induced (see Section 2.2.2 and 2.2.3, pgs. 56-60)
changes in somatosensory behavioural reflexes by the local administration of the
AMPA receptor antagonists, NBQX (Fig. 3.2 and 3.3), NS-257 (Fig. 3.5 and 3.6) and
SYM 2206 (Fig. 3.8). Intrathecal injection of the AMPA/kainate receptor antagonist,
NBQX, and the highly selective AMPA receptor antagonists, NS-257 and SYM 2206
(see Section 2.2.4 for intrathecal injections and Table 2.1 for drug details, pgs 60-63)
in rats at the peak of behavioural reflex sensitivity attenuated the ipsilaterally
sensitised behavioural measures of thermal hyperalgesia (Fig. 3.2, 3.5 and 3.8a,
respectively). The AMPA receptor antagonists had similar but somewhat less marked
effects on mechanical allodynia following CCI. NBQX significantly alleviated
mechanical allodynia at all doses tested (Fig. 3.3), and the single dose of SYM 2206
had a similar affect (Fig. 3.8b). Intrathecal NS-257 significantly reversed the
ipsilateral mechanical allodynia for the two highest doses used (Fig. 3.6b and c).
These antagonists differentially attenuated thermal and mechanical neuropathic
reflexes, as all three antagonists had a significant though short lasting effect (-60
min) on thermal hyperalgesia while NBQX and SYM 2206 had a more pronounced
effect at alleviating mechanical allodynia than did NS-257. The effects were dose-
dependent, restricted to reflexes ipsilateral but not contralateral to nerve injury and
none of the drugs had any detectable effect in nai've animals (Fig. 3.4, 3.7, and 3.9).
At the highest doses used for NBQX and NS-257, there was variation in the baseline
contralateral withdrawal responses, possibly indicative of ventral horn AMPA
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receptors effecting motor co-ordination perhaps representing the possibility of side
effects at these higher doses. Intrathecal injection of saline vehicle had no
appreciable effect on thermal hyperalgesia or mechanical allodynia following CCI
(Fig. 3.1 Oa and b, respectively). These data indicate a key role for the AMPA
receptor in the CNS in mediating nociceptive transmission following peripheral
nerve damage.
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Figure 3.2 Effects of the intrathecal administration of the AMPA receptor
antagonist NBQX on thermal hyperalgesia in rats at the peak of
neuropathic reflex sensitivity
Data represent the average hindlimb withdrawal latency ± SEM to a noxious thermal
stimulus (n=6) for each time point following the intrathecal injection of 1.5nmol (a),
5nmol (b) or 13nmol (c) ofNBQX.
Rats at the peak of ipsilateral thermal hyperalgesia, as determined by a significant
reduction in ipsilateral paw withdrawal latency ('PWL') compared to contralateral
withdrawal latency (*, p<0.05, Student's t-test), were intrathecally injected with
NBQX (at arrow). 10 min following injection, 1.5nmol (a), 5nmol (b) or 13nmol (c)
of NBQX significantly attenuated ipsilateral thermal hyperalgesia in comparison to
pre-injection ipsilateral values (f, p<0.05, One-way ANOVA followed by a
Dunnetf s test), while there was no significant alteration in the pre-/post-injection
contralateral responses. The duration of the drug effect varied in a dose-dependent
manner, with 1.5nmol and 5nmol NBQX reversing the sensitisation of ipsilateral paw
withdrawal for 30-50 min, whereas 13nmol NBQX had significant effects for up to
80 min, although variations in the contralateral withdrawal latency (c) indicate
activation of ventral AMPA receptors which implies effects on motor co-ordination.
As the drug effect wore off, ipsilateral PWL returned to baseline withdrawal
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Figure 3.3 Effects of the intrathecal administration of the AMPA receptor
antagonist NBQX on mechanical allodynia in rats at the peak of
neuropathic reflex sensitivity
Data represent the average hindlimb withdrawal threshold ± SEM to a normally
innocuous mechanical stimulus (n=6) for each time point following the intrathecal
injection of 1,5nmol (a), 5nmol (b) or 13nmol (c) of NBQX.
Rats at the peak of ipsilateral mechanical allodynia, as determined by a significant
reduction in ipsilateral paw withdrawal threshold ('PWT') compared to contralateral
withdrawal threshold (*, p<0.05, Mann-Whitney Rank Sum test), were intrathecally
injected with NBQX (at arrow). 10 min following injection, 1.5nmol (a), 5nmol (b)
or 13nmol (c) of NBQX significantly attenuated ipsilateral mechanical allodynia in
comparison to pre-injection ipsilateral values (|, p<0.05, Kruskal-Wallis ANOVA
followed by a Dunn's test), while there was no significant alteration in the pre-/post-
injection contralateral responses. The duration of the drug effect was in the range of
45-50 min for all doses of NBQX tested. As the drug effect wore off, ipsilateral PWT
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Figure 3.4 Effects of the intrathecal administration of the AMPA receptor
antagonist NBQX in naive rats
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to mechanical (von Frey filament) stimuli ± SEM for each time
point in naive, untreated rats (n=5) following the intrathecal injection of 5nmol
NBQX.
There was no significant difference withdrawal latency (a) of either hindpaw in naive
rats when testing resumed 10 min following injection, except at the latest time points
at 55-60 min where there was a significant reduction in PWL in both left and right
hindpaws (t, p<0.05, One-way ANOVA followed by a Dunnett's test). The
intrathecal injection of NBQX (arrow) had no appreciable effect on the withdrawal
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Figure 3.5 Effects of the intrathecal administration of the selective AMPA
receptor antagonist NS-257 on thermal hyperalgesia in rats at the peak of
neuropathic reflex sensitivity
Data represent the average hindlimb withdrawal latency ± SEM to a noxious thermal
stimulus (n=6) for each time point following the intrathecal injection of 28nmol (a),
83nmol (b) or 166nmol (c) of NS-257.
Rats at the peak of ipsilateral thermal hyperalgesia, as determined by a significant
reduction in ipsilateral paw withdrawal latency ('PWL') compared to contralateral
withdrawal latency (*, p<0.05 Student's t-test), were intrathecally injected with NS-
257 (at arrow). 10 min following injection, 28nmol (a), 83nmol (b) or 166nmol (c) of
NS-257 significantly attenuated ipsilateral thermal hyperalgesia in comparison to
pre-injection ipsilateral values (f, p<0.05, One-way ANOVA followed by a
Dunnett's test), while there was no significant alteration in the pre/post-injection
contralateral responses. The duration of the drug effect varied in a dose-dependent
manner, with 28nmol and 83nmol NS-257 reversing the sensitisation of ipsilateral
paw withdrawal for 40-60 min, whereas 166nmol NS-257 had significant effects for
up to 85 min, although variations in the contralateral withdrawal latency (c) indicate
activation of ventral AMPA receptors which implies effects on motor co-ordination.
As the drug effect wore off, ipsilateral PWL returned to baseline withdrawal
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Figure 3.6 Effects of the intrathecal administration of the selective AMPA
receptor antagonist NS-257 on mechanical allodynia in rats at the peak of
neuropathic reflex sensitivity
Data represent the average hindlimb withdrawal threshold ± SEM to a normally
innocuous mechanical stimulus (n=6) for each time point following the intrathecal
injection of 28nmol (a), 83nmol (b) or 166nmol (c) of NS-257.
Rats at the peak of ipsilateral mechanical allodynia, as determined by a significant
reduction in ipsilateral paw withdrawal threshold ('PWT') compared to contralateral
withdrawal threshold (*, p<0.05, Mann-Whitney Rank Sum test), were intrathecally
injected with NS-257 (at arrow). 10 min following injection, 28nmol (a), 83nmol (b)
or 166nmol (c) of NS-257 significantly attenuated ipsilateral mechanical allodynia in
comparison to pre-injection ipsilateral values (t, p<0.05, Kruskal-Wallis ANOVA
followed by a Dunn's test), while there was no significant alteration in the pre-/post-
injection contralateral responses. The duration of the drug effect varied in a dose-
dependent manner, as both 28nmol and 83nmol NS-257 reversed ipsilateral
withdrawal only within the first 25-35 min, whereas 166nmol NS-257 had significant
effects for up to 50 min. As the drug effect wore off, ipsilateral PWT returned to
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Figure 3.7 Effects of the intrathecal administration of the selective AMPA
receptor antagonist NS-257 in nai've rats
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to mechanical (von Frey filament) stimuli ± SEM for each time
point in naive, untreated rats (n=5) following the intrathecal injection of 83nmol NS-
257.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) of either hindpaw in naive rats when testing resumed 10 min
following injection (Student's t-test and Mann-Whitney Rank Sum test,
respectively). The intrathecal injection of NS-257 (arrow) had no appreciable effect
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Figure 3.8 Effects of the intrathecal administration of the selective AMPA
receptor antagonist SYM 2206 on thermal hyperalgesia and mechanical
allodynia in rats at the peak of neuropathic reflex sensitivity
Data represent the average hindlimb withdrawal latency (a) and withdrawal threshold
(b) ± SEM to a noxious thermal or normally innocuous mechanical stimulus (n=6)
for each time point following the intrathecal injection of 1.5nmol SYM 2206.
Rats at the peak of ipsilateral thermal hyperalgesia, as determined by a significant
reduction in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05 Student's t-test)
or paw withdrawal threshold (b, 'PWT; *, p<0.05 Mann-Whitney Rank Sum test)
compared to contralateral withdrawal latency, were intrathecally injected with SYM
2206 (at arrow). 10 min following injection, 1.5nmol SYM 2206 significantly
attenuated ipsilateral thermal hyperalgesia in (a) in comparison to pre-injection
ipsilateral values (f, p<0.05, One-way ANOVA followed by a Dunnett's test) while
there was no significant alteration in the contralateral response. In (b), the
ipsilaterally reduced paw withdrawal threshold to mechanical stimulation was
significantly increased (f, p<0.05, Kruskal-Wallis ANOVA followed by a Dunn's
test) with no change in contralateral responses. The effect of SYM 2206 lasted for up
to 60 min for the thermal test and 40 min for the mechanical test before the ipsilateral















Figure 3.9 Effects of the intrathecal administration of the selective AMPA
receptor antagonist SYM 2206 in nai've rats
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to mechanical (von Frey filament) stimuli ± SEM for each time
point in naive, untreated rats (n=5) following the intrathecal injection of 1.5nmol
SYM 2206.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) of either hindpaw in naive rats when testing resumed 10 min
following injection (Student's t-test and Mann-Whitney Rank Sum test,
respectively). The intrathecal injection of SYM 2206 (arrow) had no appreciable
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Figure 3.10 Effects of the intrathecal administration of saline on thermal
hyperalgesia and mechanical allodynia in rats at the peak of neuropathic
reflex sensitivity
Data represent the average hindlimb withdrawal latency (a) and withdrawal threshold
(b) ± SEM to a noxious thermal or normally innocuous mechanical stimulus (n=6)
for each time following the intrathecal injection saline vehicle.
Rats at the peak of ipsilateral thermal hyperalgesia as determined by a significant
reduction in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05 Student's t-test)
or paw withdrawal threshold (b, 'PWT'; *, p<0.05 Mann-Whitney Rank Sum test)
compared to contralateral withdrawal latency were intrathecally injected with saline
(at arrow). Saline had no discernible effect on the withdrawal latency or the
withdrawal threshold in either hindlimb when testing resumed 10 min following
injection and there was no significant effect on hindlimb withdrawal post-injection
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3.2.2 Intrathecal injection of myristoylated C-terminal inhibitory peptides
As there is little in vivo functional evidence to date on the proteins that interact with
the C-termini of GluR2 and GluRl AMPA receptor subunits, we assessed the effects
of strategies designed to block the interactions of the GluR2 subunit with GRIP/
PICK1 or NSF, and also any effects of blocking the GluRl interaction with SAP97.
For this, we investigated the effects of the local application of myristoylated peptides
(see Section 2.2.2 and 2.2.3, pgs. 56-60), mimicking the site of the C-terminal
interaction site of each of these proteins, on CCI-induced changes (see Section 2.2.4
for intrathecal injections and Table 2.1 for drug details, pgs. 60-63).
Intrathecal injection of myr-NVYGIESVKI (to block the site of GRIP/ABP/PICK1
binding on the extreme GluR2/3 C-terminus) markedly alleviated previously
developed ipsilateral thermal hyperalgesia in rats following CCI for up to 50 min
following injection (Fig. 3.1 la), but had little effect on mechanical allodynia (Fig.
3.1 lb). No effects were seen on reflexes in na'ive rats (Fig. 3.12). The inhibitory
peptide blocking the NSF binding site, myr-AKRMKVAKNAQ, had a moderate
effect in attenuating the thermal hyperalgesic state for up to 35 min (Fig. 3.13a) but
had a much smaller and shorter lasting effect on the allodynic state (Fig. 3.13b). This
peptide had no detectable effects in naive rats (Fig. 3.14). In contrast, blocking the
SAP97 site on the GluRl C-terminus with the inhibitory peptide myr-
SGMPLGATGL, had a significant effect in the reversal of thermal hyperalgesia
lasting 55 min (Fig. 3.15a) but also had a clear effect on the reversal of the allodynic
behaviour for up to 60min following injection (Fig. 3.15b). This peptide had no
effect on thermal or mechanical reflex tests in naive animals (Fig. 3.16).
This suggests there may be a role for GluRl: SAP97 interactions in the maintenance
of mechanical allodynia, whereas the GluRl: SAP97 and the GluR2: GRIP/PICK1,
GluR2: NSF interactions may all contribute to the maintenance of thermal
hyperalgesia. Only myr-SGMPLGATGL had a significant effect on the contralateral
response while neither myr-NVYGIESVKI or myr-AKRMKVAKNAQ had any
significant effect on contralateral responses and none of the inhibitory peptides had
any significant effect when tested in na'ive rats (Fig. 3.12, 3.14 and 3.16). In addition,
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an inactive control myristoylated peptide (myr-GRRNAIHDE) had no effect on the
thermal hyperalgesia or mechanical allodynia following CCI (Fig. 3.17a and b).
These data indicate, for the first time, a functional in vivo role for the AMPA
receptor interacting proteins in persistent neuropathic pain. The functional effects
varied according to which part of the GluR2/3 C-terminus or the GluRl C-terminus
was blocked. No distinction was made here between GRIP, ABP and PICK1 which
all bind to the same motif in the GluR2/3 C-terminus.
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Figure 3.11 Effects of the intrathecal administration of the GluR2:
GRIP/PICK1 motif-directed myristoylated inhibitory peptide 'myr-
NVYGIESVKI' on thermal hyperalgesia and mechanical allodynia in rats
at the peak of neuropathic reflex sensitivity
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey filament stimuli ± SEM (n=6) for each time point
before and following the intrathecal injection of 4.5nmol myr-NVYGIESVKI.
Rats at the peak of ipsilateral thermal hyperalgesia, that displayed a significant
reduction in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05 Student's t-test)
or paw withdrawal threshold (b, 'PWT'; *, p<0.05 Mann-Whitney Rank Sum test)
compared to contralateral withdrawal latency, were intrathecally injected with myr-
NVYGIESVKI (at arrow). 15 min following injection, myr-NVYGIESVKI
significantly attenuated ipsilateral thermal hyperalgesia (a) in comparison to pre-
injection ipsilateral values (f, p<0.05, One-way ANOVA followed by a Dunnett's
test) while there was no significant alteration in the contralateral response. The effect
lasted for up to 50 min for the thermal test before the ipsilateral withdrawal returned
to pre-injection, baseline latencies (*, p<0.05 Student's t-test). In contrast, myr-
NVYGIESVKI had no significant effect on ipsilateral mechanical allodynia with
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Figure 3.12 Effects of the intrathecal administration of the selective GluR2:
GRIP/PICK1 motif-directed myristoylated inhibitory peptide 'myr-
NVYGIESVKI' in naive rats
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey fdament stimuli ± SEM in naive, untreated rats
(n=5) for each time point before and following the intrathecal injection 4.5nmol myr-
NVYGIESVKI.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) between hindpaws in naive rats (Student's t-test and Mann-Whitney
Rank Sum test, respectively). The intrathecal injection ofmyr-NVYGIESVKI
(arrow) had no effect on the withdrawal latency or the withdrawal threshold in either
hindlimb when testing resumed 10 min following injection, except at one time point
(t, p< 0.05, One-way ANOVA followed by a Dunnett's test and Kruskal-Wallis
ANOVA followed by a Dunn's test, respectively).
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Figure 3.13 Effects of the intrathecal administration of the GluR2: NSF motif-
directed myristoylated inhibitory peptide 'myr-AKRMKVAKNAQ' on
thermal hyperalgesia and mechanical allodynia in rats at the peak of
neuropathic reflex sensitivity
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey filament stimuli ± SEM (n=6) for each time point
before and following the intrathecal injection of 4.5nmol myr-AKRMKVAKNAQ.
Rats at the peak of ipsilateral thermal hyperalgesia, that displayed a significant
reduction in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05 Student's t-test)
or paw withdrawal threshold (b, 'PWT'; p<0.05 Mann-Whitney Rank Sum test)
compared to contralateral withdrawal latency, were intrathecally injected with myr-
AKRMKVAKNAQ (at arrow). 15 min following injection, myr-AKRMKVAKNAQ
significantly attenuated ipsilateral thermal hyperalgesia (a) in comparison to pre-
injection ipsilateral values (|, p<0.05, One-way ANOVA followed by a Dunnett's
test) while there was no significant alteration in the contralateral response. The effect
lasted for up to 35 min for the thermal test before the ipsilateral withdrawal returned
to pre-injection, baseline latencies (*, p<0.05 Student's t-test). In contrast, myr-
AKRMKVAKNAQ had a minimal effect on ipsilateral mechanical allodynia with
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Figure 3.14 Effects of the intrathecal administration of the GluR2: NSF motif-
directed myristoylated inhibitory peptide 'myr-AKRMKVAKNAQ' in
nai've rats
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey filament stimuli ± SEM in nai've, untreated rats
(n=5) for each time point before and following the intrathecal injection of 4.5nmol
myr-AKRMKVAKNAQ.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) between hindpaws in naive rats (Student's t-test and Mann-Whitney
Rank Sum test, respectively). The intrathecal injection of myr-AKRMKVAKNAQ
(arrow) had no effect on the withdrawal latency or the withdrawal threshold in either
hindlimb when testing resumed 10 min following injection (One-way ANOVA
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Figure 3.15 Effects of the intrathecal administration of the GluRl: SAP97
motif-directed myristoylated inhibitory peptide 'myr-SGMPLGATGL' on
thermal hyperalgesia and mechanical allodynia in rats at the peak of
neuropathic reflex sensitivity
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey filament stimuli ± SEM (n=6) for each time point
before and following the intrathecal injection of 4.5nmol myr-SGMPLGATGL.
Rats at the peak of ipsilateral thermal hyperalgesia displayed a significant reduction
in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05 Student's t-test) or paw
withdrawal threshold (b, 'PWT'; p<0.05 Mann-Whitney Rank Sum test) compared to
contralateral withdrawal latency were intrathecally injected with myr-
SGMPLGATGL (at arrow). 15 min following injection, myr-SGMPLGATGL
significantly attenuated ipsilateral thermal hyperalgesia (a) in comparison to pre-
injection ipsilateral values (f, p<0.05, One-way ANOVA followed by a Dunnetf s
test) although there was a significant reduction in the contralateral response in
comparison to baseline contralateral values (f, p<0.05, One-way ANOVA followed
by a Dunnetf s test). The effect lasted for up to 55 min for the thermal test before the
ipsilateral withdrawal returned to pre-injection, baseline latencies (*, p<0.05
Student's t-test). In (b), the ipsilaterally reduced paw withdrawal threshold to
mechanical stimulation was significantly increased (f, p<0.05, Kruskal-Wallis
ANOVA followed by a Dunn's test) following injection of myr-SGMPLGATGL
with no change in contralateral responses. The effect lasted for up to 60 min for the
mechanical test before the ipsilateral withdrawal returned to pre-injection, baseline
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Figure 3.16 Effects of the intrathecal administration of the GluRl: SAP97
motif-directed myristoylated inhibitory peptide 'myr-SGMPLGATGL in
naive rats
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey filament stimuli ± SEM in naive, untreated rats
(n=5) for each time point before and following the intrathecal injection of 4.5nmol
myr-SGMPLGATGL.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) between hindpaws in naive rats (Student's t-test and Mann-Whitney
Rank Sum test, respectively). The intrathecal injection of myr-SGMPLGATGL
(arrow) had no effect on the withdrawal latency or the withdrawal threshold in either
hindlimb (One-way ANOVA followed by a Dunnett's test and Kruskal-Wallis















10 20 30 40 50













20 30 40 50
Time post-injection (mins)
134
Figure 3.17 Effects of the intrathecal administration of an inactive
myristoylated control peptide 'myr-GRRNAIHDE' in rats at the peak of
neuropathic reflex sensitivity
Data represent the (a) average hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey filament stimuli ± SEM in nai've, untreated rats
(n=5) for each time point following the intrathecal injection of 4.5nmol of the
myristoylated control peptide.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) between hindpaws in nai've rats (Student's t-test and Mann-Whitney
Rank Sum test, respectively). The intrathecal injection of the myristoylated control
peptide (arrow) had no discernible effect on the withdrawal latency or the withdrawal
threshold in either hindlimb (One-way ANOVA followed by a Dunnett's test and
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3.2.3 In situ hybridisation histochemistry
The distribution of the AMPA receptors in the spinal cord has been previously
documented under normal conditions although there is little evidence for the
distribution following neuropathic pain conditions (Furuyama et al., 1993; Tolle et
al., 1993; Harris et al., 1996). Indeed, there is almost no evidence for the specific
localisation of GluR2 interacting proteins in the spinal cord and it was of interest to
determine whether there were any alterations in expression levels following the
establishment of neuropathic sensitivity. Here, we show an analysis of GluR2,
GRIP2, NSF, GluRl and Narp mRNA in the spinal cord following CCI (see Section
2.3.1, Table 2.4 and Fig. 2.2 for probe details, pgs. 71-80). No probe for PICK1 was
readily available, as the rat cDNA has not been cloned.
(i) GluR2
There was a high basal level of GluR2 mRNA expression in the spinal cord, in terms
of both the density of expression (Fig. 3.18a and b) and the number of expressing
cells (Table 3.1). These findings were similar in untreated and sham animals, and
were in agreement with previously published work (Furuyama et al., 1993; Tolle et
al., 1993). Labelled neurones were mostly located in the dorsal horn, particularly LI,
III-V with moderate expression in LII. Few labelled cells were found in the ventral
horn of the spinal cord or the white matter. Following CCI, ipsilateral to injury in the
spinal cord there was a significant increase in the levels of GluR2 mRNA in the
superficial dorsal horn laminae I and II at the sites of primary afferent termination,
both laterally and mediolaterally (Fig. 3.18a and b). The increase in mRNA was seen
for the density of labelling while there was no significant increase in the number of
cells expressing GluR2 mRNA (Table 3.1). A representative example of this increase
in LII neurones is shown photographically in Figure 3.19 (a) in comparison to
contralateral (Fig. 3.19b), sham-operated (Fig. 3.19c) and nai've (Fig. 3.19d) samples
from the same region. No marked alterations in expression levels were seen in the
lower laminae III-V or indeed in the ventral horn motoneurones (MNS). There was
little variation in GluR2 mRNA in expression between contralateral, sham-operated
or naive samples.
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Figure 3.18 In situ hybridisation measurement of GluR2 mRNA expression
per cell in the spinal cord following CCI compared to sham-operated and
naive rats
Data represent the mean density (± SEM) of silver grains per cell expressing GluR2
mRNA for the mediolateral (a) and lateral (b) dorsal horn laminae I-V (LI-V) and
motoneurones (MNS) ipsilateral and contralateral to CCI, compared to sham-
operated and naive animals (n=4 rats, 5 sections per condition for each rat).
Ipsilateral to CCI, there was a significant increase in the number of silver grains per
cell in LI and II in both mediolateral and lateral zones when compared to
contralateral levels (*, p<0.05 Student's t-test) and when compared to sham and
naive levels (|, p<0.05, One-way ANOVA followed by a Dunnett's test) There was
no significant variation in the number of silver grains per cell in the lower dorsal
horn laminae III-V or in motoneurones following CCI. For all laminae examined,
there was no significant difference in the relative expression of GluR2 mRNA when











Table 3.1 In situ hybridisation measurement of GluR2 mRNA expressing
cells in the spinal cord following CCI compared to sham-operated and naive
rats
Data represent the mean number of cells (± SEM) expressing GluR2 mRNA for the
mediolateral and lateral dorsal horn laminae I-V (LI-V) and motoneurones (MNS)
ipsilateral and contralateral to CCI, compared to sham-operated and naive animals
(n=4 rats, 5 sections per condition for each rat).
There was no significant alteration in the number of cells expressing GluR2 mRNA
ipsilateral to CCI when compared to the contralateral dorsal horn (Student's t-test).
For all laminae examined, there was no significant difference in the relative
expression of GluR2 mRNA when comparing the contralateral to sham or naive
































































Figure 3.19 Photomicrographs of GluR2 mRNA expression in lamina II of the
spinal cord of CCI, sham-operated and naive rats
High power light field photomicrographs showing in situ hybridisation identification
of GluR2 mRNA expression in the medial zone of the superficial dorsal horn at the
site of the most marked changes in lamina II ipsilateral to CCI (a). Corresponding
regions are shown contralateral to CCI (b), following sham operation (c) and in nai've
animals (d).
Scale bar = 10 pm
142
*L ' * <





Here, GRIP2 mRNA was examined as it is reported to be the predominant form in
adult nervous system (Bruckner et al., 1999) (see Section 2.3.1, Table 2.4 and Fig.
2.2 for probe details, pgs. 71-80). GRIP2 mRNA expression was readily detected
throughout the spinal cord, with slightly greater expression in the lower laminae III-
V in na'ive and sham-operated tissue and with motoneurones showing moderate
labelling (Fig. 3.20).
Following CCI, ipsilateral to injury in the spinal cord there was a significant increase
in the levels of GRIP2 mRNA in the superficial dorsal horn laminae I and II (at the
sites of primary afferent termination) mainly mediolateral in location (Fig. 3.20a).
There was an increase in the density of mRNA expression (Fig. 3.20) as well as an
increase in the number of cells expressing GRIP2 mRNA in LI and II with little
alteration in the lower laminae III-V (Table 3.2). A representative example of this
increase in GRIP2 mRNA expression ipsilateral to CCI in LII neurones is shown
photographically in Figure 3.21 as well as comparisons to corresponding regions
from contralateral CCI (Fig. 3.21b), sham-operated (Fig. 3.21c) and naive (Fig.
3.2Id) animals. Minimal alterations in expression levels were seen in the lower
laminae (III-V) or indeed in the ventral horn motoneurones (MNS). The level of
GRIP2 mRNA did not significantly differ between contralateral, sham-operated or
nai've animals.
(iii) NSF
Under basal conditions the expression of NSF appeared to be relatively low in the
superficial dorsal horn in comparison to that for GluR2 or GRIP2. The predominant
expression of NSF mRNA was found in LII-V, with motoneurones showing
moderate labelling (Fig. 3.22).
Following CCI, there was a small though significant decrease in the density of NSF
mRNA ipsilateral to injury in the lateral zone of the superficial dorsal horn (Fig.
3.22b), specifically in LI while there was no detectable alteration in the number of
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cells expressing NSF mRNA (Table 3.3). A representative example of this lateral LI
decrease in NSF mRNA is shown in Figure 3.23a in comparison to corresponding
samples from contralateral CCI (Fig. 3.23b), sham-operated (Fig. 3.23c) and naive
(Fig. 3.23d) animals. The level of NSF mRNA did not significantly differ between
contralateral, sham-operated or naive animals.
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Figure 3.20 In situ hybridisation measurement of the density of GRIP2
mRNA expression per cell in the spinal cord following CCI compared to
sham-operated and naive rats
Data represent the mean density of silver grains (± SEM) per cell expressing GRIP2
mRNA for the mediolateral (a) and lateral (b) dorsal horn laminae I-V (LI-V) and
motoneurones (MNS) ipsilateral and contralateral to CCI, compared to sham-
operated and naive animals (n=4 rats, 5 sections per condition for each rat).
Ipsilateral to CCI, there was a significant increase in the number of silver grains per
cell in LI and II in the mediolateral zone (a) and LII in the lateral zones when
compared to contralateral levels (*, p<0.05 Student's t-test) and when compared to
sham and naive levels (f, p<0.05, One-way ANOVA followed by a Dunnett's test).
There was no significant variation in the number of silver grains per cell in the lower
dorsal horn laminae III-V or in motoneurones following CCI. For all laminae
examined, there was no significant difference in the relative expression of GRIP2
mRNA when comparing the contralateral to sham or naive values, or when







Table 3.2 In situ hybridisation measurement of GRIP2 mRNA expressing
cells in the spinal cord following CCI compared to sham-operated and nai've
rats
Data represent the mean number of cells (± SEM) expressing GRIP2 mRNA for the
mediolateral and lateral dorsal horn laminae I-V (Ll-V) and motoneurones (MNS)
ipsilateral and contralateral to CCI, compared to sham-operated and naive samples
(n=4 rats, 5 sections per condition for each rat).
There was a significant increase in the number of cells expressing GRIP2 mRNA in
the mediolateral superficial dorsal horn LI and II ipsilateral to CCI when compared
to the contralateral dorsal horn (*, p<0.05, Student's t-test) and when ipsilateral
values were compared to sham and na'ive values (|, p<0.05, One-way ANOVA
followed by a Dunnett's test). For all laminae examined, there was no significant
difference in the relative expression of GRIP2 mRNA when comparing the
































































Figure 3.21 Photomicrographs of GRIP2 mRNA expression in lamina II of the
spinal cord of CCI, sham-operated and naive rats
High power light field photomicrographs showing in situ hybridisation identification
of GRIP2 mRNA in the medial zone of the superficial dorsal horn at the site of the
most significant changes in lamina II ipsilateral to CCI (a). Corresponding regions
are shown contralateral to CCI (b), following sham operation (c) and in naive
animals (d).
Scale bar = 10 pm
150
151
Figure 3.22 In situ hybridisation measurement of NSF mRNA expression per
cell in the spinal cord following CCI compared to sham-operated and naive
samples
Data represent the mean density (± SEM) of silver grains per cell expressing NSF
mRNA for the mediolateral (a) and lateral (b) dorsal horn laminae I-V (LI-V) and
motoneurones (MNS) ipsilateral and contralateral to CCI, compared to sham-
operated and naive animals (n=4 rats, 5 sections per condition for each rat).
Ipsilateral to CCI there was a significant decrease in the number of silver grains per
cell in LI and II in the lateral zone only (b) when compared to contralateral levels (*,
p<0.05 Student's t-test) and when compared to sham and naive levels (f, p<0.05,
One-way ANOVA followed by a Dunnett's test). There was no significant variation
in the number of silver grains per cell in the lower dorsal horn laminae III-V or in
motoneurones following CCI. For all laminae examined, there was no significant
difference in the relative expression of NSF mRNA when comparing the








Table 3.3 In situ hybridisation measurement of NSF mRNA expressing cells
in the spinal cord following CCI compared to sham-operated and nai've rats
Data represent the mean number of cells (± SEM) expressing NSF mRNA for the
mediolateral and lateral dorsal horn laminae I-V (LI-V) and motoneurones (MNS)
ipsilateral and contralateral to CCI, compared to sham-operated and naive samples
(n=4 rats, 5 sections per condition for each rat).
There was no significant alteration in the number of cells expressing NSF mRNA in
the mediolateral superficial dorsal horn LI and II ipsilateral to CCI when compared
to the contralateral dorsal horn (Student's t-test) or when compared to sham and
nai've levels (One-way ANOVA). For all laminae examined, there was no significant
difference in the relative expression of NSF mRNA when comparing the


































































Figure 3.23 Photomicrographs of NSF mRNA expression in lamina I of the
spinal cord of CCI, sham-operated and naive rats
High power light field photomicrographs showing in situ hybridisation identification
of NSF mRNA in the medial zone of the superficial dorsal horn at the site of the
most significant changes in lamina I ipsilateral to CCI (a). Corresponding regions are
shown contralateral to CCI (b), following sham operation (c) and in naive animals
(d).




The pattern of constitutive expression of GluRl mRNA under basal conditions
broadly matched that of previous reports (Tolle et ah, 1993, Harris et ah, 1996) with
high expression throughout the dorsal horn especially in LIII-V (Fig. 3.24, (see
Section 2.3.1, Table 2.4 and Fig. 2.2 for probe details, pgs. 71-80). There was a
slightly lower expression in the ventral horn compared to deep dorsal horn and few
labelled cells were found in the white matter. Following CCI, a decrease in the
density of GluRl mRNA ipsilateral to injury was seen specifically in the superficial
dorsal horn LI and II in both lateral and mediolateral zones (Fig. 3.24a and b,
respectively). In addition, there was a small but significant decrease in the number of
cells expressing GluRl mRNA in the ipsilateral superficial dorsal horn (Table 3.4).
A representative example of this lateral LII decrease in GluRlmRNA ipsilateral to
CCI is shown in Figure 3.25a in comparison to corresponding regions contralateral to
CCI (Fig. 3.25b), and in sham-operated (Fig. 3.25c) and naive (Fig. 3.25d) animals.
The level of GluRl mRNA did not significantly differ between contralateral, sham-
operated and naive animals.
(v) Narp
The constitutive level of Narp mRNA expression in the superficial dorsal horn LI
and II was low under normal conditions and was predominantly concentrated in
L1II/IV. Relatively low expression was observed in ventral horn, and motoneurones
were labelled. Ipsilateral to CCI injury, there was a marked increase in the expression
of Narp mRNA in the superficial dorsal horn laminae I and II in both mediolateral
and lateral zones (Fig. 3.26 a and b), with examples represented in Figure 3.27, while
there was no change in expression ofNarp mRNA in contralateral, sham-operated or
naive dorsal horn samples. The ipsilateral increase was seen in both the density of
Narp mRNA (Fig. 3.26) and in the number of cells expressing Narp mRNA (Table
3.5).
These data indicated a differential regulation of the AMPA receptor subunits GluRl
and GluR2 in the spinal cord following the establishment of neuropathy, as GluRl
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was apparently downregulated in the superficial dorsal horn, while GluR2 mRNA
levels increased. In addition, while NSF was diminished in the dorsal horn of the
spinal cord following CCI, there was a marked increase in the levels of GRIP and
Narp mRNA expression.
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Figure 3.24 In situ hybridisation measurement of GIuRl mRNA expression
per cell in the spinal cord following CCI compared to sham-operated and
naive rats
Data represent the mean density (± SEM) of silver grains per cell expressing GluRl
mRNA for the mediolateral (a) and lateral (b) dorsal hom laminae I-V (LI-V) and
motoneurones (MNS) ipsilateral and contralateral to CCI, compared to sham-
operated and naive animals (n=4 rats, 5 sections per condition for each rat).
Ipsilateral to CCI, there was a significant decrease in the number of silver grains per
cell in LI and II in the lateral zone only (b) when compared to contralateral levels (*,
p<0.05 Student's t-test) and when compared to sham and naive levels (f, p<0.05,
One-way ANOVA followed by a Dunnett's test). In addition there was a moderate
decrease in the number of silver grains per cell in LIII when compared to
contralateral values only (*, p<0.05, Student's t-test). There was no significant
variation in the number of silver grains per cell in the lower dorsal horn laminae IV-
V or in motoneurones following CCI (One-way ANOVA). For all laminae examined,
there was no significant difference in the relative expression of GluRl mRNA when
comparing the contralateral to sham or naive values, or when comparing sham to







Table 3.4 In situ hybridisation measurement of GluRl mRNA expressing
cells in the spinal cord following CCI and compared to sham-operated and
naive rats
Data represent the mean number of cells (± SEM) expressing GluRl mRNA for the
mediolateral and lateral dorsal horn laminae I-V (LI-V) and motoneurones (MNS)
ipsilateral and contralateral to CCI, compared to sham-operated and naive samples
(n=4 rats, 5 sections per condition for each rat).
There was a significant decrease in the number of cells expressing GluRl mRNA in
the mediolateral superficial dorsal horn LI and II ipsilateral to CCI when compared
to the contralateral dorsal horn (*, p<0.05, Student's t-test) and when compared to
sham and naive levels (t, p<0.05, One-way ANOVA followed by a Dunnett's test).
For all laminae examined, there was no significant difference in the relative
expression of GluRl mRNA when comparing the contralateral to sham or naive

































































Figure 3.25 Photomicrographs of GluRl mRNA expression in lamina II of the
spinal cord of CCI, sham-operated and naive rats
High power light field photomicrographs showing in situ hybridisation identification
of GluRl mRNA in the medial zone of the superficial dorsal horn at the site of the
most significant changes in lamina I ipsilateral to CCI (a). Corresponding regions are
shown contralateral to CCI (b), following sham operation (c) and in naive animals
(d).
Scale bar = 10 pm
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Figure 3.26 In situ hybridisation measurement of Narp mRNA expression per
cell in the spinal cord following CCI compared to sham-operated and naive
rats
Data represent the mean density (+ SEM) of silver grains per cell expressing Narp
mRNA for the mediolateral (a) and lateral (b) dorsal horn laminae I-V (LI-V) and
motoneurones (MNS) ipsilateral and contralateral to CCI, compared to sham-
operated and naive animals (n=4 rats, 5 sections per condition for each rat).
Ipsilateral to CCI, there was a significant increase in the number of silver grains per
cell in LI and II in both mediolateral and lateral zones when compared to
contralateral levels (*, p<0.05 Student's t-test) and when compared to sham and
naive levels (f, p<0.05, One-way ANOVA followed by a Dunnett's test). There was
no significant variation in the number of silver grains per cell in the lower dorsal
horn laminae III-V or in motoneurones following CCI (One-way ANOVA). For all
laminae examined, there was no significant difference in the relative expression of
Narp mRNA when comparing the contralateral to sham or naive values, or when







Table 3.5 In situ hybridisation measurement of Narp mRNA expressing
cells in the spinal cord following CCI compared to sham-operated and naive
rats
Data represent the mean number of cells (± SEM) expressing Narp mRNA for the
mediolateral and lateral dorsal horn laminae I-V (LI-V) and motoneurones (MNS)
ipsilateral and contralateral to CCI, compared to sham-operated and naive animals
(n=4 rats, 5 sections per condition for each rat).
There was a significant increase in the number of cells expressing Narp mRNA in the
mediolateral and lateral superficial dorsal hom LI and II ipsilateral to CCI when
compared to the contralateral dorsal horn (*, p<0.05, Student's t-test) and compared
to sham and naive levels (t, p<0.05, One-way ANOVA followed by a Dunnetf s
test). For all laminae examined, there was no significant difference in the relative
expression ofNarp mRNA when comparing the contralateral to sham or naive


































































Figure 3.27 Photomicrographs of Narp mRNA expression in lamina II of the
spinal cord of CCI, sham-operated and nai've rats
High power light field photomicrographs showing in situ hybridisation identification
of Narp mRNA expression in the medial zone of the superficial dorsal horn at the site
of the most marked changes in lamina II ipsilateral to CCI (a). Corresponding
regions are shown contralateral to CCI (b), following sham operation (c) and in naive
animals (d).
Scale bar =10 pm
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3.2.4 Immunoblotting for AMPA receptor and associated proteins
In order to further examine expression levels following CCI, semi-quantitative
protein analysis was carried out using Western blotting for GluR2, GRIP, NSF,
PICKl and SAP97 ipsilateral and contralateral to CCI injury and compared to sham-
operated and na'ive spinal cord levels (see Section 2.2.6 and antibody details in Table
2.2, pgs. 64-68). Expression levels were compared to that of GAPDH, a ubiquitous
and constitutively expressed housekeeping enzyme, the expression of which does not
change following peripheral nerve damage (see Chapter 2, section 2.2.6 (v)).
Spinal cord segments L4-6 were hemisected into ipsilateral and contralateral sides
for animals following CCI at the peak of neuropathy and sham and na'ive animals
were used as controls. We found that levels of GluR2 (Fig. 3.28 a, lane 1 'I') and
GRIP (Fig. 3.28b, lane 1 'I') were significantly increased in the spinal cord
ipsilateral to injury with little variation in protein levels between contralateral ('C'),
sham ('S') and naive ('N') samples. Blots were stripped and reprobed for GAPDH
(lower panels) to ensure equivalent sample loading (as was also confirmed by
Coomassie staining of proteins). These increases in protein levels of GluR2 and
GRIP are in agreement with our results of the mRNA by ISHH for these molecules
that also significantly increased ipsilateral to CCI (Fig. 3.18 and 3.20, respectively).
No significant difference was seen in the levels of either PICKl (Fig. 3.28c) or the
GluR 1-interacting protein, SAP97 (Fig. 3.29) under the same conditions. In contrast
to this, and in agreement with mRNA analysis for NSF (Fig. 3.22) levels of NSF
protein (Fig. 3.28d) were slightly decreased ipsilateral to injury (T) compared to
contralateral side and sham and normal controls. Again GAPDH served as an internal
control. These data indicate that while GluR2 and GRIP protein levels are increased
following peripheral nerve injury, there is a decrease in the overall levels of NSF
ipsilateral to injury, with no apparent change in PICKl or SAP97 protein.
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Figure 3.28 Western blot analysis of GluR2, GRIP, PICK1 and NSF in the
spinal cord following CCI compared to sham-operated and naive samples
Western blot analysis (n=3) of GluR2 (a), GRIP (b), PICK1 (c) and NSF (d) in spinal
cord lysate ipsilateral (T) and contralateral ('C) to CCI in comparison to sham-
operated ('S') and naive ('N') samples. The ubiquitous housekeeping enzyme
GAPDH was used as an internal control in each case (lower panels).
Densitometric analysis (e) indicated that there was a significant increase in the levels
of GluR2 and GRIP protein in the ipsilateral spinal cord when compared to the
contralateral side (*, p<0.05, Student's t-test), while there was no significant
difference in the levels of GluR2 or GRIP protein in the contralateral compared to
either sham or naive spinal cord extract. There was no significant change in the
levels of PICK 1 protein in response to CCI. A small though significant decrease in
the levels of NSF protein was seen ipsilateral to CCI when compared to the
contralateral spinal cord (*, p<0.05, Student's t-test) while there was no significant
difference in contralateral, sham or naive levels. The minor additional bands seen in
some samples, particularly with the NSF and GluR2 antibodies, were not consistent
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Densitometric analysis of the expression of GluR2 and GluR2-interacting






GluR2 55.8 ± 1.9* 41.6 + 2.9 43.2 + 2.9 43.5 ±3.4
GRIP 126.6 + 3.5* 98.9 ±3.1 96.4 ±2.5 97.8 ±3.8
PICK1 17.5 + 2.6 15.4 + 2.4 14.1 ±2.2 17.4 ±2.8
NSF 08.5 + 2.0* 11.2 + 1.8 12.4 ±6.5 14.3 ±4.5
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Figure 3.29 Western blot analysis of the GluRl-interacting protein SAP97 in
the spinal cord following CCI compared to sham-operated and nai've
samples
Western blot analysis of SAP97 (a) in spinal cord lysate ipsilateral (T) and
contralateral ('C) to CCI in comparison to sham-operated ('S') and nai've ('N')
samples. The ubiquitous housekeeping enzyme GAPDH was used as an internal
control (lower panels).
Densitometric analysis (b) indicated that there was no significant change in the levels
of SAP97 in response to CCI and there was no significant difference in contralateral,
sham or naive levels. The minor additional bands seen in some samples were not












Densitometric analysis of the expression of the GluR1-interacting protein






SAP97 41.2 ±4.3 40.3 ±3.9 37.7 ± 1.6 41.6 ± 4.6
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3.2.5 Direct association of GluR2 with GRIP and PICK1
In order to investigate direct association between GluR2 and GRIP and PICK1 in the
spinal cord, we carried out a pilot experiment (n=2) with GluR2
immunoprecipitations on spinal cord extracts solubilised under relatively mild
detergent conditions (see methodology in Section 2.3.2 and antibody details in Table
2.2, pgs. 67, 81-83). Extracts were immunoprecipitated with a pan-GluR2 antibody
(directed against an N-terminal epitope) before probing Western blots for levels of
the GluR2 C-terminus-interacting proteins GRIP and PICK1 (See Fig. 3.30).
Whereas ISSH and Western blot analysis of GRIP in whole lysate of spinal cord
following CCI showed an ipsilateral increase, the amount of GRIP associated with
GluR2 appeared to diminish bilaterally following CCI (Fig. 3.30b). Similarly, the
amount of PICK1 associated with GluR2 appeared to decrease after CCI, but in this
case selectively on the ipsilateral side (Fig. 3.30d). GluR2 was used in each case as
an internal control for GRIP and PICK1 (Fig. 3.30a and c, respectively). Since the
levels of GRIP and PICK1 immunoreactivity associated with these
immunoprecipitates were extremely low, a degree of caution is needed in the
interpretation of these results. We next examined the possibility that the amount of
GRIP and PICK1 present in the membrane fraction of the spinal cord (and thus
available to interact with GluR2 receptors) might be altered in response to the GluR2
activation that is likely to occur in CCI or other intense afferent stimulation (see
Section 3.2.6).
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Figure 3.30 Association of GRIP and PICK1 with GluR2 immunoprecipitates
from spinal cord of CCI and naive rats
Proteins were solubilised from spinal cord samples under mild detergent conditions
and immunoprecipitated for GluR2 using an N-terminally-directed antibody followed
by collection with Protein G-Sepharose. Following SDS-PAGE and transfer to
PVDF, membranes were probed for the presence of GRIP and PICK1
immunoreactivity and for GluR2, using an independent antibody from that used in
the immunoprecipitation.
(a) shows the levels of GluR2 in the GluR2-directed immunoprecipitates as a control
for (b) which shows that ipsilateral to CCI (T), there was an apparent decrease in the
amount of GRIP associated with the GluR2 receptor (see table, e) when compared to
the contralateral ('C') of nai've samples ('N'). Non-immune IgG ('NI IgG') or IP
buffer only (buffer) served as negative controls.
(c) shows the levels of GluR2 in the GluR2-directed immunoprecipitates as a control
for (d) which shows that, ipsilateral to CCI, there was also an apparent decrease in
the levels of PICK1 protein associated with the GluR2 subunit in the spinal cord ('I')
when compared to the contralateral ('C') or naive ('N') samples. Again, non-immune
IgG ('NI IgG') or IP buffer only (buffer) served as negative controls.
(e) Densitometric analysis of the association of GRIP/PICK1 with GluR2
immunoprecipitates. Data are expressed as the density grey scale of GRIP or PICK1
immunoreactive bands as a percentage of corresponding GluR2 immunoreactivity in
the same samples. Values are the means (with individual values in parentheses) from
















% Association of GRIP and PICK1 with GluR2 in GluR2 directed
membrane immunoprecipitations
GRIP PICK1
Ipsilateral CCI 20.0(15/25.0) 46.7 (48.5/44.8)
Contralateral CCI 21.6(24.7/18.4) 111.8(125.3/98.3)
Normal 98.6(116.5/80.7) 88.6(104.0/73.2)
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3.2.6 Alterations in the subcellular distribution of GRIP and PICK1 in spinal
cord following topical AMPA treatment
Given the apparent decrease in the levels of both GRIP and PICK1 associated with
the GluR2 subunit of AMPA receptor ipsilateral to CCI, we examined any alterations
in the proportion of GRIP and PICK1 at the membrane and in the cytosol in response
to AMPA receptor stimulation. Membrane and cytosolic preparations originating
from the same spinal cord homogenates were used to assess GRIP and PICK1
immunoreactivity (see Section 2.3.2 and antibody details in Table 2.2, pgs. 67, 82-
83). AMPA was topically administered to the dorsal surface of the spinal cord in
nai've, anaesthetised rats. In whole spinal cord lysate the levels of both GRIP and
PICK1 were similar in either saline or AMPA-treated animals (Fig. 3.31).
Interestingly, in membrane preparations, there was a significant decrease in the
amount of GRIP associated with the membrane after AMPA receptor stimulation
when compared to saline treatment, while there was little effect of AMPA receptor
stimulation on the levels of cytosolic GRIP (Fig. 3.31). A similar effect was found
for PICK1 protein levels, with a significant decrease in membrane-bound PICK1 in
response to spinal AMPA receptor stimulation with little alteration in cytosolic
PICK1 protein levels (Fig. 3.31).
So, under normal conditions, there appeared to be a similar membrane and cytosolic
content of both proteins in the spinal cord. However, following AMPA receptor
stimulation there was a significant movement of both GRIP and PICK1 from the
membrane to the cytosol. This may indicate that following excessive AMPA receptor
stimulation, such as following direct activation via agonist activity or following CCI,
GRIP and PICK1 may no longer be associated with GluR2, at least at membrane
sites in the postsynaptic density.
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Figure 3.31 Investigation of the translocation of GRIP and PICK1 from the
membrane to the cytosol following AMPA receptor activation in naive rats
Western blots for (a) GRIP and (b) PICK1 following topical application of either
AMPA (500pl of 50pM AMPA in saline) or saline vehicle to the dorsal surface of
the spinal cord. Whole spinal cord lysates showed no apparent difference in
expression levels of GRIP or PICK1 following either saline vehicle or AMPA topical
administration. Samples of the spinal cord homogenate from which the whole lysates
were prepared were centrifuged at 12, 000 x g for 30 min at 4°C to prepare
corresponding membrane and cytosolic fractions. Membrane preparations showed a
marked reduction in the content of GRIP and PICK1 following AMPA receptor
stimulation in comparison to saline vehicle treatment.
Cytosolic preparations showed similar levels of the content of both proteins
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3.2.7 Measurement of GluRl phosphorylation in response to CCI in GluRl
immunoprecipitates
AMPA receptors can be modulated by phosphorylation and specifically the AMPA
receptor interacting proteins' ability to bind to the receptor may be regulated by
kinases such as PKA, CaMKII and PKC. We have shown (Fig. 3.29) that the levels
of the GluRl-interacting protein SAP97 did not appear to be altered following CCI.
Nevertheless, SAP97 may function to bring PKA into close proximity with GluRl
via AKAP79/150 (Colledge et al., 2000) and thereby might potentially serve to
facilitate GluRl phosphorylation at the PKA. target site in The GluRl C-terminus,
Ser845. In order to assess whether the phosphorylation state of the GluRl subtype of
the AMPA receptor was altered following CCI, we utilised phospho-specific
831 845antibodies for key channel-regulating residues in GluRl at Ser and Ser (CaMKII
and PKA targets, respectively, see Section 2.3.2 and antibody details in Table 2.2,
Pgs 67, 83).
There was a consistent decrease in the levels of pan-GluR 1 immunoreactivity
ipsilateral to injury when compared to contralateral, sham or naive spinal cord (Fig.
3.32a (i) and b). In contrast, levels of phospho-Ser831-GluRl immunoreactivity
increased ipsilateral to injury when compared to contralateral, sham or naive spinal
cord (Fig. 3.32a (ii) and b). There were, however, no consistently detectable
alterations in the levels of phospho-Ser -GluRl immunoreactivity as a consequence
of CCI (Fig. 3.30b).
183
Figure 3.32 Immunoblots for phospho-Ser83l-GluRl, phospho-Ser845-GIuRl
and pan-GluRl in GluRl immunoprecipitates from rats following CCI
surgery
Western blot analysis of hemisected spinal cord pan-GluRl immunoprecipitates
following sciatic nerve CCI induced 12 days previously. Spinal cord extracts were
immunoprecipitated with a pan-GluRl antibody before probing blots for levels of
phospho-Ser83l-GluRl, phospho-Ser845-GluRl or pan-GluRl immunoreactivity.
Immunoprecipitates probed with the pan-GluRl antibody showed a decrease in
levels of GluRl in the spinal cord ipsilateral to CCI injury a) (i) lane A when
compared to the contralateral (lane B) sham (lane C and D) and naive (lane E)
samples. Lane 'F' is a direct lysate of naive spinal cord to confirm the correct protein
molecular weight and demonstrates the increase in intensity of GluRl signal
following immunoprecipitation with the GluRl antibody, a) (ii) shows levels of
phospho-Ser831 -GluRl immunoreactivity in the same samples. There was a
consistent increase in the ratio of phospho-Ser83'-GluRl: pan GluRl
immunoreactivity in the spinal cord ipsilateral to CCI (lane 'A') when compared to
contralateral, sham and naive immunoprecipitates (lanes B, C, D and E,
respectively).
Only low levels of phospho-Ser845-GluRl immunoreactivity could be detected and
no consistent changes were observed. Non-specific bands seen at -40-70 kDa
represent secondary antibody cross-reactivity with the immunoprecipitating IgG and
were similar in all samples and in extract-free blanks, b) shows independent
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AMPA receptors in the superficial horn of the spinal cord mediate fast nociceptive
transmission under normal conditions and so can contribute to acute nociceptive
inputs (Yoshimura and Jessel 1990). Administration of AMPA depolarises
nociceptive neurones in the spinal cord and increases responses from noxious and
innocuous stimulation (Zhou, Bonasera and Carlton, 1996) and AMPA receptor
antagonists can disrupt acute nociceptive processing (Aaonensen, Lei and Wilcox,
1990; Mao et al., 1992a; Procter et al., 1998; Paleckova ct al., 1992).
AMPA receptor antagonists also prevent both hyperalgesia and allodynia following
CCI (Mao et al., 1992a; Budai and Larson, 1994; Cumberbatch, Chizh and Headley,
1994; Harris et al., 1996). Studies utilising the intrathecal injection of AMPA
receptor antagonists confirmed this, whereby NBQX, NS-257 and SYM 2206
showed a dose-dependent and reversible inhibition of neuropathic hyperalgesia with
less marked, but still clear effects on mechanical allodynia. This may be consistent
with reports that co-activation of AMPA and metabotropic receptors are required for
the development of mechanical allodynia (Meller, Dykstra and Gebhart, 1993).
Subunit selective antagonists are limited at this time, although a recent report
suggests that Joro spider toxin, a Ca2+-permeable AMPA/kainate receptor antagonist,
may alleviate mechanical allodynia in a model of secondary hyperalgesia (Sorkin,
Yaksh and Doom, 1999).
It has been previously shown that GluRl and GluR2 mRNA and immunoreactivity
are expressed in the dorsal horn of the spinal cord predominantly in laminae I and II.
We confirmed this in the present study using in situ hybridisation. Quantitative
analysis indicated that there was a significant increase in the density of GluR2
mRNA in spinal cord LI and II cells from rats at the peak of behavioural reflex
sensitivity, while there was no significant change in the number of cells expressing
GluR2 mRNA in this region. Similarly, Western blot analysis of whole spinal cord
lysate from rats following CCI, confirmed the increase in GluR2 at the protein level.
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In contrast to one previous report (Harris et al., 1996), we found a decrease in the
density and number of cells labelling for GluRl mRNA ipsilateral to CCI
specifically in LI and II, although basal levels of GluRl expression matched those of
previous reports (Harris et al., 1996; Al Ghoul et al., 1993; Popratiloff, Weinberg and
Rustioni, 1998). The reason for this discrepancy is unclear. Inflammation,
deafferentation and contusive spinal cord injury have all been reported to cause a
downregulation of GluRl subunits (Pellegrini-Giampietro et al., 1994; Helgren et al.,
1999; Florenzano and DeLuca, 1999; Grossman et al., 1999). Harris et al. (1996)
carried out immunohistochemistry studies in the spinal cord following CCI and
found a specific superficial dorsal horn increase in GluRl immunoreactivity.
Western blot analysis earned out here agreed with the in situ data and indicated a
decrease in GluRl levels. It is possible that the Western blot analysis of whole spinal
cord homogenate masked a lamina-specific alteration in GluRl levels in ipsilateral
dorsal horn. However, as mentioned, regionally identified GluRl mRNA levels were
also diminished ipsilateral to CCI. While alterations in mRNA do not necessarily
imply similar alterations in protein levels, the consistent decrease in both GluRl
protein and mRNA in the ipsilateral dorsal horn following CCI here seems to be at
odds with the report of Harris et al. (1996).
The functional impact of blocking the shared GRIP/PICK 1 site on the GluR2 C-
terminus was examined by the intrathecal injection of a myristoylated peptide
corresponding to the interaction motif. This reagent was striking in its attenuation of
thermal hyperalgesia following CCI though we could not distinguish between the
GRIP and PICK1 interaction using the myristoylated blocking peptide. The effects
on mechanical allodynia were, however, minimal.
A significant increase in both the density and number of cells expressing GRIP2
mRNA was found in the dorsal horn LI and II ipsilateral to CCI. Although the
presence of GRIP in the spinal cord has been previously documented (Dong et al.,
1999; Bruckner et al., 1999), the precise localisation has to date been unknown.
Western blot analysis of spinal cord following CCI confirmed the increase in the
overall levels of GRIP protein ipsilateral to injury (see Fig. 3.33 for summary).
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Due to the lack of a cDNA sequence for rat PICK1, in situ hybridisation analysis of
PICK1 mRNA expression could not be carried out and localisation could not be
determined. However, an examination of PICK1 protein levels indicated that there
was no apparent alteration in its level in rats at the peak of behavioural reflex
sensitivity. Nevertheless, we cannot rule out the possibility of some role for PICK1
in contributing to neuropathic pain.
In contrast to the increase in the overall levels of GRIP mRNA and protein in the
spinal cord ipsilateral to CCI, there appeared to be a general decrease of GRIP
protein directly associated the GluR2 subunit following CCI. While there was no
apparent alteration in the overall levels of PICK1 protein that binds to the same site
as GRIP on the GluR2 C-terminus, ipsilateral to CCI in the spinal cord, the amount
of PICK 1 protein directly associated with GluR2 was decreased ipsilateral to CCI
(see Fig. 3.33 for summary). Further experiments would be needed to confirm the
apparent contrast in bilateral/ipsilateral changes for GRIP and PICK1, respectively,
especially as very low levels of adapter protein immunoreactivity were present in the
receptor immunoprecipitates. The functional implications of these preliminary
findings are not yet clear, but it could be envisaged that the situation might arise as a
result of GluR2 receptor subunit activation.
The determinants of preferential binding of either GRIP or PICK1 to GluR2 are not
fully clear. Matsuda et al. (1999) have shown that the interaction between GRIP and
GluR2 may be regulated by kinases. Mutation of Ser880 (IESVKI) within the GluR2
C-terminus PDZ motif, a site known to be phosphorylated by PKC, can disrupt the
GRIP: GluR2 interaction while having no effect on PICK1 binding (Matsuda et al.,
1999; Chung et al., 2000; Osten et al., 2000). This would hypothetically allow for a
functional differentiation in the regulation of GRIP/ABP or PICK1 interaction with
the same site on GluR2/3 and is suggestive of a potential role for protein
phosphorylation in the regulation of the GluR2: GRIP interaction (Matsuda et al.,
1999). We could not examine a role for this site in neuropathic pain due to the lack
of availability of phospho-specific-Ser880 antibodies.
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The GluR2: GRIP interaction may also be disrupted by the activation of the calcium-
activated proteinase calpain which can truncate GRIP and cause dissociation of its C-
terminal interaction with GluR2 (Lu et al., 2001). Calpain activity has been reported
to increase following spinal cord injury (perhaps as a result of elevated Ca2+ levels)
and blocking calpain may inhibit apoptosis following spinal cord injury (Ray et al.,
2000).
The PICK1 PDZ domain is reported to be less selective (T/SXV) than GRIP
(ESVKI) and may result in a preferential binding of PICK1 to GluR2 (Chung et al.,
OOA
2000). However, recent evidence suggests that PKC phosphorylation of Ser
reduces GluR2 binding to GRIP without affecting PICK1: GluR2 binding and causes
an internalisation of surface expressed GluR2 subunits (Chung et al., 2000; Matsuda
et al., 2000). Moreover, LTD induction in hippocampal slices and cerebellar Purkinje
cells increases Ser880 phosphorylation and infusion of a peptide that disrupts the
binding of PICK1 can inhibit hippocampal LTD expression (Kim et al., 2001;
Matsuda et al., 2000). The lack of alteration in PICK1 levels following CCI may
theoretically have implications for the ability of PKC to modulate the AMPA
receptor. However, the increases in phospho-Ser83,-GluRl immunoreactivity seen
ipsilateral to CCI (the CaMKII/PKC phosphorylation site on GluRl) indicate that
this change occurs irrespective of unaltered levels of PICK 1 expression.
The functional significance of GluR2/3-PDZ domain protein interactions in sensory
synaptic transmission has been examined by disruption with synthetic peptides (as
we used) by perfusion into cultured spinal neurones and suggests that PKC and
interactions of the GluR2/3 C-terminus are important for unmasking silent
glutamatergic synapses between sensory afferents and spinal cord dorsal horn
neurones (Li et al., 1999). In addition, peptides corresponding to the phosphorylated
motif in the GluR2 tail (which selectively blocks PICK1) and the dephosphorylated
motif (which blocks binding of both GR1P/ABP and PICK1) have been reported to
attenuate cerebellar LTD (Xia, 2000; Matsuda et al., 2000).
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Figure 3.33 Summary schematic of the main changes observed in GluRl- and
GluR2-associated proteins in the spinal cord ipsilateral to CCI
This schematic represents a summary of the results presented in this chapter. The
expression of GluRl mRNA decreased ipsilateral to CCI, while phosphorylation of
its C-terminal tail at Ser831 by PKC/CaMKII was increased indicating greater
regulation of this subunit by CaMKII/PKA following CCI which may lead to an
enhancement of AMPA receptor responsiveness. Levels ofNarp mRNA, reported to
cause clustering of GluRl in dissociated spinal neurones increased ipsilateral to CCI.
No change was seen in GluRl regulation by PKA as indicated by a lack of alteration
of Ser845 expression. As the anchoring protein SAP97 reportedly facilitates PKA
localisation to sites of action, we examined expression and functional inhibition of
SAP97. However, while a SAP97 targeted site-specific inhibitory myristoylated
peptide caused reduced hyperalgesia and allodynia following CCI, there was no
detectable change in the expression of SAP97 protein.
The expression of GluR2 increased ipsilateral to CCI indicative of decreased ion
permeability through AMPA receptors containing this subunit. There was decreased
expression of the classical fusion protein NSF ipsilateral to CCI which may imply
less AMPA receptor cycling and blocking the NSF binding site on the GluR2 C-
terminus decreased hyperalgesia following CCI possibly as a result of a reduction in
AMPA receptor current. At a different site on the GluR2 C-terminus, the IESVKI
site binds to both PICK1 and GRIP. The expression of PICK1 is unchanged
following CCI, while there is a marked upregulation in the levels of GRIP. Blocking
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Several GRIP-associated proteins (GRASPs) have been identified that bind to
distinct PDZ domains within GRIP. GRASP-1 is a neuronal RasGEF associated with
GRIP and AMPA receptors in vivo and may regulate neuronal Ras signalling and
contribute to the regulation of AMPA receptor distribution (Ye et al., 2000).
Overexpression of GRASP-1 in cultured neurones downregulates synaptic AMPA
receptor clusters (Ye et ah, 2000). The function of the remaining PDZ domains of
GRIP are unknown at present though they are likely to mediate distinct interactions,
possibly anchoring the AMPA receptor to cytoskeletal proteins or coupling the
receptor to intracellular enzymes.
Blocking the distinct NSF interaction site on the GluR2 C-terminus alleviated the
thermal hyperalgesia characteristic of the CCI model with little effect on mechanical
allodynia. Infusion of this same inhibitory peptide in hippocampal neurones reduces
AMPA receptor current and synaptic abundance. Given the role of NSF in vesicular
trafficking, blocking this site may affect AMPA receptor transport to the synapse that
could affect the receptor's ability to relay nociceptive information (Song et ah, 1998;
Liithi et ah, 1999). The levels of NSF mRNA decreased in density ipsilateral to
injury specifically in LI while there was no detectable alteration in the number of
cells expressing NSF mRNA. NSF protein also decreased in the spinal cord
ipsilateral to CCI. The functional implications of this are not clear and it seems likely
that only one facet of the change in NSF is likely to relate to the role of GluR2. One
possibility is that a downregulation of NSF may imply a reduction in AMPA receptor
recycling and this hypothetical lack of rundown of AMPA receptor activity could
influence the maintenance of the persistent pain state. Loading of peptides
corresponding to the NSF-binding domain of GluR2 into rat hippocampal CA1
pyramidal neurones results in a marked, progressive decrement of AMPA receptor-
mediated synaptic transmission (Nishimune et ah, 1998). This reduction in synaptic
transmission is also observed when an anti-NSF monoclonal antibody is loaded into
CA1 neurones. These results demonstrate a previously unsuspected functional
interaction in the postsynaptic neurone between two major proteins, AMPA and
NSF, involved in synaptic transmission and suggest that a rapid NSF-dependent
modulation of AMPA receptor function may occur in vivo.
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We report a marked increase in both the density and number of cells expressing Narp
mRNA in the superficial dorsal horn LI and II ipsilateral to CCI. As no antibodies for
this molecule are commercially available, Western blot analysis could not be carried
out. The functional impact of an increase in Narp mRNA in neuropathic pain is
difficult to interpret, given the limited knowledge about Narp in general, and since no
specific site of interaction ofNarp with either the GluRl or GluR2 subunits has been
established, this could not be examined in vivo.
Narp is enriched at excitatory synapses on neurones from both the hippocampus and
spinal cord and its overexpression increases the number of excitatory but not
inhibitory synapses in cultured spinal neurones. In particular, Narp can function as an
extracellular aggregating factor for AMPA receptors (O'Brien et al., 1999). It has
been reported that >90% of GluRl clusters on spinal neurones had associated Narp
immuno-staining and that Narp over-expression can increase the number of pre¬
synaptic terminals in spinal neurones (O'Brien et al., 1999). Because Narp is
dramatically upregulated in neurones in response to patterned synaptic activity and is
expressed at relatively high levels in developing and adult brain, Narp may play a
critical role in linking activity with the development and plasticity of excitatory
synapses. Also, inhibitory axons do not appear to express Narp (O'Brien et al., 1999).
With this in mind, it is plausible that an increase in Narp following the development
of neuropathic pain behaviours in CCI could lead to an increase in AMPA receptor-
related synapses in neurones in the spinal cord and facilitate their responsiveness.
The presence of GluR2 in an AMPA receptor assembly will limit calcium flow
through the ion channel and may serve a neuroprotective role. The proteins
interacting with the GluR2 C-terminus may contribute to its regulation, localisation
and proximity to signalling pathways. However, the effects of the PDZ domain
protein interactions with GluR2 on ion flow, if any, are not known. The high levels
of GluR2 in LII may have implications for nociceptive transmission due to the
calcium impermeability conferred by this subunit (Burnashev et al., 1992b). AMPA
receptors can exist in the absence of GluR2 subunit, as functional AMPA receptors
are present (in CA1 at least) in GluR2 knockout mice, which display enhanced LTP
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and increased calcium permeability, indicating that this subunit may not be essential
for AMPA receptor function (Jia et al., 1996). Cells expressing Ca2+-permeable
AMPA receptors (so presumably lacking the GluR2 subunit) can be found in LI and
LII0of the superficial dorsal horn, while there are low numbers of Ca2+-permeable
AMPA receptors in Llf corresponding to the high expression of GluR2 subunits in
this region (Engleman, Allen and MacDermott, 1999) and calcium flow through
AMPA receptors is likely to activate downstream second messenger pathways that
feedback onto the receptor and modulate its activity by mechanisms such as
phosphorylation.
Although no direct examination of ion flow through AMPA receptors was carried out
here, we examined the ability of the intracellular kinases, CaMKII/PKC and PKA to
activate their respective target serine residues on the GluR 1 C-terminus following
CCI. The afferent barrage produced following the induction of CCI (causing the
over-activation or sensitisation of dorsal horn neurones) could therefore potentially
result in increased AMPA receptor ion permeability and increased activation of
second messenger pathways.
Kinases themselves have been shown to be involved in dorsal horn nociceptive
transmission mediated by the activation of postsynaptic glutamate receptors, and
excitatory transmission in LII of the spinal cord can be enhanced by intracellularly-
applied CaMKII (Kolaj et al., 1994). Activators of PKC and PKA also facilitate
spinal neurone responsiveness to inputs (Cerne, Rusin and Randic, 1993).
Immunoprecipitates probed with a pan-GluRl antibody showed a decrease in levels
of GluRl in the spinal cord ipsilateral to CCI injury and a relative increase in
phospho-Ser831 protein levels ipsilateral to CCI when compared with controls. In
agreement with a recent report of increased brainstem phospho-Ser83l-GluRl
immunoreactivity following inflammation in pain modulatory regions (Guan et al.,
2001), this suggests that AMPA receptors can be modulated by phosphorylation
during chronic pain.
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It is possible that SAP97 may function to bring PKA into proximity with GluRl via
o4s
AKAP79/150 to modulate phosphorylation at Ser . However, we report that the
levels of SAP97 protein appear to be unaltered following CCI and the
phosphorylation state of the GluRl subtype of AMPA receptor at Ser845 is similarly
unaltered ipsilateral to CCI. However, blocking the site of interaction of SAP97
within the GluRl C-terminus using the synthetic myristoylated peptide attenuated
both thermal hyperalgesia and mechanical allodynia following CCI. Thus, the
functional role of the SAP97 interaction with AMPA receptor subunit GluRl appears
to participate in the maintenance of neuropathic pain although the mechanism by
which this acts is unclear.
Bidirectional changes in the efficacy of neuronal synaptic transmission, such as
hippocampal long-term potentiation (LTP) and long-term depression (LTD), are
thought to be mechanisms for information storage in the brain. Aspects of LTP and
LTD may be mediated by the modulation of AMPA receptor phosphorylation. LTP
and LTD reversibly modify the phosphorylation of the AMPA receptor GluRl
subunit. However, contrary to the hypothesis that LTP and LTD are the functional
inverse of each other, LTP and LTD are associated with the phosphorylation and
dephosphorylation, respectively, of distinct GluRl phosphorylation sites. LTD
induction in naive synapses dephosphorylates the major cyclic-AMP-dependent
protein kinase (PKA) site, whereas in potentiated synapses the major CaMKII site is
dephosphorylated. Conversely, LTP induction in nai've synapses and depressed
synapses increases phosphorylation of the CaMKII site and the PKA site,
respectively. LTP is differentially sensitive to CaMKII and PKA inhibitors
depending on the history of the synapse such that identical stimulation conditions
recruit different signal-transduction pathways depending on previous synaptic events
(Lee et al., 2000). AMPA receptor function can be rapidly regulated during the forms
of synaptic plasticity known as long-term potentiation and depression (LTP and
LTD) and this regulation is sensitive to manipulation of PDZ domain interactions,
suggesting that AMPA-PDZ interaction may be a key factor in dynamic regulation of
receptor function (Li et ah, 1999).
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The fact that GluRl and GluR2 subunits of AMPA receptor interact with different
sets of PDZ domain containing proteins may well imply a differential role for each
subunit and our results indicate a differential regulation of the AMPA receptor
subunits GluR 1 and GluR2 in the spinal cord following the establishment of
neuropathic sensitisation, as GluRl was apparently downregulated in the superficial
dorsal horn, while GluR2 mRNA and protein levels increased. In addition, while
NSF was diminished in the dorsal horn of the spinal cord following CCI, there was a
marked increase in the levels of GRIP and Narp mRNA expression. Although it is
difficult to elucidate the precise function of PDZ domain-containing proteins and
other interacting partners of the GluR2 receptor, GRIP/PICK 1 and NSF appear likely
to play some functional role in the modulation of AMPA receptor- dependent
nociceptive transmission during neuropathic pain.
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CHAPTER 4: Lack of neuropathic pain behaviour and disruption of
spinal NMDA receptor function in PSD-95 mutant mice
4.1: Introduction
A signalling complex of -2000 kDa can be isolated from mouse forebrain,
comprising the NMDA receptor linked to adapter proteins, signalling, cytoskeletal
and cell adhesion proteins (Husi et al., 2000; Husi and Grant, 2001). As mentioned in
the general introduction, the NMDA receptor (NR) is composed of two main
subunits whereby the NR1 subunit is the key functional subunit of all NMDA
receptor assemblies, while the NR2 subunits determine the subtype-specific channel
characteristics (Chen, Luo and Raymond, 1999). NR2 subunits possess a long
intracellular C-terminus enabling them to interact with the membrane associated
guanylate kinase (MAGUK) family of proteins, which so far contains PSD-
95/SAP90, Chapsyn-110/PSD-93, hDlg/SAP97 and SAP 102. The MAGUKs contain
three amino-terminal PDZ domain repeats, a Src homology 3 (SH3) domain and a
guanylate kinase (GK)-like domain (Kennedy, 1997) and are 70-80% homologous in
sequence (Kim and Sheng, 1996).
The best characterised MAGUK protein is PSD-95, which interacts with the NR2
subunits of NMDA receptor. The interaction occurs via the first and second PDZ
domains of PSD-95 and the NR2 C-terminal peptide sequence, 'SIESDV' (Kornau et
al., 1995; Niethammer, Kim and Sheng, 1996).
4.1.1 MAGUK family of proteins
Interest began with the discovery, using yeast 2-hybrid screening, that MAGUKs
acted as interaction partners for the C-terminus of NMDA receptor subunits and K+
channels (Kornau, Seeburg and Kennedy, 1997). Domain analysis of PSD-95 defined
the PDZ repeats as modular protein-binding sites that recognise short consensus
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peptide sequences in the NR2 C-termini. PSD-95 interacts most strongly with the
NR2B subunit and both of these proteins are highly enriched in the PSD (Moon,
Apperson and Kennedy, 1994; Kennedy, 1997).
PSD-95 is believed to cluster and immobilise the NMDA receptor at the postsynaptic
membrane via interactions with the cytoskeleton, and to function as a bridge or
molecular scaffold for signalling to downstream pathways (Niethammer, Kim and
Sheng, 1996; Craven and Bredt, 1998). Some mechanisms by which PSD-95 can
stabilise the NMDA receptor complex have been identified. Members of the PSD-95
family can multimerise by two distinct mechanisms via the formation of N-terminal
disulfide bridges or via PDZ: PDZ domain interactions (Hsueh, Kim and Sheng,
1997; Kim et al., 1996; Craven, El-Husseini and Bredt, 1999). This is thought to
result in the local grouping of ion channels and may be a simple mechanism for
clustering a specific mixture of ion channels.
N-terminal palmitoylation of PSD-95 may regulate association of PSD-95 with the
membrane (Topinka and Bredt, 1998). The neuronal cell adhesion molecule,
neuroligan, whose extracellular regions tightly bind to p-neurexins on the
presynaptic terminal membrane to form intercellular junctions, binds to PDZ3 of
PSD-95 (Irie et al., 1997). In addition, PSD-95 may immobilise the NMDA receptor
via its secondary interactions with the microtubule and actin cytoskeleton. For
example, CRIPT and MAPI A, both microtubule-binding proteins, bind to PSD-95
providing a direct link to microtubules that may affect synaptic clustering of
receptors (Passafaro et al., 1999; Brenman et al., 1998) and an interaction between
the actin binding protein, a-actinin-2 with the NR1 subunit may anchor the NMDA
receptor to the actin cytoskeleton (O'Brien, Lau and Huganir, 1998).
Proteins known to interact with the SH3/GK domains include guanylate kinase-
associated protein (GKAP), MAPI A, the KA2 kainate receptor subunit and the
kinase/phosphatase scaffolding adapter AKAP79/150 (Naisbitt et al., 1997; Brenman
et al., 1998; Garcia et al., 1998; Colledge et al., 2000; Kim et al., 1995). Another
novel protein, Cypin, may act as a cytosolic regulator of PSD-95 and Cypin
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overexpression in hippocampal neurones can disrupt PSD-95 postsynaptic trafficking
(Firestein et al., 1999).
4.1.2 MAGUK-associated signalling machinery
Various signalling molecules interact with PSD-95 bringing them into close
proximity with the NMDA receptor in the postsynaptic membrane (Sheng, 1996).
Citron, a protein target for the activated form of the small GTP-binding protein Rho,
binds to PDZ3 of PSD-95 and is present at glutamatergic synapses in a complex with
PSD-95 and NMDA (Furuyashiki et al., 1999; Zhang et al., 1999). SynGAP, an
abundant synaptic Ras GTPase-activating protein, can bind to all 3 PDZ domains of
PSD-95. SynGAP can be phosphorylated by CaMKII, which is reported to reduce its
GAP activity (Chen et al., 1998). In addition, PSD-95 can assemble a postsynaptic
protein complex containing nNOS and NMDA receptors, where nNOS can bind to
PSD-95 via a PDZ: PDZ domain interaction (Christopherson et al., 1999).
4.1.3 Functional modulation of NMDA receptors
NMDA receptor subunits are functionally modulated by serine/threonine and
tyrosine kinases, which has implications for receptor activity. The functional
influence of kinases on the NMDA receptor may be as a result of direct
phosphorylation or phosphorylation of associated proteins. Either may involve
adapters such as the PDZ domain-containing proteins. NMDA receptor signalling is
mediated by the combined functions of the NR1 and NR2 receptor-channel subunits
together with their associated proteins. The C-terminal domains of the NR1 and NR2
subunits all contain sites of PICA and PKC phosphorylation, while tyrosine kinase
phosphorylation sites are believed to be limited to NR2 subunits (Tingley et al.,
1997; Leonard and Hell, 1997; Lau and Huganir, 1995).
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CaMKII and calcium-dependent regulation
Calcium regulation of NMDA receptors has been proposed to involve a linkage
between the receptor and the cytoskeleton that may be facilitated by interactions with
PSD-95 (Rosenmund and Westbrook, 1993). Calmodulin binds, in a calcium-
dependent manner, to the C-terminus of NR1 subunits and a-actinin-2 can bind to
the C-terminus of both NR1 and NR2B subunits (Ehlers et ah, 1996; Wyszynski et
al., 1997). In vitro, a-actinin-2 and calmodulin bind competitively to the initial 30
amino acids of the NR1 C-terminus, to a segment known as CO that is common to all
NR1 splice variants (Wyszynski et al., 1997; Ehlers et al., 1996; Hollmann and
Heinemann, 1994, Section 1.7.6). Calmodulin binding to NR1 has been proposed to
mediate a calcium-dependent inactivation of the NMDA receptor causing a reduction
in the channel open probability (Legendre, Rosenmund and Westbrook, 1993; Krupp
et al., 1998) and this channel inactivating effect of calmodulin can be prevented by
co-expression of a-actinin-2 (Zhang et al., 1998; Hisatsune et al., 1997).
Furthermore, the NMDA receptor: PSD-95 complex in the forebrain incorporates the
Ca2+-dependent protein kinase, CaMKII, which docks to NR2 subunits, where it is
2_|_
predicted to respond readily to NMDA receptor-mediated Ca entry (Gardoni et al.,
1999; Husi and Grant, 2001). After activation by Ca2+/calmodulin, CaMKII has Ca2+-
independent activity (by autophosphorylating at a threonine reside at position 286,
Thr286) that prolongs its activation even after the intracellular Ca2+ concentration
returns to basal levels (Hanson et al., 1989; Fukunaga, Rich and Soderling, 1989).
Both aCaMKII and PSD-95 bind to the NR2 subunits in a mutually competitive
manner (Gardoni et al., 1999). NR2B but not NR2A or NR1 are believed to be
responsible for the autophosphorylation-dependent targeting of CaMKII, this
modification inducing a direct high-affinity binding to the NR2B C-terminus (Strack
and Colbran, 1998). Inhibitors of the serine/threonine phosphatases PP1 and PP2A
have been reported to increase the phosphorylation and activity of CaMKII and
CaMKIV, while inhibitors of PP2B (calcineurin) only increase the phosphorylation
and activity of CaMKIV (Kasahara, Fukunga and Miyamoto, 1999).
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CaMKII activity also has implications for NMDA receptor-mediated stimulation of
the Ras-MAPK pathway. SynGAP, a regulatory protein that binds to PSD-95,
stimulates the GTPase activity of Ras suggesting that it negatively regulates Ras
activity (Kim et al., 1998). Inhibition of SynGAP by CaMKII will stop inactivation
of GTP-bound Ras and may be one of the modulatory influences in the activation of
the MAPK pathway (Chen et ah, 1998).
PKA andPKC
Regulatory phosphorylation of NMDA receptor subunits by kinases such as PKC and
PKA may increase the degree of Ca entry evoked by NMDA receptor stimulation
(Tingley et ah, 1997; Westphal et ah, 1999). Electrophysiological responses of spinal
neurones to NMDA are known to be facilitated by PKC and PKA (Cerne, Jiang and
Randic 1992; Heppenstall and Fleetwood-Walker, 1997). Whole cell current
responses to NMDA are enhanced by cAMP analogs and by intracellular application
of cAMP or a catalytic subunit of PKA (Cerne, Rusin and Randic, 1993). NR1,
NR2A and NR2B subunits are all substrates for PKC and PKA where PKC
ROD RQA
phosphorylates serine residues Ser and Ser on NR1 and PKA phosphorylates
serine residue Ser897 (Tingley et ah, 1997; Leonard and Hell, 1997). It has been
shown that levels of NR1 phosphorylated protein at Ser897 in spinothalamic tract cells
are increased in the spinal cord following capsaicin injection (Zou, Lin and Willis,
2000). Furthermore, PKC-mediated phosphorylation ofNR1 may decrease its
affinity for calmodulin and so attenuate calmodulin-dependent inactivation of the
receptor (Hisatsune et ah, 1997).
Signalling enzymes may be recruited to NMDA receptors through simultaneous
association with two A-kinase anchoring proteins (AKAPs), AKAP79/150 and
Yotiao (Colledge et ah, 2000; Lin et ah, 1998). AKAP79/150 has been shown to bind
to PSD-95, which could provide a mechanism to favour NMDA receptor (or ion
channel) phosphorylation through preferential recruitment of regulatory kinases
(Colledge et ah, 2000). AKAP79/150 provides a scaffold for PKA, PKC, and
calcineurin (PP2B). Interestingly, PSD-95 competes with calcineurin for binding to
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AKAP79/150 in vitro and interaction of AKAP79/150 with PSD-95 appears to
exclude the phosphatase calcineurin from the complex, suggesting that this AKAP
may preferentially target kinases but not phosphatases to NMDA receptors at the
PSD (Colledge et ah, 2000).
Through interaction with the CI splice variant of NR1, the anchoring protein Yotiao
targets both PKA (via RII subunits) and the phosphatase PP1 to NMDA receptor
complexes, conferring bi-directional regulation of NMDA receptor activity (Lin et
ah, 1998; Feliciello et ah, 1999; Westphal et ah, 1999). When PP1 is anchored to
Yotiao, it is active and so limits NMDA receptor channel activity. Activation of PKA
can overcome PP1 activity and enhance NMDA receptor currents (Westphal et ah,
1999). In addition, stimulation ofNMDA receptors leads to reduced PP2A
phosphatase activity, whereas association of PP2A with NMDA receptors increases
its phosphatase activity and dephosphorylates Ser897 of NR1 (Chan and Sucher,
2001).
Tyrosine Kinases
Members of the tyrosine kinase family, such as Src and Fyn have also been
implicated in NMDA receptor modulation, whereby protein tyrosine kinases can
increase NMDA receptor currents (Wang and Salter, 1994). Src co-
immunoprecipitates with NMDA and regulates the function of NMDA receptors at
hippocampal synapses and in dorsal horn neurones (Yu et ah, 1997). In addition,
PKC enhancement of NMDA receptor currents can be blocked with tyrosine kinase
inhibitors and Src mutant mice lack this PKC-dependent upregulation of NMDA
receptor function (Lu et ah, 1999). PSD-95 is believed to promote Fyn
phosphorylation of NR2A and mutant mice with a Fyn deficit have been shown to
display reductions in this phosphorylation (Tezuka et ah, 1999). The NR1 subunit is
not believed to contain tyrosine phosphorylation sites (Lau and Huganir, 1995).
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4.1.4 In vivo function of PSD-95
To date, there has been limited functional information for the role of PSD-95 in vivo.
In cultured cortical neurones, antisense PSD-95 can attenuate NMDA receptor-
mediated excitotoxicity and blocks Ca2+-activated nitric oxide production
specifically without affecting NMDA channels currents (Sattler et ah, 1999).
Furthermore, PSD-95 binds to neuronal NOS (nNOS), an interaction that is
competitively inhibited by an nNOS C-terminal ligand known as CAPON (Carboxy-
terminal PDZ ligand of nNOS). Axotomy decreases PSD-95 and CAPON mRNA in
facial motoneurones while nNOS levels increase (Che, Tamatani and Tohyama,
2000). Disruption of PSD-95 impairs the induction of synaptic plasticity and forms
of learning in the hippocampus (Migaud et al., 1998). A possible cause for this may
an uncoupling of the NMDA receptor from PSD-95, which will disrupt links to other
cytosolic signalling proteins that propagate or modify the signal generated by the
receptor. Despite the pronounced effects on NMDA receptor-mediated plasticity,
PSD-95 mutations did not affect synaptic NMDA receptor currents, indicating that
the intracellular signalling components of the complex, that have been outlined
above, may participate selectively in neuronal plasticity.
The truncated mutation of PSD-95 was located midway through PDZ3, thus
rendering the SH3 and GK domains (and possibly the PDZ domain itself) ineffective
in mediating associated signalling pathways. The LacZ reporter gene was inserted
here as a marker for transcription (Fig. 4.1). Here, using these PSD-95 mutant mice,
we have addressed the possibility that the neuropathic sensitisation of spinal dorsal
horn neurones may depend on adapter-mediated mechanisms of NMDA receptor
function.
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Figure 4.1 Schematic representation of the site of PSD-95 mutation
This schematic shows the NMDA (NR1 and NR2) receptors in the postsynaptic
membrane. The C-termini of the NR2 subunits bind to PSD-95 via a specific C-
terminal peptide 'SIESDV' to PDZ1 and PDZ2 of PSD-95. The truncating mutation
in the PSD-95 mutant mice occurred in PDZ3, downstream of the NR2 interaction












Chapter 2 (sections 2.2 and 2.4) contains the details of methods used in this chapter.
4.2.1 Expression of the hybrid PSD-95 (truncated): P-galactosidase protein
Since the NMDA receptor is implicated in neuropathic pain and the PSD-95-docking
NR2B subunit of the receptor is selectively expressed in superficial dorsal horn
(Boyce et al., 1999) while the NR2A subunit of the NMDA receptor shows a more
widespread dorsal horn distribution (Ma and Hargreaves, 2000), we first examined
whether PSD-95 is expressed in the adult mouse spinal cord and, if so, where it is
localised.
In (heterozygous) mice carrying a targeted mutation in the PSD-95 gene and a LacZ
reporter of PSD-95 gene expression (Migaud et al., 1998) histochemical analysis of
the expression of p-galactosidase (see Section 2.4.1, pgs. 84-85) showed specific
staining in the superficial dorsal horn of the spinal cord with P-galactosidase-positive
cells restricted to lamina II (Fig. 4.2a and b). This expression ranged throughout
lumbar and thoracic spinal cord, extending undiminished throughout longitudinal
sections (Fig. 4.2c).
Dorsal root entry zones showed no expression of the reporter gene (Fig. 4.2d).
Further analysis of the peripheral nervous system provided no evidence for
expression of P-galactosidase in dorsal root ganglion DRG or sciatic nerve (Fig. 4.2e
and f, respectively), indicating that PSD-95 expression is restricted to the CNS.
Hippocampus was used as a control for positive expression (Fig. 4.2g). This dorsal
horn distribution is coincident with the distribution of NR2A and B subunits with
which PSD-95 interacts most strongly (Boyce et al., 1999; Shibata et al., 1999). The
specific expression of PSD-95 in lamina II with NMDA receptor subunits suggests
the potential involvement of PSD-95-mediated signals in neuropathic pain.
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Figure 4.2 p-galactosidase expression in the lumbar spinal cord (L3-L6) of
heterozygous PSD-95 mutant mice
(a) 10 pm transverse section, showing specific localisation of P-galactosidase
positive cells (blue) in lamina II of the superficial dorsal horn at xlO
magnification.
(b) Inset of (a), showing positive cells at higher (x40) magnification.
(c) 10pm thick longitudinal sections cut though the region of positive expression
in lamina II showing the spread of P-galactosidase positive cells in segments
L3-L6. Expression extended through out lumbar, thoracic and cervical
segments with moderate expression in brainstem (not shown).
(d) 10pm longitudinal spinal cord section equivalent to that in (c) but showing
the site of peripheral dorsal root entry (arrow) where no P-galactosidase
positive cells were observed.
(e) Transverse section of dorsal root ganglion showing no p-galactosidase
expression.
(f) Transverse section of sciatic nerve (tibial branch) showing no P-galactosidase
expression.
(g) Positive staining was confirmed in the hippocampal region of the brain.




4.2.2 NMDA receptor complex in spinal cord
The NMDA receptor present in the spinal cord may be in complexes with PSD-95 as
previously shown in forebrain structures (Husi et al., 2000). This possibility was
tested by isolating spinal cord multiprotein complexes using both antibody- and
peptide-based affinity separations (see Section 2.4.2, pgs. 85-86), which target either
NMDA receptor subunits or PSD-95 (Husi and Grant, 2001; Husi et ah, 2000). Wild-
type spinal cord extracts contained NR1, NR2A, NR2B and PSD-95 (Fig. 4.3a).
Experiments which were carried out to assess the composition of spinal NMDA
receptor complexes in wild-type spinal cord (as described previously for forebrain,
Husi et ah, 2000) confirmed that spinal NR1, NR2B and PSD-95-directed
immunoprecipitates contained immunoreactivity for NR1, NR2B and PSD-95 (Fig.
4.3b). Forebrain extract was used as a positive control (Fig. 4.3c).
4.2.3 The effects of PSD-95 mutation on the development of neuropathic reflex
sensitivity following CCI
Since PSD-95-associated NMDA receptor complexes were present in spinal cord at a
major site of nociceptive primary afferent termination in lamina II, we examined the
CCI model of neuropathic pain in homozygous PSD-95 mutant mice (see Sections
2.2.1, 2.2.2 and 2.2.3 and Fig. 2.1, pgs 56-60).
Following CCI, wild-type mice progressively developed marked ipsilateral thermal
hyperalgesia, mechanical allodynia and cold allodynia while responses of the
contralateral paw remained at baseline levels (Fig. 4.4a, b and c, respectively).
Significant differences for thermal hyperalgesia measured as the paw withdrawal
latency ('PWL' in sees) are shown between pre-operative compared to post-operative
values on the same side (Fig. 4.4a) and ipsilateral and contralateral values following
CCI (Fig. 4.4a). Paw withdrawal to mechanical stimulation (paw withdrawal
threshold, 'PWT') for wild-type mice showed significant differences between pre-
and post-operative values on the ipsilateral side (Fig. 4.4b) and between ipsilateral
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Figure 4.3 Association of PSD-95 with NMDA receptor subunit proteins in
wild-type spinal cord
(a) Direct immunoblots of 1 OOpg whole spinal cord extract in wild-type mice
(n=8) probed with NR1, NR2A, NR2B and PSD-95 antibodies showing
expression of all proteins in the spinal cord.
(b) Directed affinity separations with an NR2B C-tenninal hexapeptide reagent
('pep 6' SIESDV targeting motif on NR2 subunits), or antibodies for NR1,
NR2B and PSD-95 subsequently probed with NR1, NR2A, NR2B and PSD-
95 antibodies showing physical association of these proteins with each other
in spinal tissue.
(c) 50pg forebrain extract are shown for comparison.
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and contralateral values (Fig. 4.4b). The Suspended Paw Elevation Time (SPET) in
response to a cold (4°C) thermal stimulus in wild-type mice showed significant
differences between pre- and post-operative values (Fig. 4.4c) and between
ipsilateral and contralateral responses (Fig. 4.4c).
The alteration in sensitivity in wild-type mice was evident as early as day 4, with
maximal changes occurring at day 8/9 onwards. All CCI-evoked changes in
behavioural reflex responses had resolved spontaneously within 22-23 days. Neither
thermal hyperalgesia nor mechanical allodynia could be detected at any time point in
PSD-95 mutant mice that had undergone identical CCI surgery (Fig. 4.4d and e,
respectively), while cold allodynia was severely attenuated, reaching statistical
significance at only one time point (Fig. 4.4f). The basal latencies for thermal
nociceptive responses were similar in PSD-95 mutant compared to wild-type mice
(Fig. 4.4a and d, respectively). There was, however, a lowered mechanical
withdrawal threshold in wild-type mice when compared to PSD-95 mutant mice (Fig.
4.4b and e, respectively). Paw withdrawal tests for both mutant and wild-type mice
were consistent with previously reported values for mice (Gillespie et al., 2000).
These data indicate a key role for PSD-95 in the CNS in the sensitisation of
behavioural reflex responses that is characteristic of the neuropathic pain state.
4.2,4 Morphological analysis of the sciatic nerve
In order to exclude the possibility that any of these changes were associated with
abnormalities in the pattern of myelination in sciatic afferents, we examined axon
diameter and myelin thickness profiles by light and electron microscopy (see
Sections 2.4.3, 2.4.4 and Fig. 2.3, pgs. 86-89), firstly in naive wild-type and
homozygous PSD-95 mutant mice prior to constriction injury.
The axon diameters of fibres (A8 and A[1 class) were similar in naive wild-type and
homozygous PSD-95 mutant mice (Fig. 4.5a and d, respectively) and no significant
differences were observed (Chi2 test and Kolmogorov-Smirnov test for normality). In
addition, the myelin thickness profiles for myelinated fibres expressed in terms of G-
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Figure 4.4 Behavioural analyses of wild-type and PSD-95 mutant mice with
chronic constriction injury to the sciatic nerve
Data represent the average hindlimb withdrawal latency ± SEM from a noxious
thermal stimulus (paw withdrawal latency, 'PWL' a and d), a normally innocuous
mechanical stimulus (paw withdrawal threshold, 'PWT b and e) or a cold (4°C)
thermal stimulus (suspended paw elevation threshold, 'SPET', c and f) for each day
prior to and following CCI (n=8, wild-type; n=9, PSD-95 mutant mice).
Wild-type mice (a), showed significant differences between pre- and post-operative
values on the ipsilateral side for the noxious thermal stimulus (|, p<0.05; t, p<0.01,
One-way ANOVA followed by a Dunnett's test) with a significant reduction in
withdrawal latency compared to contralateral values (*, p<0.05; **, p<0.01,
Student's t-test) while no significant differences reflecting thermal hyperalgesia were
seen in the mutants following CCI (d).
Wild-type mice (b) showed significant differences between pre- and post-operative
values on the ipsilateral side for the mechanical stimulus (f, p<0.05; Kruskal-Wallis
ANOVA followed by a Dunn's test) with a significant ipsilateral reduction in
withdrawal threshold compared to contralateral values (**, p<0.01, Mann-Whitney
Rank Sum Test), while no significant differences were seen on any day of testing for
the PSD-95 mutant (e) indicating the lack of development of mechanical allodynia.
Wild-type mice in (c) showed significant differences between pre- and post-operative
values for the cold test (f, p<0.05; f, p<0.01, One-way ANOVA followed by a
Dunnett's test) with a significant ipsilateral increase in withdrawal compared to
contralateral values (*, p<0.05; **, p<0.01, Student's t-test). The SPET in response
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ratio (axon diameter/ external myelin diameter) showed little variation between wild-
type and PSD-95 mutant mice under normal conditions (Fig. 4.5b and e,
respectively). Finally, electron microscopic analysis of the diameters of
unmyelinated C fibres indicated little variation between nai've wild-type and
homozygous PSD-95 mutant mice (Fig. 4.5c and f, respectively) with no significant
difference between the two groups (Chi2 test and Kolmogorov-Smirnov test for
normality). The morphological similarity is shown in photomicrographs for wild-
type (Fig. 4.6a) and PSD-95 mutant (Fig. 4.6b) mice. The size, distribution and
numbers of myelinated and unmyelinated axons seen were in accordance with
previous reports (Sommer et al., 1995; Guilbaud et al., 1993).
In order to rule out the possibility that morphological differences in the
demyelination of primary afferents were contributing to the lack of sensitivity in
mutant mice, we carried out identical experiments to those described above on the
sciatic nerve of both groups of mice following CCI (see Sections 2.4.3, 2.4.4 and Fig.
2.3, pgs. 86-89). Following constriction, light microscopic analysis showed that wild-
type and PSD-95 mutant mice had a similar amount of demyelination distal to the
ligation site with the same extent of large myelinated fibre loss (Fig. 4.7a and b; Fig.
4.8a and b, respectively) and no significant difference in the extent of demyelination
• 2observed (Chi test and Kolmogorov-Smirnov test for normality). There was little
variation in the number and size of unmyelinated C-fibres distal to the site of ligation
for wild-type and PSD-95 mutant mice (Fig. 4.7c and d respectively; Chi test and
Kolmogorov-Smirnov test for normality) in accordance with previous reports
(Guilbaud et al., 1993). No significant alterations in any fibre type could be detected
proximal to ligation (data not shown).
These analyses indicated that there were no significant morphological differences in
axons either under normal conditions or following constriction injury between wild-
type and PSD-95 mutant mice that might account for the lack of behavioural
development seen in the PSD-95 mutant mice.
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Figure 4.5 Morphological analysis of the tibial branch of the sciatic nerve of
naive wild-type and PSD-95 mutant mice
The frequency distribution of the axon diameters of myelinated fibres in the A5/A|3
diameter range from the tibial branch of the sciatic nerve in naive wild-type (a, n=3)
and naive PSD-95 mutant mice (d, n=3). In each nerve, 750 fibres were used for
diameter measurement. No significance differences were observed at the light
microscopy level for myelinated A fibre diameter distributions between wild-type
and PSD-95 mutant mice (%2 test).
The myelin sheath thickness of myelinated fibres in terms of G ratio
(internal/external diameter) as a function of the external diameter is shown in naive
wild-type (b, n=3) and naive PSD-95 mutant (e, n=3) mouse sciatic nerve. No
significant difference in the G ratio range of myelinated fibres was observed.
The frequency distribution of the axon diameters of unmyelinated C-fibres from the
tibial branch of the sciatic nerve in naive wild-type (c, n=2) and naive PSD-95
mutant mice (f, n=2) is shown. In each nerve, 250 unmyelinated fibres were used for
axon diameter measurement. At the electron microscope level, C-fibre clusters were












13X mmm3 g7p... 03' M03 3̂-
















































11111 ■ I.. ■
o> 'V b- <b^
Q>- Q>- <3- 0>-
N N* * ^ <P
Axon Diameter (jam)
219
Figure 4.6 Photomicrographs of the tibial branch of the sciatic nerve of naive
wild-type and PSD-95 mutant mice
(a) shows a photomicrograph of the tibial branch of the sciatic nerve of naive wild-
type mice observed by electron microscopy, showing a normal distribution of both
small and large myelinated fibres and unmyelinated C-fibre clusters.
(b) shows a photomicrograph of the tibial branch of the sciatic nerve of naive PSD-
95 mutant mice observed by electron microscopy also showing a normal distribution
of myelinated fibres and C-fibre clusters. These represent typical examples of fibre
morphology
Scale bar = 10pm
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Figure 4.7 Morphological analysis following CCI of the tibial branch of the
sciatic nerve of wild-type and PSD-95 mutant mice distal to ligation
(a) and (b) show the frequency distribution of the axon diameters of myelinated
fibres from the tibial branch of the sciatic nerve in wild-type (a, n=3) and PSD-95
mutant (b, n=3) mice following CCI, showing a reduction in the number of medium
and large diameter fibres distal to the site of ligation. There was no significant
difference between the two groups and both wild-type and PSD-95 mice showed
similar levels of demyelination.
(c) and (d) show the frequency distribution of the axon diameters of unmyelinated C-
fibres from the tibial branch of the sciatic nerve in naive wild-type (c, n=2) and PSD-
95 mutant (d, n=2) mice following CCI. There was no significant difference in
frequency distribution when compared to naive results and there was no significant
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Figure 4.8 Light microscopy images of the tibial branch of the sciatic nerve
of wild-type and PSD-95 mutant mice following CCI distal to ligation
In (a), a light micrograph image of wild-type tibial nerve distal to ligation shows a
loss of larger myelinated fibres as represented in Figure 4.6 (a) and in (b), an image
of PSD-95 mutant tibial nerve distal to ligation shows a similar loss of larger
myelinated fibres as represented in Figure 4.7 is shown. These represent typical
examples of fibre morphology.
Scale bar = 10pm
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4.2.5 Behavioural reflex effects of the NMDA receptor antagonist (R)-CPP
following CCI
The NMDA receptor is consistently documented to be involved in the central
sensitisation of pain pathways following afferent nerve damage. To examine whether
the lack of injury-induced sensitisation in pain behaviours in the homozygous PSD-
95 mutant mice might relate to the role of PSD-95 as an NMDA receptor adapter
protein, we assessed the contribution of spinal NMDA receptors to the CCI-induced
changes here by the local administration of a highly selective NMDA receptor
antagonist, (R)-CPP (see Section 2.2.4 and compound details in Table 2.1, pgs. 60-
63).
In wild-type mice, the ipsilateral thermal hyperalgesia brought about by CCI was
reversed by (R)-CPP with dose-dependent effects in each case from 50-200pmole/in
lOpl saline, while the drug had no significant effect on responses elicited from the
uninjured hindlimb of wild-type mice (Fig. 4.9a, b, and c). Again, in wild-type mice,
the ipsilateral mechanical allodynia brought about by CCI could be reversed by (R)-
CPP with dose-dependent effects in each case from 50-200pmole/in lOpl, although
there was a trend toward elevated paw withdrawal thresholds in the von Frey test
(Fig. 4.10a, b and c) on the contralateral side.
Intrathecal injection of (R)-CPP in PSD-95 mutant mice following CCI had no effect
on responses from either hindlimb of PSD-95 mutants (where the development of
neuropathic sensitisation had failed to occur) to either thermal or mechanical stimuli
(Fig. 4.1 la and b, respectively). The elevated baseline threshold for mechanical
withdrawal reflexes seen bilaterally in the PSD-95 mutants was unaffected by (R)-
CPP, indicating that this change is not caused by contralateral NMDA receptor
activation (Fig. 4.1 lb).
As a control, the intrathecal injection of (R)-CPP in naive wild-type mice had no
effect on thermal or mechanical withdrawal responses (Fig. 4.12a and b,
respectively). Similarly, the intrathecal injection of (R)-CPP in naive PSD-95 mutant
mice had no effect on thermal or mechanical withdrawal responses (Fig. 4.13a and b,
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respectively). As a further control, the intrathecal injection of the saline vehicle in
wild-type mice following CCI had no effect on the presence of thermal and
mechanical reflex sensitivity (Fig. 4.14a and b, respectively) and did not affect
withdrawal thresholds of PSD-95 mutant mice at any time (Fig. 4.15a and b).
These findings show that the prevention of neuropathic sensitisation seen in PSD-95
mutant mice can be mimicked by spinal NMDA receptor blockade in wild-type mice,
consistent with the idea that disruption of some aspect of spinal NMDA receptor
function in the mutant may be responsible for the failure of sensitisation.
4.2.6 Intrathecal administration of the agonist NMDA in naive mice
Behavioural changes following CCI were bilaterally mimicked in naive wild-type
mice by acute intrathecal administration of 0.25nmol/in lOpl NMDA (see Section
2.2.4 and compound details in Table 2.1, pgs 60-63). Statistically significant
development of thermal hyperalgesia in wild-type mice could be seen following
intrathecal NMDA (Fig. 4.16a). In striking contrast, behavioural responses of PSD-
95 mutant mice to the noxious thermal stimulus were unaffected by intrathecal
administration ofNMDA (Fig. 4.16a). Similarly, in naive wild-type mice, intrathecal
administration ofNMDA mimicked (bilaterally) the mechanical allodynia seen
unilaterally after CCI (Fig. 4.16b). In PSD-95 mutant mice, the effect of NMDA was
completely abrogated (Fig. 4.16b).
These findings indicate that spinal NMDA receptor function (as monitored by a
physiological read-out of neuropathic pain behaviour) is profoundly disrupted in
PSD-95 mutant mice and spinal NMDA receptor activation adequately mimics
neuropathic sensitisation in wild-type mice in a manner that is disrupted by PSD-95
mutation. The observations suggest that failure of proper NMDA receptor function in
the dorsal horn of PSD-95 mutants is responsible for the lack of neuropathic
sensitisation observed.
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Figure 4.9 Effects of the intrathecal administration of the selective NMDA
receptor antagonist (R)-CPP on thermal hyperalgesia in wild-type mice at
the peak of neuropathic reflex sensitivity
Data represent the average hindlimb withdrawal latency ± SEM to a noxious thermal
stimulus of wild-type mice (n=7) for each time point following the intrathecal
injection of 50pmol (a), lOOpmol (b) or 200pmol (c) of (R)-CPP.
Wild-type mice at the peak of ipsilateral thermal hyperalgesia, as determined by a
significant reduction in ipsilateral paw withdrawal latency ('PWL') compared to
contralateral withdrawal latency (*, p< 0.05, Student's t-test), were intrathecally
injected with (R)-CPP (at arrow). 10 min following injection, 50pmol (a), lOOpmol
(b) or 200pmol (c) of (R)-CPP significantly attenuated ipsilateral thermal
hyperalgesia in comparison to pre-injection ipsilateral values (f, p<0.05, One-way
ANOVA followed by a Dunnett's test) while there was no significant alteration in
the pre-/post- injection contralateral responses. The duration of the drug effect varied
in a dose-dependent manner, with 50pmol (R)-CPP reversing the sensitisation of
ipsilateral paw withdrawal for 20 min, whereas lOOpmol and 200pmol (R)-CPP had
significant effects for around 50 min. As the drug effect wore off, ipsilateral PWL
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Figure 4.10 Effects of the intrathecal administration of the selective NMDA
receptor antagonist (R)-CPP on mechanical allodynia in wild-type mice at
the peak of neuropathic reflex sensitivity
Data represent the average hindlimb withdrawal threshold ± SEM to a normally
innocuous mechanical stimulus of wild-type mice (n=7) for each time point
following the intrathecal injection of 50pmol (a), lOOpmol (b) or 200pmol (c) of (R)-
CPP.
Wild-type mice at the peak of ipsilateral mechanical allodynia, as determined by a
significant reduction in ipsilateral paw withdrawal latency ('PWL') compared to
contralateral withdrawal latency (*, p< 0.05, Mann-Whitney Rank Sum test), were
intrathecally injected with (R)-CPP (at arrow). 10 min following injection, 50pmol
(a), lOOpmol (b) or 200pmol (c) of (R)-CPP significantly attenuated ipsilateral
mechanical allodynia in comparison to pre-injection ipsilateral values (f, p<0.05,
Kruskal-Wallis ANOVA followed by a Dunn's test) while there was no significant
alteration in the pre-/post- injection contralateral responses. The duration of the drug
effect varied in a dose-dependent manner, with 50pmol (R)-CPP reversing the
sensitisation of ipsilateral paw withdrawal for 20 min, whereas lOOpmol reversed
ipsilateral sensitisation for 40 min and 200pmol (R)-CPP had significant effects for
up to 50 min. However, at this highest dose (c) there were variations in the
contralateral response, indicative of effects on motor co-ordination. As the drug
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Figure 4.11 Effects of the intrathecal administration of the selective NMDA
receptor antagonist (R)-CPP in PSD-95 mutant mice following CCI
Data represent the average (a) hindlimb withdrawal threshold to noxious heat and (b)
withdrawal threshold to mechanical (von Frey filament) stimuli ± SEM for each time
point in PSD-95 mutant mice that had previously undergone CCI (n=7), following
the intrathecal injection of 1 OOpmol of (R)-CPP.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) of either hindpaw in PSD-95 mutant mice that had undergone CCI
when testing resumed 10 min following injection of the antagonist (Student's t-test
and Mann-Whitney Rank Sum test, respectively). The intrathecal injection of (R)-
CPP (at arrow) had no significant effect on the withdrawal latency or withdrawal
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Figure 4.12 Effects of the intrathecal administration of the selective NMDA
receptor antagonist (R)-CPP in naive wild-type mice
Data represent the average (a) hindlimb withdrawal threshold to noxious heat and (b)
withdrawal threshold to mechanical (von Frey filament) stimuli ± SEM for each time
point in naive wild-type mice (n=5) following the intrathecal injection of lOOpmol of
(R)-CPP.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) of either hindpaw in naive wild type mice when testing resumed 10
min following injection (Student's t-test and Mann-Whitney Rank Sum test,
respectively). The intrathecal injection of (R)-CPP (at arrow) had no significant

































Figure 4.13 Effects of the intrathecal administration of the selective NMDA
receptor antagonist (R)-CPP in nai've PSD-95 mutant mice
Data represent the average (a) hindlimb withdrawal threshold to noxious heat and (b)
withdrawal threshold to mechanical (von Frey filament) stimuli ± SEM for each time
point in naive PSD-95 mutant mice (n=5) following the intrathecal injection of
lOOpmol of (R)-CPP.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) of either hindpaw in naive PSD-95 mutant mice when testing
resumed 10 min following injection (Student's t-test and Mann-Whitney Rank Sum
test, respectively). The intrathecal injection of (R)-CPP (at arrow) had no significant
































Figure 4.14 Effects of the intrathecal administration of saline in wild-type
mice at the peak of neuropathic reflex sensitivity
Data represent the average (a) hindlimb withdrawal to noxious heat and (b)
withdrawal threshold to mechanical (von Frey filament) stimuli ± SEM for each time
point in wild type mice (n=6) at the peak of behavioural reflex sensitivity following
the intrathecal injection of saline vehicle.
Wild type mice at the peak of ipsilateral thermal hyperalgesia, as determined by a
significant reduction in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05
Student's t-test) or paw withdrawal threshold (b, 'PWT'; *, p<0.05 Mann-Whitney
Rank Sum test) compared to contralateral withdrawal latency, were intrathecally
injected with saline (at arrow). 10 min following injection, saline had no discernible
effect on the withdrawal latency or the withdrawal threshold in either hindlimb and
there was no significant effect on hindlimb withdrawal post-injection when
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Figure 4.15 Effects of the intrathecal administration of saline in PSD-95
mutant mice following CCI
Data represent the average (a) hindlimb withdrawal to noxious heat and (b)
withdrawal threshold to mechanical (von Frey filament) stimuli ± SEM for each time
point in PSD-95 mutant mice that had previously undergone CCI surgery (n=6)
following the intrathecal injection of saline vehicle.
There was no significant difference in either withdrawal latency or threshold (a and
b, respectively) of either hindpaw in PSD-95 mutant mice following CCI (Student's
t-test and Mann-Whitney Rank Sum test, respectively). Saline (at arrow) had no
discernible effect on the withdrawal latency or the withdrawal threshold in either
hindlimb and there was no significant effect in hindlimb withdrawal post-injection
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Figure 4.16 Effects of the intrathecal administration of the agonist NMDA in
naive wild-type and PSD-95 mutant mice
Data are represented as the mean bilateral response ± SEM to the paw withdrawal
latency to noxious thermal stimulation (a) and the paw withdrawal threshold to
mechanical stimulation (b) for each time point prior to ('baseline') and 10 min
following the intrathecal administration of NMDA (0.25nmol in lOpl, at arrow) to
naive wild-type (A) and naive PSD-95 mutant (A ) mice (n=6 wild-type; n=7 for
PSD-95 mutant mice).
Wild-type mice showed significant development of thermal hyperalgesia following
intrathecal injection of NMDA when compared to pre-drug administration values in
response to thermal stimulation (a, *, p<0.01, One-way ANOVA) and in response to
mechanical stimulation (b, *, p<0.01, Kruskal-Wallis one-way ANOVA). No
development of thermal hyperalgesia post-NMDA administration was seen in PSD-
95 mutant mice when compared to pre-injection values (One-way ANOVA), nor was
there any development of mechanical allodynia post-drug administration when

















4.2.7 Behavioural reflex effects of intrathecal injection of CaMKII inhibitors
• *71
Since the primary action of activated NMDA receptors is the gating of Ca entry,
which can stimulate the Ca2+-activated protein kinase, CaMKII, we investigated
whether CaMKII activity is necessary for the NMDA-dependent sensitisation of
spinal neurones by the intrathecal injection of CaMKII inhibitors in wild-type mice
following CCI (see Section 2.2.4 and compound details in Table 2.1, pgs 60-63).
Intrathecal injection of the potent, selective CaMKII inhibitor myristoyl-autocamtide
2-related inhibitory peptide (myr-AIP) clearly reversed the neuropathic thermal
hyperalgesia for up to 70 min (Fig. 4.17a) and mechanical allodynia for up to 45 min
(Fig. 4.17b) seen in wild-type mice following CCI. Similarly, intrathecal injection of
the selective CaMKII inhibitor KN-93 reversed thermal hyperalgesia for 45 min (Fig.
4.18a) and mechanical allodynia for up to 65 min (Fig. 4.18b) in wild-type mice
following CCI.
An analogue of KN-93 with reduced activity against CaMKII, KN-92, showed less
effects on neuropathic sensitisation to the noxious thennal stimulus (Fig. 4.19a) and
to the mechanical stimulus (Fig. 4.19b).
These observations support the behavioural reflex evidence for a key role of the
NMDA receptor and its downstream target CaMKII in neuropathic sensitisation and
indicate that acute blockade at either point in this pathway is effective in reversing
established neuropathic sensitisation.
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Figure 4.17 Effects of the selective CaMKII inhibitor myristoyl-autocamtide
2-related inhibitory peptide on thermal hyperalgesia and mechanical
allodynia in wild-type mice at the peak of neuropathic reflex sensitivity
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey filament stimuli ± SEM (n=8) for each time point
before and following the intrathecal injection of lnmol myristoyl-autocamtide 2-
related inhibitory peptide ('myr-AIP', lnmol in lOpl saline).
Wild-type mice at the peak of ipsilateral thermal hyperalgesia as determined by a
significant reduction in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05
Student's t-test) or paw withdrawal threshold (b, 'PWT'; *, p<0.05 Mann-Whitney
Rank Sum test) compared to contralateral withdrawal latency were intrathecally
injected with myristoyl-autocamtide 2-related inhibitory peptide (at arrow). 10 min
following injection, myristoyl-autocamtide 2-related inhibitory peptide significantly
attenuated ipsilateral thermal hyperalgesia (a) in comparison to pre-injection
ipsilateral values (t, p<0.05, One-way ANOVA followed by a Dunnett's test) while
there was no significant alteration in the contralateral response. The effect lasted for
up to 70 min for the thermal test and 45 min for the mechanical test before the
ipsilateral withdrawal returned to pre-injection, baseline thresholds (*, p<0.05
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Figure 4.18 Effects of the CaMKII inhibitor KN-93 on thermal hyperalgesia
and mechanical allodynia in wild-type mice at the peak of neuropathic
reflex sensitivity
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey stimuli ± SEM to a noxious thermal or normally
innocuous mechanical stimulus (n=9) for each time point before and following the
intrathecal injection of 120pmol KN-93.
Wild-type mice at the peak of ipsilateral thermal hyperalgesia as determined by a
significant reduction in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05
Student's t-test) or paw withdrawal threshold (b, 'PWT'; *, p<0.05 Mann-Whitney
Rank Sum test) compared to contralateral withdrawal latency, were intrathecally
injected with KN-93 (at arrow). 10 min following injection, 120pmol KN-93
significantly attenuated ipsilateral thermal hyperalgesia in (a) in comparison to pre-
injection ipsilateral values (|, p<0.05, One-way ANOVA followed by a Dunnett's
test) while there was no significant alteration in the contralateral response. In (b), the
ipsilaterally reduced paw withdrawal threshold to mechanical stimulation was
significantly increased (|, p<0.05, Kruskal-Wallis ANOVA followed by a Dunn's
test) with no change in contralateral responses. The effect of KN-93 lasted for up to
45 min for the thermal test and 65 min for the mechanical test before the ipsilateral
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Figure 4.19 Effects of the less active control analogue KN-92 on thermal
hyperalgesia and mechanical allodynia in wild-type mice at the peak of
neuropathic reflex sensitivity
Data represent the average (a) hindlimb withdrawal latency to noxious heat and (b)
withdrawal threshold to von Frey stimuli ± SEM to a noxious thermal or normally
innocuous mechanical stimulus (n=8) for each time point before and following the
intrathecal injection of 120pmol of the less active KN-93 analogue, KN-92 as
indicated....
Wild-type mice at the peak of ipsilateral thermal hyperalgesia as determined by a
significant reduction in ipsilateral paw withdrawal latency (a, 'PWL'; *, p<0.05
Student's t-test) or paw withdrawal threshold (b, 'PWT'; *, p<0.05 Mann-Whitney
Rank Sum test) compared to contralateral withdrawal latency, were intrathecally
injected with KN-92 (at arrow). 10 min following injection, 120pmol KN-92
moderately attenuated ipsilateral thermal hyperalgesia in (a) in comparison to pre-
injection ipsilateral values (f, p<0.05, One-way ANOVA followed by a Dunnett's
test) while there was no significant alteration in the contralateral response. In (b), the
ipsilaterally reduced paw withdrawal threshold to mechanical stimulation was
moderately increased (f, p<0.05, Kruskal-Wallis ANOVA followed by a Dunn's
test) with no change in contralateral responses. The effect of KN-92 lasted for up to
35 min for the thermal test and 40 min for the mechanical test before the ipsilateral
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4.2.8 CaMKII activity in wild-type and PSD-95 mutant mice
Following activation, CaMKII autophosphorylates at Thr ' to produce a
constitutively active form of the enzyme (Hanson et al., 1989). To provide a
biochemical index of the activation state of CaMKII, we isolated CaMKII by
immunoprecipitation from spinal cord extracts and measured the proportion of its
activity that was constitutive in order to monitor NMDA receptor-mediated Ca2+
entry. We assessed CaMKII activation responses in PSD-95 mutant mice to establish
whether functional communication between the NMDA receptor and CaMKII might
be disrupted by the PSD-95 mutation (see Section 2.4.5, pgs 90-91).
The proportion of immunoprecipitated CaMKII activity that was constitutive (rather
than maximally evoked by Ca2 ' addition in vitro) was measured after topical
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application of NMDA (with its co-agonist glycine), of the Ca ionophore,
ionomycin or of saline vehicle to dorsal surface of the spinal cord of naive wild-type
and PSD-95 mutant mice. There was no significant difference in the proportion of
constitutive CaMKII activity in the increased response to either NMDA or
ionomycin between wild-type and PSD-95 mutant mice (Table 4.1a). This response
to NMDA/glycine was similar to that of ionomycin, and so must be assumed to
represent a ceiling level of response. Also, the mean maximal CaMKII activity
(evoked by Ca2+/calmodulin addition in vitro) in immunoprecipitates from PSD-95
mutant mice spinal cord was unaltered from that seen in wild-type mice (108.3 ±
13.7 and 97.8 ±13.1 pmoles/min/pg original extract protein, respectively), indicating
that CaMKII expression is not likely to be altered in the mutant mice. So, spinal
2+
NMDA receptor function at the level of acute agonist-induced Ca entry in response
to agonist stimulation is not affected in na'ive PSD-95 mutant mice, a result that is
consistent with earlier studies in the hippocampus of these animals (Migaud et al.,
1998).
In wild-type mice with chronic constriction injury, there was a clear increase in
constitutive CaMKII activity ipsilateral, but not contralateral to injury (Table 4.1b).
This increase was reversed by topical application of the selective NMDA
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Table 4.1 Effects of acute intrathecal drug administration and of chronic
nerve injury (CCI) on CaMKII activation in spinal cord of wild-type and PSD-
95 mutant mice
(a) Saline vehicle, NMDA (500 pM) with the co-agonist glycine (100 pM), or
ionomycin (10 pM), were topically applied to the dorsal surface of L3-L6
spinal cord in naive wild-type and PSD-95 mutants. Data are expressed as the
percentage of maximal CaMKII activity and are means ± SEM (n=4/6).
Statistically significant differences are shown as *, p<0.05 by Mann-Whitney
U test, compared to corresponding saline values.
(b) Saline vehicle or (R)-CPP (10 pM) or saline vehicle were applied in a volume
of 500pl to the dorsal surface of L3-L6 spinal cord in wild-type and PSD-95
mutant mice at the peak of neuropathic reflex sensitivity following CCI. Data
are expressed as the percentage of maximal CaMKII activity and are means ±
SEM (n=4/6). Statistically significant differences are shown as *, p<0.05 by




of drug to spinal
dorsal horn
Constitutive CaMKII activity (% of maximal activity)
(a) In naive mice Wild-type PSD-95 Mutant
Saline 25.4 ±3.9 21.1 ±3.0
NMDA/glycine 36.2 ±3.7 * 32.4 ±4.1 *
lonomycin 33.5 ±2.1 * 30.0 ±2.8 *











Saline 35.0 ±2.8 * 16.3 ±2.3 16.9 ± 1.8 13.9 ± 1.6
(R)-CPP 12.9 ±1.6 18.1 ±3.6 - -
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receptor antagonist (R)-CPP to the spinal cord for 15 min immediately prior to
removal. This increase in constitutive CaMKII activity was absent in PSD-95 mutant
mice following CCI (Table 4.1b).
7 i
Since both acute NMDA-induced Ca entry and the ability of CaMKII to respond to
Ca2+ elevation appear to be normal in the mutant mice, it seems likely that a factor
facilitating the functional coupling between the NMDA receptor and CaMKII is the
key element altered in CCI.
4.2.9 NMDA receptor modulation by phosphorylation
Disruption of the function of an NMDA receptor modulatory factor in PSD-95
mutant mice is likely to be responsible for the non-sensitising phenotype observed.
One possible candidate for such a modulatory factor might be the regulatory
phosphorylation ofNMDA receptor subunits by kinases such as PKC and PKA,
which may specifically increase the degree of Ca2+ entry evoked by a given
concentration of NMDA (Tingley et al., 1997; Westphal et al., 1999).
In order to directly assess whether the phosphorylation state of the NMDA receptor
was altered following CCI, we utilised phospho-specific antibodies for key channel-
regulating residues in NR1 at Ser896 and Ser897 (PKC and PKA targets, respectively,
see Sections 2.2.6 and 2.4.6 and antibody details in Table 2.3, pgs. 64-66, 69, 91).
Small reductions in the levels of pan-NRl immunoreactivity were seen ipsilateral to
CCI (Fig. 4.20a; in accordance with a previous report (Hama et al., 1995) and our
unpublished data from the rat CCI model). These reductions were similar in PSD-95
mutant mice to those in wild-type mice (Fig. 4.20a). Figure 4.20 shows that the
OQ7
extent to which Ser of the NR1 subunit was phosphorylated was specifically
increased ipsilateral to CCI in wild-type mice (Fig. 4.20b). 4-5 fold greater ratios of
phospho-Ser897-NRl :pan-NRl immunoreactivity were seen ipsilateral to CCI
compared to those on the contralateral side (Fig. 4.20c). In PSD-95 mutant mice, the
OQ7
corresponding CCI-induced increment in Ser -NR1 phosphorylation was almost
completely prevented (Fig. 4.20b).
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Figure 4.20 Immunoblots for phospho-Ser897-NRl and pan-NRl in NR1
immunoprecipitates from wild-type and PSD-95 mutant mice following
CCI surgery
Western blot analysis of hemisected spinal cord pan-NRl immunoprecipitates
following sciatic CCI induced 12 days previously.
(a) Immunoprecipitated samples derived from either two wild-type (+/+) or two
PSD-95 mutant (-/-) mice, ipsilateral or contralateral to the injury were
probed with antibodies for pan-NRl.
(b) Immunoprecipitated samples derived from either two wild-type (+/+) or two
PSD-95 mutant (-/-) mice, ipsilateral or contralateral to the injury were
probed with antibodies for phospho-Ser897-NRl (same samples as in a)
above). Non-specific bands seen at -40-70 kDa represent cross-reactivity
with the immunoprecipitating IgG and were similar in all samples and in
extract-free blanks.
(c) ECL films from 4 separate determinations were scanned and the specific
densities of the -120 kDa NR1 bands were analysed by densitometry.
Arbitrary grey scale values were normalised to the wild-type contralateral
OQ7
values in each case and then mean relative phospho-Ser -NR1: pan-NRl





























Phospho-Ser8%-NR 1 immunoreactivity could not be reliably detected in these
experiments. These results suggest that a mechanism of regulatory phosphorylation
of NR subunits is a prime candidate for the mechanism of facilitated NMDA receptor
function which is necessary for neuropathic sensitisation and which is disrupted in
PSD-95 mutants.
4.2.10 Further examination of PKA signalling
NMDA receptor phosphorylation by PKA is implicated in the regulation of
neuropathic sensitisation. PSD-95 can link kinase-docking adapters such as
AKAP79/150 to the NMDA receptor (Colledge et al., 2000), and such adapters,
together with relevant kinases can be isolated in association with NMDA
receptor:PSD-95 complexes (Husi et al., 2000). As the SH3 and GK domains of
PSD-95 are absent in the PSD-95 mutant mice, and the presence of these two
domains is believed to be important for AKAP79/150 association with the NMDA
receptor, it was of interest to determine whether there were any alterations in the
protein: protein interactions whereby PKA is targeted to the postsynaptic membrane
via a PSD-95 interaction. Given the apparent increase in PKA phosphorylation at
Ser897 on NR1 ipsilateral to injury in wild-type mice, and the lack of this injury-
induced increase in PSD-95 mutant mice, we hypothesised that there may be some
interruption of PKA targeting to the NMDA receptor as a consequence of the PSD-
95 mutation, possibly due to a disrupted linkage via AKAP79/150. We examined this
question by isolating spinal cord multiprotein complexes from nai've wild-type and
naive PSD-95 mutant samples using the peptide-based affinity separations, targeting
the SIESDV site in NR2 subunits as described in Section 4.2.2 (Husi and Grant, Husi
et al., 2000) and carried out a small-scale analysis of the NR2-associated PKA-
related proteins that may be altered as a consequence of the mutation. We used
antibodies against the regulatory PKA subunits, Rlla and RIip, which bind to
AKAP79/150 (Coghlan et al., 1995) as well as an antibody targeted against
AKAP150 (the rat isoform) itself, and an antibody against the NMDA receptor
subunit NR1 as well as GAPDH were used as controls for protein levels (Fig. 4.21).
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Figure 4.21 Immunoblots for NR1, Rlla, RII|3 and AKAP150 in 'pep6' NR2
C-terminal resin immunoprecipitates from nai've wild-type and PSD-95
mutant mice
Western blot analysis of spinal cord 'pep6' C-terminal (SIESDV) resin of NR2
immunoprecipitates derived from either 8 wild-type (+/+) or 8 PSD-95 mutant (-/-)
mice were probed with antibodies for NR1 (a), Rlla (b), RII(3 (c) and AKAP150 (d).
Levels of NR1 protein were used as a relative indication of NMDA receptor levels in
+/+ and -/- samples and the ubiquitous housekeeping enzyme GAPDH was used as
an internal control (lower panels). There was no significant difference in the levels of














































































There were no discernible alterations in the levels of NR1 (Fig. 4.21a), Rlla (Fig.
4.21b), RIip (Fig. 4.21c) or AKAP150 (Fig. 4.21d) when nai've wild-type samples
were compared to nai've PSD-95 mutant samples (see Sections 2.2.6 and 2.4.6 and
antibody details in Table 2.3, pgs. 64-66, 69).
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4.3: Discussion
Spinal NMDA receptors have a well-established role in the central mechanisms of
neuropathic pain. Intrathecal application of selective NMDA receptor antagonists
inhibit the behavioural reflex thermal hyperalgesia and mechanical allodynia that are
characteristic of neuropathic pain models (Chaplan, Malmberg and Yaksh, 1997; Tal
and Bennett, 1993; Boyce et al., 1999; Mao et al., 1993) and the mRNA and protein
for NMDA receptor subunits are all expressed in dorsal spinal cord (Luque et al.,
1994; Boyce et al., 1999; Yung, 1998). We addressed the potential role of the
NMDA receptor-adapter protein PSD-95. Generation of transgenic mice expressing a
truncating mutation part way through the sequence of the PSD-95 gene (Migaud et
al., 1998) enabled us to address the spinal distribution, the relation to NMDA
receptors and the functional role of PSD-95 in neuropathic pain.
Histochemical staining for the ff-galactosidase reporter incorporated into the mutant
construct showed expression in many cells within lamina II of the superficial dorsal
horn of heterozygous mice. This corresponds to known regions of high NMDA
receptor expression and to zones of termination of fine afferents in the regulation of
sensory processing (and matches a recent report of the immunoreactivity for native
PSD-95 in spinal cord; Tao et al., 2000). No evidence was found for |3-galactosidase
staining in dorsal root entry zones, DRG or afferent fibres. NMDA receptors have
been proposed to regulate afferent transmitter release (Liu, Mantyh and Basbaum,
1997), and NR1 as well as NR2B subunits have been detected in primary afferent
neurones and DRG (Watanabe, Mishina, and Inoue, 1994; Ma and Hargreaves,
2000). However, our evidence suggests that any such peripheral NMDA receptor
complexes that occur would lack the adapter PSD-95. In the spinal cord of wild-type
mouse, protein: protein interaction studies using immuno- or affinity- reagents (Husi
et al., 2000) for NR1, NR2B or PSD-95 confirmed that each of these could harvest
complexes showing immunoreactivity for NR1, NR2A, NR2B and PSD-95.
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The functional impact of the truncated PSD-95 construct on neuropathic pain-related
behaviours was striking. Thermal hyperalgesia, mechanical allodynia and cold
allodynia brought about by peripheral nerve ligation injury were completely (or
almost completely) abrogated in homozygous PSD-95 mutant mice. There was no
evidence for motor deficit in these mice as locomotion, motor grip function and the
ability to execute the behavioural reflex responses appeared normal. The pre-nerve
injury response sensitivity and that of the contralateral paw after injury was no
different between mutant and wild-type mice in the thermal hyperalgesia and cold
allodynia tests. The basal response thresholds to mechanical stimuli appeared to be
elevated in the PSD-95 mutant mice. This would be consistent with the idea that
some PSD-95-mediated function was contributing to maintaining the sensitivity of
the basal reflex to mechanical stimuli. Nevertheless, the lower threshold in wild-type
mice was insensitive to the NMDA receptor antagonist (R)-CPP suggesting lack of
direct involvement of this receptor. It is important to note that different strains of
mice have been shown to exhibit different responses in a variety of nociceptive
behavioural reflex tests (Mogil et al., 1999). Further work would be necessary to
confirm and extend this observation here. These results indicate that the cellular
role(s) of PSD-95, which are disrupted by the truncation mutation, are essential for
the processes that underlie hyperaesthesia in a neuropathic pain model.
Since alterations and degeneration of afferent myelin sheaths could potentially elicit
changes that contribute to the development of pain-related behaviours (Guilbaud et
al., 1993; Sommer et al., 1995; Coggeshall et al., 1993; Campbell et al., 1988), we
investigated the morphology of sciatic nerve fibres in PSD-95 mutant mice. No
alterations in axon profiles, myelination or local responses to constriction injury were
apparent, consistent with the idea that central sites, where PSD-95 is expressed, are
likely to be the location of the key changes.
Studies utilising the intrathecal injection of NMDA receptor antagonist and agonist
confirmed that the hyperalgesia and allodynia of the CC1 model (as adapted by us for
use in mice) are indeed dependent on NMDA receptors at a spinal site. The selective
NMDA receptor antagonist (R)-CPP showed a concentration-dependent and
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reversible inhibition of the neuropathic hyperalgesia and allodynia in wild-type mice.
Its specificity was indicated by the lack of effect on contralateral responses in wild-
type mice and on responses from either side in PSD-95 mutants where the
sensitisation had failed to develop. Conversely, the intrathecal injection of the
agonist, NMDA, mimicked the thermal hyperalgesia and mechanical allodynia that
could be caused by nerve injury in wild-type mice, but appeared ineffective in the
PSD-95 mutant mice. This is consistent with a recent preliminary report of attenuated
tail flick responses to NMDA in rats treated with PSD-95 antisense oligonucleotide
(Tao et al., 2000). Beyond implicating NMDA receptor function in the injury-
induced sensory changes, these data suggest that the failure of a key ligand-gated
signal from spinal NMDA receptors in the PSD-95 mutant mice may be responsible
for their lack of neuropathic sensitisation.
Since the primary action of NMDA receptor complexes is the gating of Ca2+/ Na+
entry, we examined the role of a major Ca2+-regulated kinase, CaMKII, in
neuropathic sensitisation. CaMKII is an abundant protein of the postsynaptic density
complex, which contains NMDA receptors (Kennedy, 1997), can be isolated in
molecular complexes associated with NR1 or NR2 subunits (Husi et ah, 2000) and
may dock directly to NR2A or B subunits (Gardoni et ah, 1999). This location, as
well as data implicating NMDA receptor-mediated CaMKII activation in the cellular
sensitisation occurring during long-term potentiation in hippocampus (Nicoll and
Malenka, 1995; Lisman et ah, 1997), suggests that the enzyme may be a good
candidate as a contributor to neuropathic sensitisation. Consistent with this
hypothesis, the thermal hyperalgesia and mechanical and cold allodynia following
CCI in wild-type mice were attenuated by the selective CaMKII inhibitors,
myristoyl-autocamtide 2-related inhibitory peptide, KN-93 and to a lesser extent by
KN-92 (a less active congener of KN-93).
Following its activation by Ca2+, CaMKII becomes autophosphorylated to generate a
constitutively active, Ca2+-independent form of the enzyme (Hanson et ah, 1989).
We therefore measured the fraction of authentic CaMKII activity that was
constitutive as a monitor of the recent history of Ca2+ elevation. Increments in the
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fraction of constitutively active CaMKII were no different when a high concentration
of NMDA, and its co-agonist glycine, was topically applied to the dorsal spinal cord
between wild-type and PSD-95 mutant mice. These responses were similar in extent
to those elicited by the Ca M ionophore, ionomycin, and are therefore likely to be at
7+
ceiling level. This suggests that the maximally-activated Ca entry function of the
NMDA receptor is unaltered by the PSD-95 mutation and that NMDA receptor
complexes do not appear to be incorrectly assembled or dysfunctional in the mutant,
7+
with regard to Ca entry.
Nevertheless, CCI caused a clear increment in constitutive CaMKII activity (that was
NMDA receptor-dependent) in spinal cord tissue from the ipsilateral compared to the
contralateral side of wild-type mice and this response was minimal in PSD-95
mutants. Total CaMKII kinase activity and immunoreactivity was unaltered by CCI
or by the PSD-95 mutation. It therefore seems possible that a critical role of PSD-95
with regard to neuropathic hyperalgesia/ allodynia could be in enabling a mechanism
whereby the sensitivity of the NMDA-mediated Ca2+ entry response is enhanced by
CCI. In such a situation, the sensitivity of NMDA receptor Ca2+ entry to relatively
low concentrations of agonist (as during CCI in vivo) might well be greater, while
the maximal extent of the response may be unaltered. Adapter-mediated
contributions to cellular compartmentalisation of relevant proteins or actions as
molecular scaffolds to facilitate intracellular signalling could potentially underlie
such modulation.
The interaction between NMDA and PSD-95 potentially increases the complexity of
signalling networks at excitatory synapses and may provide a structural framework
that permits preferential targeting of kinases to NMDA receptors. Presumably, such a
highly organized kinase-substrate complex might ensure rapid and efficient
phosphorylation of NMDA receptor ion channels in response to local synaptic
signals (Colledge et al., 2000). One basis for a facilitation ofNMDA receptor
function during CCI might be its regulatory protein phosphorylation through kinases
such as PKC (Chen and Huang, 1992) or PKA (Westphal et al., 1999).
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Here, we report a specific increase in the levels of PKA phosphorylation ipsilateral to
CCI in wild-type mice, with no alteration in PKC phosphorylation. In spinal cord
neurones, PKC can potentiate NMDA-mediated current (Gerber and Randic, 1989)
and there is evidence for a facilitation of NMDA receptor responses in dorsal horn
neurones by concurrent neuropeptide and metabotropic glutamate receptor activation,
that may occur in neuropathic and other chronic pain models (Heppenstall and
Fleetwood-Walker, 1997; Bleakman et al., 1992) and which may involve PKC and/or
PKA (Kolaj et al., 1994). Moreover, in vitro, expression of PSD-95 may act to inhibit
PKC-induced potentiation of the NMDA receptor ion channel (Yamada et al., 1999).
Therefore, the lack of PKC-induced phosphorylation may not be too surprising as
previous reports have shown that NMDA receptors assembled from subunits that
lack all known PKC sites can still show PKC-induced potentiation thereby indicating
that PKC may be acting indirectly (Zheng et al., 1999).
NMDA receptor-ligand binding sites and NR1 protein levels are reduced in the
dorsal horn following peripheral nerve injury (CCI) and inflammation (Aanonsen et
al., 1990; Hama et al., 1995; Sloan et al., 1991). The NR1 subunit contains three
regions of alternative splicing, Nl, CI and C2 (Zukin and Bennett, 1995). As
mentioned in the introduction, the AKAP, Yotiao interacts with the CI exon of NR1
subunits, and may act to induce a stable Yotiao: PKA: NR1 complex that could
promote PKA-mediated modulation ofNMDA receptor activity (Lin et al., 1998;
Feliciello et al., 1999). Through interaction with the CI splice variant, Yotiao targets
both PKA and active PP1 phosphatase to NMDA receptor complexes, conferring bi¬
directional regulation of NMDA receptor activity (Westphal et al., 1999). While NR1
is highly expressed throughout the spinal cord and sensory ganglion (Kus, Saxon and
Beitz, 1995), the CI is present in only -10% of total NR1 protein in the spinal cord
and spinal cord injury causes no significant change in overall NR1 or CI cassette
expression (Grossman et al., 2000; Prybylowski et al., 2001). Moreover, the
expression of Yotiao is very low in spinal cord tissue (Husi, unpublished). Thus, a
different mechanism of PKA-mediated potentiation of NMDA receptors may account
for increased PKA phosphorylation ipsilateral to injury in wild-type mice.
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One potential explanation for these observations is that the AKAP79/150 signalling
scaffold no longer can be recruited to glutamate receptors through interaction with
MAGUK proteins (Colledge et al., 2000). AKAP79/150 previously has been shown
to provide a scaffold for three signalling enzymes: PKA, PKC, and calcineurin
(PP2B). Interestingly, PSD-95 competes with calcineurin for binding to
AKAP79/150 in vitro so that when bound to MAGUKs, AKAP79/150 may
preferentially target kinases but not phosphatases to NMDA receptors (Colledge et
ah, 2000). However, there were no alterations in the levels of NMDA receptor-
associated AKAP150 or PKA subunits in the PSD-95 mutant mice, although we
cannot rule out the possibility that they may be bound to other NMDA receptor
complex-related interaction partners. The precise basis for the PSD-95-dependent
facilitation of NMDA receptor function caused by CCI remains to be elucidated.
The site of truncation of the PSD-95 molecule may give some clue as to the protein
docking events that may be crucial to the functional disruption of neuropathic pain.
The first and second PDZ domains of PSD-95 are unaltered in the mutant although
part of its third PDZ domain, and the SH3 and the guanylate kinase (GK) domains
are deleted (Migaud et ah, 1998). Interactions of NR2 subunits, Shaker K+ channels
and nNOS (which involve PDZ1 and 2 domains) should in principle be retained
(Kornau et ah, 1995; Sheng and Wyszynski, 1997; Christopherson et ah, 1999).
PDZ3 domain interactions such as with the microtubule binding protein CRIPT,
neuroligin and citron may be prevented (Passafarro et ah, 1999; Irie et ah, 1997;
Zhang et ah, 1999). SynGAP, which can interact with PDZ1, 2 and 3 of PSD-95 and
may regulate the MAPK pathway (Chen et ah, 1998), shows no detectable expression
in spinal cord (data not shown). The influences of the PSD-95 mutation on in vivo
cellular interactions between proteins may be more complex. Intermolecular
interactions between the SH3 and GK domains of PSD-95 may restrict its
intermolecular binding (McGee and Bredt, 1999), although such interactions have
reportedly no effects on the ability of PSD-95 to cluster K+ channels (Shin et ah,
2000). Further complexities may be present if the truncated PSD-95 mutant protein
does not undergo identical intracellular trafficking and localisation to that of the
wild-type protein (Migaud et ah, 1998).
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Figure 4.22 Summary schematic of the main findings with PSD-95 mutant
mice following CCI
This schematic represents a summary of the results presented in this chapter. PSD-95
is exclusively expressed in the superficial laminae of the dorsal horn and associates
with NR2 subunits ofNMDA receptor as has been shown in other regions of the
nervous system. PSD-95 mutant mice fail to develop the characteristic behavioural
sensitivity to thermal and mechanical stimuli following CCI although this is not a
consequence of differential demyelination following CCI as a result of the mutation,
as the constriction injury does cause demyelination to the same extent as that noted
in wild-type littermate controls. In addition, activation of spinal NMDA receptors by
local intrathecal application failed to result in behavioural sensitisation in the PSD-95
mutant mice as it does in the wild-type mice.
Despite this, Ca2 entry through the NMDA receptor in PSD-95 mutant mice
functions normally, although the increment in CaMKII activity that normally follows
ipsilateral to injury in wild-type mice was absent in the PSD-95 mutant mice. This
may indicate that the mechanisms responsible for the lack of sensitivity lies
downstream of PSD-95, such as with the PKA anchoring protein AKAP79/150
which localises PKA to its site of action and which is dislocated from the complex as
a result of the mutation. We noted that levels of PKA activation of the NR1 subunit,
as measured by examination of the levels of phospho-Ser897 protein, were elevated
ipsilateral to CCI in the spinal cord of wild-type mice but not in PSD-95 mutant
mice. However, the underlying cause of this difference is unknown as there was no
apparent difference in the expression of spinal cord AKAP79/150 or of RJIa, RII(3














1. Increased PKA phosphorylation ipsilateral in wild-
type mice but NOT in PSD-95 mutants
2. This is not due to a loss of PKA localisation as a
result of the mutations as there was no difference
between wild-type and PSD-95 mutant mice in the
levels of PKA subunits or the PKA anchoring protein
AKAP79/150
Ca2+ and CaMKII in PSD-95 mutants:
1. Ca2+ entry through the NMDA receptor in
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CaMKII activation
.2. Pharmacologically blocking CaMKII inhibits
hyperalgesia and allodynia in wild-type mice
3. Biochemically measured spinal CaMKII
activity was increased in wild-type mice but
NOT in PSD-95 mutant mice
PSD-95 mutant mice pain phenotype:
1. Highly specific superficial dorsal horn
expression of PSD-95-LacZ mutant reporter (no
PNS expression)
2. PSD-95 associates with NMDA receptor
subunits in wild-type the spinal cord
3 No behavioural sensitivity following CCI
despite normal myelination and expected levels
of demyelination associated with wild-type CCI
4. Behavioural sensitivity could not be induced
in PSD-95 mutants with in vivo NMDA receptor
activation
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There is the possibility that postsynaptic densities lacking PSD-95 may use
Chapsynl 10/PSD-93 or SAP 102 for ligand localisation. However, little is known
about the physiological diversity that may derive from differences in MAGUK
content at glutamatergic synapses. SAP97 and PSD-95 PDZ domains 1 and 2 have
similar binding affinities for the NR2 C-terminal sequence which may indicate that
both are comparable in their capability to interact with NMDA receptors, while all
three PDZ domains of SAP 102 are capable of binding the NR2 motif (Miiller et al.,
1996). So, which interaction actually occurs in vivo depends primarily on which
member of the MAGUK family co-distributes with the receptors in neuronal cells
(Miiller et al., 1996).
While data for the other MAGUK members is lacking, they contain the same
domains, and share NR2 subunits and K+ channels as common targets such that it
might be expected that, if present in the spinal cord, other MAGUKs of this family
might compensate in the regulation of NMDA receptor pathway. However, this
possibility is not supported here, given the complete absence of neuropathic reflex
sensitivity development following peripheral nerve injury. Proteomic analysis of the
NMDA receptor complex in the forebrain of wild-type and PSD-95 mutant mice
indicate that there is no alteration in the levels of Chapsynl 10/PSD-93 or SAP97 as a
consequence of the mutation, whereas there is an increase in SAP 102 (Husi et al.,
2000). Moreover, evidence from Chapsynl 10/PSD-93 knockout mice suggests that
MAGUKs may not be essential for the normal development of structure and function
of certain central synapses but may participate during extreme physiological
situations (McGee et al., 2001).
In addition, forebrain analysis of the PSD-95 mutant indicates that there are no
overall alterations in the levels of GKAP, Yotiao, PKC, PKA CaMKII, or the
phosphatases PP1, PP2A or PP2B. Nor were there apparent alterations in any of the
molecules involved in the MAPK pathway or nNOS levels associated with the
NMDA receptor complex (Husi et al., 2000). It is possible that PSD-95 may be the
only functional MAGUK as far as the spinal cord is concerned, although this remains
to be shown.
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Although the critical docking partner for PSD-95 in its role in neuropathic
sensitisation cannot be readily discerned at present, the present studies firmly
establish that this molecule plays a key role in the facilitation of NMDA receptor
function which underlies neuropathic pain-related behaviours. The neuropathic
sensitisation of spinal sensory reflexes is therefore dependent on spinal NMDA
receptors and the failure of this sensitisation in PSD-95 mutant mice indicates that
NR: PSD-95 interactions in spinal cord play a key role in the development of
neuropathic pain.
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CHAPTER 5: Summary and Conclusions
Neuropathic pain encompasses a group of painful disorders due to peripheral or
central nervous system dysfunction as a result of injury to the nervous system. The
chronic pain that develops manifests as hyperalgesia, allodynia and spontaneous
pain. The mechanisms underlying neuropathic pain are complex, involving both
peripheral and central anatomical and neurochemical changes that can persist long
after the injury has healed. The morphological and functional alterations that occur in
the central nervous system during neuropathic pain highlight the neuroplasticity
inherent in the CNS. Animal models that reproduce the mechanisms underlying
neuropathic pain have led to a better understanding of the cellular events involved.
Here, we have used the chronic constriction injury model (CCI, Bennett and Xie,
1988), which mimics many of the behavioural changes symptomatic of neuropathy.
Basic research with this animal model has shown that a number of
pathophysiological and biochemical changes occur in the nervous system as a result
of the peripheral nerve injury.
The AMPA and NMDA subtypes of ionotropic glutamate receptors have long been
the focus of research in the mechanisms of spinal nociceptive transmission. The
AMPA receptors have widespread expression in the spinal cord and not only mediate
the fast synaptic currents arriving at the dorsal horn of the spinal cord in response to
acute primary afferent stimulation, but also participate in mediating chronic
neuropathic transmission (Aanonsen, Lei and Wilcox, 1990; Budai and Larson, 1994;
Mao et al., 1992a). NMDA receptor subunits are also present in the spinal cord tissue
with differential regional expression. However, postsynaptic membranes must
undergo sufficient depolarisation, such as in response to high threshold primary
afferent stimulation as in the case of peripheral nerve injury, before the NMDA
receptor ion channel becomes activated. Spinal administration of AMPA or NMDA
receptor agonists can enhance dorsal horn neurone responses to noxious stimulation
(Aanonsen, Lei and Wilcox, 1990) and produce spontaneous pain behaviours and
hyperalgesia (Zhou, Bonesara and Carlton, 1996). In addition, NMDA receptor
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antagonists can reduce the frequency dependent wind-up of dorsal horn neurones
following repetitive C-fibre stimulation (Davies and Lodge, 1987) and attenuate the
raised behavioural sensitivity characteristic of peripheral neuropathy (Mao et al.,
1993; Tal and Bennett, 1993). To this date, the factors determining the relative
contribution of AMPA and NMDA receptors to neuropathic pain mechanisms are
poorly understood.
The work presented here has been concerned with an examination of the mechanisms
underlying neuropathic pain following peripheral nerve injury, focussing on the
ionotropic glutamate receptors AMPA and NMDA, their respective intracellular
interacting proteins and regulation of specific subunits by phosphorylation under
conditions of peripheral nerve injury. This research has utilised behavioural,
pharmacological, histochemical and biochemical techniques to investigate the role of
recently identified proteins differentially interacting with the C-terminal domains of
the ionotropic AMPA and NMDA glutamate receptors in mediating neuropathic
sensitivity at the behavioural and cellular level.
5.1 AMPA receptor involvement in neuropathic pain
Firstly, the involvement of AMPA receptors in mediating hyperalgesia and
mechanical allodynia was examined by the intrathecal injection of the AMPA
receptor antagonists, NBQX, NS-257 and SYM 2206 in rats with established
neuropathic reflex sensitisation following chronic constriction injury (Bennett and
Xie, 1988). These AMPA receptor antagonists all alleviated thermal hyperalgesia
and mechanical allodynia to varying degrees and in a dose-dependent manner with
no effects in uninjured animals; observations consistent with a particular role for
AMPA receptors in the persistent pain behaviours that develop following induction
of CCI (Budai and Larson, 1994; Mao et al., 1992a).
The expression of the AMPA receptor subunits GluRl and GluR2, with reported
predominant dorsal over ventral horn expression (Harris et al., 1996; Tolle et al.,
1995) was examined using in situ hybridisation histochemistry for mRNA level
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analysis and Western blot for protein level analysis. mRNA expression was
examined in rats with maximal development of neuropathic reflex sensitivity as
indicated by behavioural reflex sensitisation following CCI. We confirmed that the
mRNAs for the GluRl and GluR2 subunits were specifically localised in the dorsal
horn of the spinal cord with moderate to weak labelling in ventral horn under normal
conditions. We noted an ipsilateral reduction in the levels of GluRl mRNA in the
superficial laminae of the dorsal horn as compared to control contralateral, sham and
naive expression levels, whereas overall levels of GluR2 mRNA in the spinal cord
increased significantly in the superficial laminae. Western blot analysis, carried out
to further characterise AMPA receptor subunit protein levels, revealed similar results
to that described for mRNA, whereby GluRl protein levels were diminished
ipsilateral to CCI as compared to control levels, while GluR2 levels increased in
ipsilatcral spinal cord. While the increased GluR2 levels ipsilateral to CCI agrees, the
GluRl result is in disagreement with one previously published paper reporting that
levels of GluRl (as assessed by immunohistochemistry) increase ipsilateral to CCI
(Harris et ah, 1996). The reason for this is unclear although here both ISHH levels of
GluRl mRNA and Western blot of GluRl protein were consistent in showing
decreases ipsilateral to CCI. Western blot of whole spinal cord may mask lamina-
specific alterations in GluRl protein levels ipsilateral to CCI although regionally
identified GluRl mRNA levels were also diminished ipsilateral to CCI. While
alterations in mRNA do not necessarily imply similar alterations in protein levels, the
consistent decrease in both GluR 1 protein and mRNA in the ipsilateral dorsal horn
following CCI in comparison to increases of GluRl protein in the report of Harris et
al. (1996) suggest that further study is required to resolve the issue.
It is possible that changes in the relative expression of the GluRl and 2 subunits
throughout the dorsal horn or even within individual neurones may contribute to the
functional changes occurring in the established neuropathic state following CCI. The
presence of GluR2 subunits renders the AMPA receptor ion channel impermeable to
Ca2+ (Burnashev et al., 1992a). However, there appears to be a differential
expression of GluRl and GluR2 in the superficial dorsal horn (as examined by
AMPA-induced cobalt loading), whereby cells expressing Ca2+-permeable AMPA
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receptors (so presumably lacking the GluR2 subunit) can be found in LI and LII0,
"\ i
while there are low numbers of Ca -penneable AMPA receptors in LI I,
corresponding to the high expression of GluR2 subunits in this region (Engelman,
Allen and MacDermott, 1999; Tolle et ah, 1993).
We examined the possibility of modulation of AMPA receptors by kinases such as
CaMKII/PKC and/or PKA, which are known to target the GluRl subunit. Following
CCI, spinal cord GluR 1-directed immunoprecipitates were probed with phospho-
specific antibodies targeted against phospho-Ser831 (CaMK.II/PKC site) and phospho-
Ser845 (PKA site) on the C-terminus of GluRl subunits. Previous studies have shown
that dorsal horn responses to ionotropic glutamate receptor agonists can be enhanced
by PKA and PKC activation and may result in hyperalgesia (Cerne, Jiang and
Randic, 1992; Aley and Levine, 1999; Munro, Fleetwood-Walker and Mitchell,
1994; Coderre, 1993; Mao, et ah, 1992b). In addition, GluRl phosphorylation of
Ser831 by CaMKII potentiates GluRl current in the hippocampus (Derkach, Barria
and Soderling, 1999) while PKA-mediated phosphorylation at Ser845 increases
AMPA responsiveness through a modulation of channel gating and channel open
probability without affecting channel conductance (Banke et al., 2000). Here,
o-> 1
following CCI, we document increases in phospho-Ser -GluRl immunoreactivity
in GluRl immunoprecipitates in the ipsilateral spinal cord, compared to contralateral,
sham and nai've controls. This suggests that peripheral nerve injury may
preferentially promote CaMKII/PKC phosphorylation of AMPA receptors although
the underlying mechanisms mediating this are unknown to date.
5.2 GluRl and GluR2 receptor subunit interactions with additional proteins
potentially involved in neuropathic pain
We examined here for the first time, using a number of complementary approaches,
the in vivo function of GRIP, PICK1 and NSF (which are known to interact with the
GluR2 C-terminus) and SAP97 (which is known to interact with the GluRl C-
terminus). The vast majority of studies to date on these docking proteins have been
biochemical with very little in vivo functional data. The use of motif-targeted
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myristoylated peptides enabled us to investigate functional, in vivo roles for the
proteins interacting with the GluRl C-tenninus (SAP97) and the GluR2 C-terminus
(GRIP/PICK1 or NSF). These results showed that blocking the GluR2 C-termini
motifs for interactions with either GRIP/PICK 1 or NSF was effective at alleviating
thermal hyperalgesia following CCI, with minimal effects on mechanical allodynia
behaviours. In contrast, blocking the interaction of SAP97 with GluRl attenuated
both hyperalgesia and allodynia following CCI. None of the myristoylated peptides
had any effects when administered to nai've animals. The data presented here indicate
that the interaction of GR1P/PICK1 and NSF with the C-tenninus of the GluR2
subunit and the interaction of SAP97 with the C-tenninus of the GluRl subunit of
AMPA receptor may well play a role in the mechanisms underlying neuropathic pain
reflex sensitisation following peripheral nerve injury.
Infusion of the same peptide used here to block GRIP and PICK1 into cultured spinal
neurones has shown that PKC and the interaction of GRIP and PICK1 with the
GluR2/3 C-terminus may be important for unmasking silent glutamatergic synapses
between sensory afferents and spinal cord dorsal horn neurones (Li et al., 1999). In
culture, induction of cerebellar LTD causes phosphorylation of Ser880 within the
GluR2 C-terminal PDZ motif (Matsuda et al., 2000) and this phosphorylation causes
dissociation of GRIP from GluR2 without affecting PICK1 binding, disruption of
GluR2 clusters and internalisation of GluR2 subunits (Matsuda et al., 2000). Hence,
O OA
blocking Ser phosphorylation has been reported to attenuate cerebellar LTD (Xia,
2000; Matsuda et al., 2000).
In situ hybridisation histochemistry enabled us to localise GRIP, and NSF mRNA in
the spinal cord under basal conditions and following CCI, as well as documenting
Narp mRNA levels, a protein proposed to cause clustering of GluRl-containing
AMPA receptor subunits. Western blot analyses of protein levels were carried out in
parallel where possible. In situ hybridisation analysis of GRIP, NSF and Narp
mRNA expression in the spinal cord indicated that all were present to varying
degrees under normal conditions with all showing moderate expression in the
superficial laminae of the dorsal horn (at prime sites for mediating the processing of
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nociceptive information) as well as throughout the lower dorsal horn laminae III-V.
Expression of these interacting proteins was differentially altered following CCI.
GRIP and Narp mRNA expression were significantly increased specifically in the
superficial dorsal horn ipsilateral to CCI, and Western blot analysis of GRIP
immunoreactivity revealed a similar increase in GRIP protein levels. Increases in
GRIP levels at the peak of neuropathic reflex sensitisation and the anti-hyperalgesic
and allodynic effects of blocking the GRIP interaction with the GluR2 C-terminal
domain suggest this is an important molecule that becomes activated following the
induction of CCI. Though our in situ hybridisation analysis indicated an ipsilateral
increase in Narp mRNA following CCI, corresponding Western blot analysis could
not be carried out due to the lack of commercially available antibodies. NSF mRNA
was decreased in the superficial laminae ipsilateral to CCI, as was NSF ipsilateral
spinal cord protein expression as indicated by Western blot analysis. PICK1 mRNA
analysis could not be carried out due to the lack of published sequence for the rat
cDNA, although Western blot analysis revealed no significant alteration of overall
PICK1 protein levels as a result of peripheral nerve injury. Overall, levels of SAP97
protein were also apparently unaltered in the spinal cord in response to CCI.
The specific location of GluR2 in Lllj, as well as increases in GluR2 and GRIP
mRNA (with corresponding increases in protein levels of GluR2 and GRIP) in areas
innervated by specific subsets of capsaicin-sensitive afferents suggests that they may
play a key role in mediating neuropathic pain. Decreases in the levels ofNSF mRNA
and protein in this region may imply a reduction in AMPA receptor recycling and
this hypothetical lack of rundown of AMPA receptor activity could influence the
maintenance of the persistent pain state.
The functional implications of the GluR2: NSF interaction are unclear. Decreases in
mRNA and protein levels could affect the receptor's ability to relay nociceptive
information (Song et al., 1998; Liithi et al., 1999). Loading of peptides corresponding
to the NSF-binding domain of GluR2 into rat hippocampal CA1 pyramidal neurones
results in a marked, progressive decrement of AMPA receptor-mediated synaptic
transmission (Nishimune et al., 1998). A downregulation of NSF may imply a
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reduction in AMPA receptor recycling and this hypothetical lack of rundown of
AMPA receptor activity could influence the maintenance of the persistent pain state
although it is likely that only one facet of the change in NSF relates to the role of
GluR2.
Limited information is available for Narp at this time and although we show levels of
Narp mRNA increasing ipsilateral to CCI, the functional significance of this is
difficult to elucidate. It has been reported that >90% of GluRl clusters have
associated Narp immuno-staining and the over-expression of Narp increases the
number of pre-synaptic terminals in spinal neurones (O'Brien et al., 1999). Narp is
dramatically upregulated in neurones in response to patterned synaptic activity so
that it may play a critical role in linking activity with the development and plasticity
of excitatory synapses. So, it is plausible, based on this information, that an increase
in Narp following the development of neuropathic pain behaviours in CCI could lead
to an increase in AMPA receptor-related synapses in neurones in the spinal cord and
facilitate their responsiveness, although this remains to be determined.
Physical association of GRIP/PICK 1 with the GluR2 C-terminus in the spinal cord
under normal conditions was confirmed by probing GluR2-directed
immunoprecipitates for the presence of docking proteins. This same approach was
used to uncover any alterations in GRIP and PICK1 association with GluR2
following either CCI or the direct activation of spinal AMPA receptors by the topical
application of the agonist, AMPA. In contrast to the mRNA and protein analyses
showing ipsilateral increases in overall levels of GRIP, the amount of GRIP
associated with GluR2 subunits appeared to diminish bilaterally following CCI.
PICK1 levels directly associated with GluR2 also diminished but unilaterally in the
ipsilateral spinal cord. This indicates that association of these two proteins with
GluR2 is differentially altered under conditions of peripheral nerve injury. It is
possible that the apparent relative dissociation of GRIP and PICK1 from GluR2 in
CCI reflects a process resulting from activation of the receptor. The fact that similar
observations were made following application of the agonist AMPA would be
consistent with this. The bilateral changes in GRIP rather than PICK1 may reflect an
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associated bilateral activation of AMPA receptors, although the results with
intrathecal AMPA receptor antagonists do not suggest any major contralateral
activation (at least at the time of testing). There is now some evidence for GRIP
having additional non-AMPA receptor-related roles (Dong et ah, 1999b), so
additional demands on cellular pools of GRIP in CCI may complicate the factors
influencing GluR2:GRIP association (and perhaps contribute to the contralateral
changes observed).
Overall levels of GRIP and PICK1 protein in membrane and cytosolic fractions were
examined in response to the dorsal topical application of either saline or AMPA to
assess whether stimulation-induced intracellular translocation of these proteins might
play a role in influencing their GluR2 association and overall function. In agreement
with previous work (Wyszynski et al., 1998), we found that a large proportion of
GRIP appeared to be cytosolic and indeed, stimulation of AMPA receptors caused a
translocation of GRIP from a GluR2 membrane-associated location to the cytosol. A
similar translocation from the membrane to the cytosol was noted for PICK1.
Activation-induced translocation of these docking proteins is therefore an important
factor to consider in their possible roles during neuropathic pain states.
5.3 PSD-95 in NMDA receptor-mediated neuropathic pain
Several techniques were utilised to examine the role of the NMDA receptor
interacting protein PSD-95, which docks to the NR2 subunits of the NMDA receptor,
in neuropathic pain. The expression of PSD-95 in the spinal cord was specifically
localised to the superficial dorsal horn LI I of the spinal cord. Small-scale NR and
PSD-95-directed immunoprecipitations were undertaken and confirmed a direct
association of PSD-95 with NMDA receptor subunits in the spinal cord.
Mutant mice expressing a truncated form of the PSD-95 molecule were utilised to
determine any potential role of PSD-95 in the development of neuropathic reflex
sensitivity. We have shown that the interaction of PSD-95 with the NR2 subunits of
NMDA receptors plays a crucial part in the transmission of (NMDA-related)
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nociceptive information as PSD-95 mutant mice displayed a striking lack of
neuropathic sensitisation normally associated with peripheral nerve injury in
comparison to the development of sensitised behavioural reflexes seen in wild-type
mice. This lack of behavioural sensitisation in PSD-95 mutant mice was not due to
either basal morphological differences in the peripheral nerve as a general result of
the mutation, as axon profiles of myelinated and unmyelinated fibres appeared
normal when compared to wild-type, nor found to be due to a differential
demyelination in comparison to wild-type mice as a result of CCI surgery.
Studies utilising NMDA receptor antagonist and agonist were used to confirm
NMDA receptor-associated mediation of behavioural sensitivity. The intrathecal
injection of the NMDA antagonist (R)-CPP significantly alleviated thermal
hyperalgesia in wild type mice at the peak of CCI-induced behavioural alterations in
a dose-dependent manner, while no effects were seen in parallel experiments with
PSD-95 mutant mice. Additionally, intrathecal injection of NMDA, to act as an in
vivo activator of spinal NMDA receptors, resulted in the well-characterised
hyperalgesic and allodynic response in wild-type mice only, with no apparent
alterations in PSD-95 mutant behavioural responses.
The specific distribution of PSD-95 in LII suggests an important role for this
molecule in mediating neuropathic sensitisation. However, PSD-95 is a member of
the MAGUK family of proteins that have high homology between their PDZ
domains. Little is known about the physiological diversity that may derive from
differences in MAGUK content at glutamatergic synapses although it is likely that
the NR2 subunits expressed throughout the spinal cord interact with other members
of the MAGUK family of proteins and which interaction actually occurs in vivo
depends primarily on which member of the MAGUK family co-distributes with
NMDA receptors in neuronal cells (Miiller et al., 1996). NR2 subunits and K+
channels are common targets for MAGUKS and it might be expected that, if present
in the spinal cord, other MAGUKs of this family might compensate in the regulation
of NMDA receptor pathway. However, here postsynaptic densities lacking PSD-95
do not appear to use any other members of the MAGUK family of proteins such as
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Chapsynl 10/PSD-93 or SAP 102 instead, given the complete absence of neuropathic
reflex sensitivity development following peripheral nerve injury. Thus, it is possible
that PSD-95, given its highly specific localisation, is key to neuropathic behavioural
sensitisation while the localisation and functional role of other MAGUKS in the
spinal cord remains to be determined.
5.4 NMDA receptor-mediated Ca2+ entry and phosphorylation
NMDA receptor- mediated rises in intracellular calcium can activate CaMKII and the
NMDA receptor: PSD-95 complex (in the forebrain) incorporates CaMKII, which
docks to NR2 suhunits and is predicted to respond readily to NMDA receptor-
mediated Ca2+ entry (Gardoni et al., 1999; Husi and Grant, 2001). CaMKII inhibitors
inhibit dorsal horn neurone responses to mustard oil applications (Young, et ah,
1995) and the active autophosphorylated form of CaMKII can increase excitatory
transmission in dorsal horn neurones (Kolaj et ah, 1994). To examine any potential
role of CaMKII in mediating behavioural reflex sensitisation following CCI, we used
the intrathecal injection of two CaMKII inhibitors, myristoyl-autocamtide-2 related
inhibitory peptide and KN-93, in mice at the peak of neuropathic reflex sensitisation.
We report here that intrathecally applied CaMKII inhibitors can alleviate thermal
hyperalgesia and mechanical allodynia that occurs following CCI in wild-type mice.
Given this evidence supporting a role for CaMKII in neuropathic sensitisation, we
used CaMKII activation as a biochemical marker for Ca2+ entry in response to
NMDA receptor stimulation elicited by the topical application of the agonist NMDA
in wild-type and PSD-95 mutant mice. There was a significant increase in CaMKII
enzymic activity of spinal cord extracts from both wild-type and PSD-95 mutant
mice following topical application of maximally-effective concentrations of either
NMDA or the Ca2^ ionophore, ionomycin. This indicated that the overall ability of
the NMDA receptor to mediate Ca2+ entry into the postsynaptic cell was unaffected
by the PSD-95 mutation, suggesting an intact NMDA receptor ion channel, an
observation consistent with previous electrophysiological observations on
hippocampal neurones in these mutant mice (Migaud et al., 1998). Using the same
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protocols, CaMKII activity was increased in the ipsilateral dorsal horn of wild-type
mice following CCI and this increment could be prevented by topical application of
the NMDA receptor antagonist (R)-CPP. No such alteration in CaMKII activity was
seen in PSD-95 mutant mice following CCI. These observations suggest that while
9+
NMDA-activated Ca entry mechanisms are still basically intact in PSD-95 mutant
mice, some mechanism which facilitates the involvement or activation of NMDA
receptors after CCI becomes selectively prevented in the PSD-95 mutants.
We examined modulation ofNMDA receptors by the kinases PKC and/or PICA
following CCI at NR1 C-terminal sites by immunoprecipitation with phospho-
OQZ OQ-7
specific antibodies targeted against phospho-Ser (PKC site) and phospho-Ser
(PKA site) on the C-terminus of NR1 subunits of the NMDA receptor. Regulatory
phosphorylation of NMDA receptor subunits by kinases such as PKC and PKA may
increase the degree of Ca2+ entry evoked by NMDA receptor stimulation (Tingley et
ah, 1997; Westphal et ah, 1999). Electrophysiological responses of spinal neurones
to NMDA are facilitated by PKC and PKA activation (Cerne, Rusin and Randic
1993; Heppenstall and Fleetwood-Walker, 1997) and NR1 phosphorylation at the
PKA Ser897 site is reported to increase following capsaicin injection in spinothalamic
tract cells (Zou, Lin and Willis, 2000).
The levels of phospho-Ser897-NR1 associated with NR1 immunoprecipitates were
increased in wild type mice ipsilateral to injury following CCI, with no apparent
alterations in levels in PSD-95 mutant mice following CCI. To identify a possible
OQ-7
underlying cause for the apparent inability of PKA to phosphorylate phospho-Ser -
NR1 residues in PSD-95 mutant mice, we carried out small scale NR2B-directed
immunoprecipitates of naive wild-type and PSD-95 mutant spinal cord. The site of
truncation of the PSD-95 molecule in the mutants removes a site of interaction with
the AKAP, AKAP79/150, a PKA anchoring protein that is believed to localise PKA
to target sites. We hypothesised that a disrupted linkage via PSD-95 of AKAP79/150
to target sites may have accounted for the lack of injury-induced increases in
phospho-Ser897-NRl in the PSD-95 mutant mice. Nevertheless, we could detect no
alterations in the levels of NR2B-associated AKAP79/150 or of two PKA subunits
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Rlla and RIip, which bind to AKAP79/150. The lack of CCI-induced NR1
OQ7
phosphorylation at Ser and of sensitised reflex function in the PSD-95 mutant
mice therefore does not seem to be due to a disrupted AKAP79/150 linkage.
5.6 Potential therapeutic implications
This project provides new insight into the mechanisms by which AMPA and NMDA
receptor subunits, by virtue of their intermolecular interaction, might contribute to
neuropathic pain processing. Regulation of AMPA and NMDA receptors following
peripheral nerve damage is likely to be influenced by the ability of their intracellular
interacting proteins to dictate specificity of targeting and/or linkages to additional
signalling pathways. Although many of the underlying mechanisms are still
unknown, we showed not only that intracellular proteins acting directly at AMPA
and NMDA receptor subunit C-terminal motifs are localised at spinal sites of
nociceptive processing but also that synthetic peptide blockers or knockout of these
proteins can specifically attenuate behavioural sensitisation following nerve injury.
The apparently more restricted localisation of these proteins, in comparison to the
more widespread expression of AMPA and NMDA receptors themselves may be
advantageous for specificity of action. While analgesic/anti-hyperalgesic targeting is
now focussing on the development of subunit selective pharmacological
manipulations of regionally localised AMPA and NMDA receptors in the spinal cord
(Sorkin, Yaksh and Doom, 1999; Boyce et al., 1999), the work presented here
contributes to an understanding of how AMPA and NMDA receptor subunit function
may be regulated in response to peripheral nerve injury.
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